Substituted oxazoles for the treatment of cancer

Abstract

There are provided compounds, their preparation and their use in the treatment of medical conditions including cancers and immune disorders. ##STR00001##

Claims

1. A compound of formula IVA: ##STR00346## or a pharmaceutically acceptable salt thereof, wherein: X.sub.1 is N; X.sub.2 is O; Q.sup.1 is phenyl, optionally substituted with a substituent selected from the group consisting of halogen, CN, NO.sub.2, alkyl, halogeno alkyl, alkyl(aryloxy), NH.sub.2, OH, alkoxy, halogeno alkoxy, aryloxy, SH, thioalkoxy, halogeno thioalkoxy, thioalkyl(aryloxy), thioaryloxy, cycloalkyl, and aryl; Q.sup.2 is phenyl, optionally substituted with a substituent selected from the group consisting of halogen, CN, NO.sub.2, alkyl, halogeno alkyl, alkyl(aryloxy), NH.sub.2, OH, alkoxy, halogeno alkoxy, aryloxy, SH, thioalkoxy, halogeno thioalkoxy, thioalkyl(aryloxy), thioaryloxy, cycloalkyl, and aryl; R is H, CN, NO.sub.2, alkyl, (CH.sub.2)CN, alkoxy, halogeno thioalkoxy, S(O).sub.2R.sup.1, or cycloalkyl; R is H, CN, NO.sub.2, alkyl, (CH.sub.2)CN, alkoxy, halogeno thioalkoxy, S(O).sub.2R.sup.1, or cycloalkyl; each Ri is independently H, CN, NO.sub.2, alkyl, (CH.sub.2).sub.nCN, alkoxy, halogeno thioalkoxy, S(O).sub.2R.sup.1, or cycloalkyl; each R.sup.1 is independently alkyl, cycloalkyl, or aryl; m is 0, 1, 2, 3, or 4; and n is 1, 2, 3, 4, 5, or 6.

2. The compound according to claim 1, wherein the compound is selected from the group consisting of: ##STR00347## ##STR00348## ##STR00349## ##STR00350## ##STR00351## ##STR00352## ##STR00353## ##STR00354## ##STR00355## or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A method for inhibiting a KRAS mutant in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

5. The method according to claim 4, wherein the KRAS mutant is G12C, G12D, G12V, or G13D.

6. A method for stimulating an interferon gene in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

7. The method according to claim 6, wherein the interferon gene is a human interferon gene or a mouse interferon gene.

8. A method for targeting an ETS transcription factor in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

9. The method according to claim 8, wherein the ETS transcription factor is ERG or ETV.

10. A method for targeting a GATA transcription factor in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

11. The method according to claim 10, wherein the GATA transcription factor is GATA2.

12. A compound selected from the group consisting of: ##STR00356## or a pharmaceutically acceptable salt thereof.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) In the appended drawings:

(2) FIG. 1.1a) ERG-dependent reporter assay in HEK293 cells indicated that compounds 648, 697, 698 and 699 (in Table 2 below) are ERG inhibitors. HEK293 cells were transiently transfected with empty vector (for the NT) or ERG-expressing plasmid as well as pRL-TK (internal control) and PUx3-Luc reporter. Cells were then exposed to DMSO vehicle or compounds at designated doses for 48 hours. Experiments were done in triplicate.

(3) FIG. 1.1b) ERG-dependent reporter assay in HEK293 cells indicated that compounds 639, 651, 659, 662 and 675 (in Table 2 below) are ERG inhibitors. Experiments were done as described above in FIG. 1.1a).

(4) FIG. 1.1c) ERG-dependent reporter assay in HEK293 cells indicated that compounds 661, 673 and 678 (in Table 2 below) are ERG inhibitors. Experiments were done as described above in FIG. 1.1a).

(5) FIG. 1.1d) ERG-dependent reporter assay in HEK293 cells indicated that compounds V131, V154 and V151 (in Table 6 below) are ERG inhibitors. Experiments were done as described above in FIG. 1.1a).

(6) FIG. 1.2 ESE-1 dependent reporter assay in HEK293 cells indicated that compounds 698, V131 and V154 are ESE-1 inhibitors. Experiments were done as described above in FIG. 1.1a) except that ERG plasmid was replaced by ESE-1 plasmid.

(7) FIG. 1.3 ETS-2 dependent reporter assay in HEK293 cells indicated that compound V154 is an ETS-2 inhibitor. Experiments were done as described above in FIG. 1.1a) except that ERG plasmid was replaced by ETS-2 plasmid.

(8) FIG. 1.4a) ETV1-dependent reporter assay in HEK293 cells indicated that compounds 650, 651, 652, 653, 654, 656 and 662 (in Table 2 below) are ETV1 inhibitors. Experiments were done as described above in FIG. 1.1a) except that ERG plasmid was replaced by ETV1 plasmid.

(9) FIG. 1.4b) ETV1-dependent reporter assay in HEK293 cells indicated that compounds 636, 637, 638, 655, 697, 700 and 708 (in Table 2 below) are ETV1 inhibitors. Experiments were done as described above in FIG. 1.1a) except that ERG plasmid was replaced by ETV1 plasmid.

(10) FIG. 1.4c) ETV1-dependent reporter assay in HEK293 cells indicated that compounds 641, 657, 661 and 675 are ETV1 inhibitors. Experiments were done as described above in FIG. 1.1a) except that ERG plasmid was replaced by ETV1 plasmid.

(11) FIG. 1.4d) ETV1-dependent reporter assay in HEK293 cells indicated that compounds 648, 827, 832, 838 and 830 (in Table 3 below) are ETV1 inhibitors. Experiments were done as described above in FIG. 1.1a) except that ERG plasmid was replaced by ETV1 plasmid.

(12) FIG. 1.5a) Surface Plasmon Resonance (SPR) analysis indicated that compound 648 (in Table 2 below) has direct binding with human ERG protein. Steady-state kinetics of compound 648, YK-4-279 (positive control) and bicalutamide (Bic) (negative control) over amine-coupled ERG surfaces with 50 M injection (25 L/min120 sec association+120 sec dissociation). High-density ERG (6000 RU) and reference surface (no ERG) were amine-coupled to CM5 sensors using BIACORE 3000 instrumentation. YK-4-279 is a known ERG inhibitor. Bic is an antagonist of the androgen receptor.

(13) FIG. 1.5b) Preliminary SPR data to characterize binding affinity of compound 648. Rapid on/off kinetics for compound 648 when titrated over amine-coupled ERG surfaces at 0, 10, 20, 30, 40, and 50 M (25 L/min120 sec association+120 sec dissociation). After DMSO solvent correction, fitting of the data to a steady-state affinity model predicts low micromolar K.sub.D values for compound 648.

(14) FIG. 1.6 Compounds 648, 698 and 891 at 10 M inhibit expression of EZH2, c-Myc and ERG in VCaP cells. VCaP cells were exposed to DMSO vehicle control, 648, 698 and 891 at 10 M for 72 hours in DMEM medium plus 10% FBS or phenol red-free DMEM medium plus 10% charcoal-stripped FBS (CS-FBS).

(15) FIG. 1.7 Compound 648 potently inhibits invasion of VCaP and C4-2B cells, but not the DU145 cells. Invasion assay was performed using (8.0 m pore size) BD Matrigel Invasion chambers in 24-well plate (Catalog: 354480, BD Biosc.). 750 L medium (with 20% FBS) was added into lower chamber of each well (DMEM for VCaP, RPMI 1640 for C4-2B and DU145). Next, 510.sup.5 VCaP or 510.sup.5 C4-2B or 110.sup.4DU145 cells in 500 L medium (with 0.5% FBS) were seeded into the upper chamber of each well. DMSO vehicle or compounds in DMSO solution were added into upper chamber to reach the designated doses. After 48 hours incubation, the invasive cells attached to the lower surface of the membrane insert were fixed in 10% formalin at room temperature for 30 minutes and stained with 0.05% crystal violet. The number of invasive cells was then counted under a microscope. Invasion experiments were performed in duplicate. ***p<0.0001 when compared with vehicle control.

(16) FIG. 1.8 Cytotoxicity of compounds 827 and 832 in the ETV1-postive LNCaP cells as evaluated by MTT assay (72 hours).

(17) FIG. 2.1a) GATA2-dependent reporter assay in IHH cells indicated that compounds 673 and 676 are GATA2 inhibitors. K7174 is a known GATA2 inhibitor. The IHH cells were transiently transfected with empty vector (for the NT) or human GATA2-expressing plasmid as well as pRL-TK (internal control) and GATA-Luc reporter plasmids. Cells were exposed to DMSO vehicle or compounds for 48 h. Experiments were in triplicate.

(18) FIG. 2.1b) GATA2-dependent reporter assay in IHH cells indicated that compounds 650, 675, 631 and 632 are GATA2 inhibitors. Experiments were done as described above in FIG. 2.1a).

(19) FIG. 2.2a) GATA2-dependent reporter assay in IHH cells indicated that compounds 817, 830, 770 and 795 are GATA2 inhibitors. Experiments were done as described above in FIG. 2.1a).

(20) FIG. 2.2b) GATA2-dependent reporter assay in IHH cells indicated that compounds 817, 830, 831, 834, 838, 839 and 840 are GATA2 inhibitors. Experiments were done as described above in FIG. 2.1a).

(21) FIG. 2.2c) GATA2-dependent reporter assay in IHH cells indicated that compounds 684, 685, 686, 687, 784 and 795 are GATA2 inhibitors. Experiments were done as described above in FIG. 2.1a).

(22) FIG. 2.2d) GATA2-dependent reporter assay in IHH cells indicated that compounds 719, 866 and 693 are GATA2 inhibitors. Experiments were done as described above in FIG. 2.1a).

(23) FIG. 2.2e) GATA2-dependent reporter assay in IHH cells indicated that V248, 858, 859 and 860 are GATA2 inhibitors. Experiments were done as described in FIG. 2.1a).

(24) FIG. 2.2f) GATA2-dependent reporter assay in IHH cells indicated that 868, 869, 870, 871 and 872 are GATA2 inhibitors. Experiments were done as described in FIG. 2.1a).

(25) FIG. 2.2g) GATA2-dependent reporter assay in IHH cells indicated that 880, 881, 882, 883 and 884 are GATA2 inhibitors. Experiments were done as described in FIG. 2.1a).

(26) FIG. 2.3a) GATA3-dependent reporter assay in IHH cells indicated that compounds 673, 676, 770 and 817 at 5 M are inactive against GATA3, indicating these compounds are selective toward GATA2 (see FIG. 2.2). In contrast, K7174 is active against GATA3. The IHH cells were transiently transfected with empty vector (for the NT) or human GATA3-expressing plasmid as well as pRL-TK (internal control) and GATA-Luc reporter plasmids. Cells were exposed to DMSO vehicle or compounds for 48 hours. Experiments were done in triplicate.

(27) FIG. 2.3b) GATA3-dependent reporter assay in IHH cells indicated that compounds 673, 675, 676 and 817 at 10 M are inactive against GATA3. Experiments were done as described above in FIG. 2.3a).

(28) FIG. 2.3c) GATA3-dependent reporter assay in IHH cells indicated that compounds 687, 693, 784 and 795 at 10 M are inactive against GATA3, whereas compounds 650 and 686 are active against GATA3. Experiments were done as described in FIG. 2.3a).

(29) FIG. 2.4 Compound 673 selectively inhibits GATA2 among GATA family members. In contrast, K7174 is not selective. GATA1-, GATA2-, GATA3- and GATA4-dependent reporter assays were done in IHH cells which were exposed to DMSO vehicle, compound 673 or K7174 (M) in CSS medium for 48 hours.

(30) FIG. 2.5a) Specific binding of compounds (50 M each in PBST running buffer containing 5% DMSO) to amine-coupled GATA2 (9,000 RU) at 25 L/min (reference-subtracted data with DMSO solvent correction), as assessed by Surface Plasmon Resonance (SPR) analysis: solid black line, compound 817; solid grey line, compound 673; dashed black line, V248; dotted grey line, compound 670; flat baseline, bicalutamide (BIC) (0 RU=negative control).

(31) FIG. 2.5b) Specific and dose-dependent binding of compound 673 to amine-coupled GATA2 (9,000 RU) at 25 L/min (reference-subtracted data with DMSO solvent correction) (0-50 M, 2-fold dilution series in PBST running buffer containing 5% DMSO), as assessed by SPR analysis.

(32) FIG. 2.6a Western blot analysis revealed that compound 673 suppresses the androgen receptor (AR) signaling in C4-2B prostate cancer cells. Compound 673 also inhibits GATA2 expression in C4-2B cells.

(33) FIG. 2.7 Compound 673 is cytotoxic in KRAS-mutant NSCLC cells (A549 and H23), but is not toxic the KRAS wild-type NSCLC cells (H322). Cells were exposed to vehicle or compounds (M) for 72 hours. Viable cells were evaluated by MTT assays.

(34) FIG. 2.8 Compound 673 is equally cytotoxic to LNCaP cells stably transfected with empty vector pcDNA3.1 (LNCaP-pcDNA) and LNCaP cells stably transfected with GATA2-expressing plasmid (LNCaP-GATA2) (upper figure). In contrast, antiandrogen bicalutamide (BIC) is less active in LNCaP-GATA2 cells when compared with its activity in LNCaP-pcDNA cells. Cells were exposed to DMSO vehicle or compounds for 72 hours. Vial cells were evaluated by MTT assays. Experiments were done in triplicate.

(35) FIG. 2.9 GATA2 overexpression confers resistance to antiandrogen in prostate cancer cells. (A) PSA-luc reporter assay and (B) Western Blot analysis revealed the attenuated inhibition effect of Bic (Bicalutamide) in LNCaP-GATA2 cells in FBS medium; (C) Colony formation assay and quantification of LNCaP-pcDNA and LNCaP-GATA2 cells exposed to 1 M BIC in FBS medium for 28 days indicated that GATA2 expression confers resistance to BIC. *p<0.05, **p<0.001.

(36) FIG. 2.10 (A) Plasmid construct for expressing fusion protein IRF3DBD-GATA2NTD, in which GATA2 NTD is fused to the DBD of IRF3; (B) ISRE-luc reporter assay in PC3 cells showed that compound 673 at 5 M is active against fusion protein IRF3DBD-GATA2NTD, but inactive against wild-type IRF3. This indicates that 673 is targeting the GATA2 NTD. **p<0.005 when compared with DMSO vehicle.

(37) FIG. 2.11 By breaking AR-GATA2 feedback loop, compound 673 suppresses the AR signaling in CRPC cells. (A) GATA-luc or PSA-luc reporter assay in LNCaP-GATA2 cells following 72 hours treatment with BIC or 673 in CSS medium; (B and C) WB analysis indicated that, in contrast to Bic, 673 is effective in suppressing AR signaling in LNCaP-GATA2 cells in FBS medium (B) and in CRPC cells, including HP-LNCaP, C4-2B and 22Rv1, in CSS medium (C). Cells were exposed to DMSO vehicle, BIC, 673 or K7174 at designated doses (M) for 72 hours.

(38) FIG. 2.12 Synergistic effect of compound 673 with bicalutamide (BIC) in PSA-luc reporter assay (A) and BrdU cell proliferation assay (B) in LNCaP-GATA2 cells in regular medium (RPM11640 plus 10% FBS). (A) PSA-luc reporter assay in LNCaP-GATA2 cells, which were exposed to DMSO vehicle, BIC, 673, or equi-molar combination of Bic and 673 for 72 hours in FBS medium. RLU, relative luciferase unit; (B) BrdU Cell Proliferation Assay (Assay Kit #6813, Cell Signaling Tech.). LNCaP-GATA2 cells were exposed to DMSO vehicle, Bic, 673 or equi-molar combination of Bic and 673 for 48 hours. In the last 8 hours, 10 M BrdU was added to the plate. **p<0.001, ***p<0.001 when compared with BIC at the same doses; #p<0.05, ##p<0.001 when compared with 673 at the same doses.

(39) FIG. 3.1a) Compounds 640, 670, 672, 676, 677, 681, 761, 762 and 770 activate human STING (hSTING) in ISRE-luc reporter assay in 293T cells. ISRE-luc (reporter), pRL-TK (internal control) and hSTING-expressing plasmids were transiently transfected into 293T cells. Cells were exposed to DMSO vehicle control or compounds for 24 hours. Experiments were done in triplicate.

(40) FIG. 3.1b) Compounds 641, 650, 656 and 660 activate hSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described above in FIG. 3.1a).

(41) FIG. 3.1c) Compounds 671, 673, 678, 830, 831, 817, 834 and 840 activate hSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described above in FIG. 3.1a).

(42) FIG. 3.1d) Compounds 653, 698, 916, 917, 918, 919 and 920 activate hSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described above in FIG. 3.1a).

(43) FIG. 3.1e) Compounds 689, 693 and 838 activate hSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described above in FIG. 3.1a).

(44) FIG. 3.2 Compounds 640, 672, 681, 761 and 817 activate mouse STING (mSTING) in ISRE-luc reporter assay in 293T cells. ISRE-luc (reporter), pRL-TK (internal control) and mSTING-expressing plasmids were transiently transfected into 293T cells. Cells were exposed to DMSO vehicle control or compounds for 24 hours. Experiments were done in triplicate.

(45) FIG. 3.3 Specific, dose-dependent binding of compound 817 (0-50 M, 2-fold dilution series in PBST running buffer containing 5% DMSO) to amine-coupled human STING (8,700 RU) at 25 L/min (reference-subtracted data with DMSO solvent correction), as assessed by SPR analysis.

(46) FIG. 3.4a) Compounds 1011, 1012, 1013, 1033, 1035, 1036, 1037 and 874 at 10 M activate hSTING and/or mSting in ISRE-luc reporter assay in 293T cells. ISRE-luc (reporter), pRL-TK (internal control) and hSTING- or mSTING-expressing plasmids were transiently transfected into 293T cells. Cells were exposed to DMSO vehicle control or compounds for 24 hours. Experiments were done in triplicate.

(47) FIG. 3.4b) Compounds 795, 874, 1038, 1039, 1040, 1041 and 1042 activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a). DMXAA (DMX) is a known agonist of mSTING and was included as a control.

(48) FIG. 3.4c) Compounds 1096, 1097, 1098, 1099, 1100, 1103 and 1104 activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a).

(49) FIG. 3.4d) Compounds 1120, 1121, 1122, 1123, 1124, 1125, 1126 and 1127 activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a).

(50) FIG. 3.4e) Compounds 1129, 1137, 1139, 1140, 1141, 1142, 1143 and 1188 activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a).

(51) FIG. 3.4f) Compounds 1173, 1174, 1175, 1176, 1177, 1178 and 1179 at 10 M activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a).

(52) FIG. 3.4g) Compounds 1180, 1181, 1182, 1183, 1184, 1227 and 1228 at 20 M activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a).

(53) FIG. 3.4h) Compounds 1285, 1286, 1287, 1288, 1289 and 1176 activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a).

(54) FIG. 3.4i) Compounds 1357, 1360, 1361, 1364 and 1366 activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a).

(55) FIG. 3.4j) Compounds 1369, 1370, 1372 and 1373 activate hSTING and/or mSTING in ISRE-luc reporter assay in 293T cells. Experiments were done as described in FIG. 3.4a).

(56) FIG. 3.5 Compounds 834, 874, 761, 840 and 1176 activate interferon signaling pathway in THP-1 cells. THP1 cells were treated for 16 hours with the indicated concentration (M) of compounds or DMSO vehicle control. Whole-cell extracts were prepared and subjected to Western blot analysis with the antibodies as indicated.

(57) FIG. 4.1 SPR analysis. Left panels, SPR sensorgrams for compounds 784 and 895 binding to 3500 RU amine-coupled KRAS (G12D mutant) at 25 L/min in PBS-T containing 1 M GDP. Right panels, corresponding non-linear regression analyses of steady-state binding responses versus concentration to determine apparent equilibrium dissociation constants (K.sub.D).

(58) FIG. 4.2a) KRAS mutant-dependent NF-kB-luc reporter assays in HEK293 cells. Compounds 784 and 895 at 10 M potently inhibit KRAS 12D, 12V and 12C-dependent NF-kB-luc reporter assay. NF-kB-luc reporter, pRL-TK internal control and KRAS 12D or 12V or 12C mutant-expressing plasmids were transiently transfected into HEK293 cells. NT cells were transfected with NF-kK-luc, pRL-TK and empty vector. Cells were exposed to DMSO vehicle or compounds at designated dose for 24 hours. Experiments were done in triplicate.

(59) FIG. 4.2b) Compounds 1043, 1100 and 1103 potently inhibit KRAS 12D-dependent NF-kB-luc reporter assay in HEK293 cells. Experiments were done as described in FIG. 4.2a).

(60) FIG. 4.2c) Compounds 1144 and 1322 potently inhibit KRAS 12D-dependent NF-kB-luc reporter assay in HEK293 cells. Experiments were done as described in FIG. 4.2a).

(61) FIG. 4.3a) Compounds 784, 895 and 1144 potently inhibit NF-kB-luc reporter assay in Panc 10.05 cells. NF-kB-luc reporter and pRL-TK internal control were transiently transfected into Panc 10.05 cells. Cells were exposed to DMSO vehicle or compounds at designated dose for 24 hours. Experiments were done in triplicate. RLU, relative luciferase unit.

(62) FIG. 4.3b) Compounds 1175, 1176 and 1187 potently inhibit NF-kB-luc reporter assay in Panc 10.05 cells. Experiments were done as described in FIG. 4.3a).

(63) FIG. 4.3c) Compounds 1200, 1201, 1209, 1210, 1211 and 1212 potently inhibit NF-kB-luc reporter assay in Panc 10.05 cells. Experiments were done as described in FIG. 4.3a).

(64) FIG. 4.3d) Compounds 1100, 1186, 1188, 1211 and 1237 potently inhibit NF-kB-luc reporter assay in Panc 10.05 cells. Experiments were done as described in FIG. 4.3a).

(65) FIG. 4.3e) Compounds 1249, 1250, 1257, 1258, 1259, 1261 and 1262 potently inhibit NF-kB-luc reporter assay in Panc 10.05 cells. Experiments were done as described in FIG. 4.3a).

(66) FIG. 4.3f) Compounds 1249, 1257, 1261 and 1273 potently inhibit NF-kB-luc reporter assay in Panc 10.05 cells. Experiments were done as described in FIG. 4.3a).

(67) FIG. 4.3g) Compounds 1274, 1275, 1276, 1298, 1300, 1301, 1302 and 1303 at 20 M potently inhibit NF-kB-luc reporter assay in Panc 10.05 cells. Experiments were done as described in FIG. 4.3a).

(68) FIG. 4.3h) Compounds 1320, 1322, 1345 and 1348 potently inhibit NF-kB-luc reporter assay in Panc 10.05 cells. Experiments were done as described in FIG. 4.3a).

(69) FIG. 4.3i) Compounds 1367, 1368, 1369, 1371, 1372, 1373 and 1374 at 20 M inhibit NF-kB-luc reporter assay in Panc 10.05 cells. Experiments were done as described in FIG. 4.3a).

(70) FIG. 4.4a) Western blot analysis indicated that compounds 784 and 895 dose-dependently suppressed phosphorylation of ERK and induced apoptosis in Panc 10.05 cells. C-PARP, cleaved PARP. Panc10.05 cells were exposed to DMSO vehicle or compounds at designated doses for 24 hours.

(71) FIG. 4.4b) Western blot analysis indicated that compounds 1100, 1186, 1187, 1200 and 1237 at 10 M potently suppressed phosphorylation of ERK in Panc 10.05 cells. Panc10.05 cells were exposed to DMSO vehicle or compounds at designated doses for 24 hours.

(72) FIG. 4.4c) Western blot analysis indicated that compounds 1186, 1187, 1209, 1237, 1306 and 895 at 10 M potently suppressed phosphorylation of ERK in HCT-116 cells. HCT-116 cells were exposed to DMSO vehicle or compounds at designated doses for 24 hours.

(73) FIG. 4.5) MTT analysis indicated that compounds 1186 and 1261 dose-dependently inhibit proliferation of Panc10.05 pancreatic cancer cells, H23 non-small lung cancer cells and HCT-116 colorectal cancer cells. Panc 10.05, H23 and HCT-116 cells express endogenous KRAS 12D, 12C and 13D mutants, respectively. Cells were exposed to DMSO vehicle or compounds at designated doses for 72 hours. Experiments were done in triplicate.

(74) FIG. 5 General formulae of compounds according to embodiments of the invention.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

(75) Before the present invention is further described, it is to be understood that the invention is not limited to the particular embodiments described below, as variations of these embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

(76) In order to provide a clear and consistent understanding of the terms used in the present specification, a number of definitions are provided below. Moreover, unless defined otherwise, all technical and scientific terms as used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains.

(77) As used herein, the word a or an when used in conjunction with the term comprising in the claims and/or the specification may mean one, but it is also consistent with the meaning of one or more, at least one, and one or more than one. Similarly, the word another may mean at least a second or more.

(78) As used herein, the words comprising (and any form of comprising, such as comprise and comprises), having (and any form of having, such as have and has), including (and any form of including, such as include and includes) or containing (and any form of containing, such as contain and contains), are inclusive or open-ended and do not exclude additional, unrecited elements or process steps.

(79) As used herein, term alkyl or alk represents a monovalent group derived from a straight or branched chain saturated hydrocarbon comprising, unless otherwise specified, from 1 to 15 carbon atoms and is exemplified by methyl, ethyl, n- and iso-propyl, n-, sec-, iso- and tert-butyl, neopentyl and the like and may be optionally substituted with one, two, three or, in the case of alkyl groups comprising two carbons or more, four substituents independently selected from the group consisting of: (1) alkoxy of one to six carbon atoms; (2) alkylsulfinyl of one to six carbon atoms; (3) alkylsulfonyl of one to six carbon atoms; (4) alkynyl of two to six carbon atoms; (5) amino; (6) aryl; (7) arylalkoxy, where the alkylene group comprises one to six carbon atoms; (8) azido; (9) cycloalkyl of three to eight carbon atoms; (10) halo; (11) heterocyclyl; (12) (heterocycle)oxy; (13) (heterocycle)oyl; (14) hydroxyl; (15) hydroxyalkyl of one to six carbon atoms; (16) N-protected amino; (17) nitro; (18) oxo or thiooxo; (19) perfluoroalkyl of 1 to 4 carbon atoms; (20) perfluoroalkoxyl of 1 to 4 carbon atoms; (21) spiroalkyl of three to eight carbon atoms; (22) thioalkoxy of one to six carbon atoms; (23) thiol; (24) OC(O)R.sup.A, where R.sup.A is selected from the group consisting of (a) substituted or unsubstituted C.sub.1-6 alkyl, (b) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (c) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (d) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (e) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (25) C(O)R.sup.B, where R.sup.B is selected from the group consisting of (a) hydrogen, (b) substituted or unsubstituted C.sub.1-6 alkyl, (c) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (d) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (e) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (f) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (26) CO.sub.2R.sup.B, where R.sup.B is selected from the group consisting of (a) hydrogen, (b) substituted or unsubstituted C.sub.1-6 alkyl, (c) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (d) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (e) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (f) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (27) C(O)NR.sup.CR.sup.D, where each of R.sup.C and R.sup.D is independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; (28) S(O)R.sup.E, where R.sup.E is selected from the group consisting of (a) alkyl, (b) aryl, (c) arylalkyl, where the alkylene group comprises one to six carbon atoms, and (d) hydroxyl; (29) S(O).sub.2R.sup.E, where R.sup.E is selected from the group consisting of (a) alkyl, (b) aryl, (c) arylalkyl, where the alkylene group comprises one to six carbon atoms, and (d) hydroxyl; (30) S(O).sub.2NR.sup.FR.sup.G, where each of R.sup.F and R.sup.G is independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; and (31) NR.sup.HR.sup.I, where each of R.sup.H and R.sup.I is independently selected from the group consisting of (a) hydrogen; (b) an N-protecting group; (c) alkyl of one to six carbon atoms; (d) alkenyl of two to six carbon atoms; (e) alkynyl of two to six carbon atoms; (f) aryl; (g) arylalkyl, where the alkylene group comprises one to six carbon atoms; (h) cycloalkyl of three to eight carbon atoms, (i) alkcycloalkyl, where the cycloalkyl group comprises three to eight carbon atoms, and the alkylene group comprises one to ten carbon atoms, (j) alkanoyl of one to six carbon atoms, (k) aryloyl of 6 to 10 carbon atoms, (l) alkylsulfonyl of one to six carbon atoms, and (m) arylsulfonyl of 6 to 10 carbons atoms, with the proviso that no two groups are bound to the nitrogen atom through a carbonyl group or a sulfonyl group.

(80) The terms alkoxy or alkyloxy as used interchangeably herein, represent an alkyl group attached to the parent molecular group through an oxygen atom.

(81) The term alkylthio or thioalkoxy as used interchangeably herein, represents an alkyl group attached to the parent molecular group through a sulfur atom.

(82) The term alkylene as used herein, represents a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon by the removal of two hydrogen atoms, and is exemplified by methylene, ethylene, isopropylene and the like.

(83) The term alkenyl as used herein, represents monovalent straight or branched chain groups of, unless otherwise specified, from 2 to 15 carbons, such as, for example, 2 to 6 carbon atoms or 2 to 4 carbon atoms, containing one or more carbon-carbon double bonds and is exemplified by ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl and the like and may be optionally substituted with one, two, three or four substituents independently selected from the group consisting of: (1) alkoxy of one to six carbon atoms; (2) alkylsulfinyl of one to six carbon atoms; (3) alkylsulfonyl of one to six carbon atoms; (4) alkynyl of two to six carbon atoms; (5) amino; (6) aryl; (7) arylalkoxy, where the alkylene group comprises one to six carbon atoms; (8) azido; (9) cycloalkyl of three to eight carbon atoms; (10) halo; (11) heterocyclyl; (12) (heterocycle)oxy; (13) (heterocycle)oyl; (14) hydroxyl; (15) hydroxyalkyl of one to six carbon atoms; (16) N-protected amino; (17) nitro; (18) oxo or thiooxo; (19) perfluoroalkyl of 1 to 4 carbon atoms; (20) perfluoroalkoxyl of 1 to 4 carbon atoms; (21) spiroalkyl of three to eight carbon atoms; (22) thioalkoxy of one to six carbon atoms; (23) thiol; (24) OC(O)R.sup.A, where R.sup.A is selected from the group consisting of (a) substituted or unsubstituted C.sub.1-6 alkyl, (b) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (c) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (d) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (e) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (25) C(O)R.sup.B, where R.sup.B is selected from the group consisting of (a) hydrogen, (b) substituted or unsubstituted C.sub.1-6 alkyl, (c) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (d) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (e) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (f) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (26) CO.sub.2R.sup.B, where R.sup.B is selected from the group consisting of (a) hydrogen, (b) substituted or unsubstituted C.sub.1-6 alkyl, (c) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (d) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (e) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (f) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (27) C(O)NR.sup.CR.sup.D, where each of R.sup.C and R.sup.D is independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; (28) S(O)R.sup.E, where R.sup.E is selected from the group consisting of (a) alkyl, (b) aryl, (c) arylalkyl, where the alkylene group comprises one to six carbon atoms, and (d) hydroxyl; (29) S(O).sub.2R.sup.E, where R.sup.E is selected from the group consisting of (a) alkyl, (b) aryl, (c) arylalkyl, where the alkylene group comprises one to six carbon atoms, and (d) hydroxyl; (30) S(O).sub.2NR.sup.FR.sup.G, where each of R.sup.F and R.sup.G is independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; and (31) NR.sup.HR.sup.I, where each of R.sup.H and R.sup.I is independently selected from the group consisting of (a) hydrogen; (b) an N-protecting group; (c) alkyl of one to six carbon atoms; (d) alkenyl of two to six carbon atoms; (e) alkynyl of two to six carbon atoms; (f) aryl; (g) arylalkyl, where the alkylene group comprises one to six carbon atoms; (h) cycloalkyl of three to eight carbon atoms; (i) alkcycloalkyl, where the cycloalkyl group comprises three to eight carbon atoms, and the alkylene group comprises one to ten carbon atoms, (j) alkanoyl of one to six carbon atoms, (k) aryloyl of 6 to 10 carbon atoms, (l) alkylsulfonyl of one to six carbon atoms, and (m) arylsulfonyl of 6 to 10 carbons atoms, with the proviso that no two groups are bound to the nitrogen atom through a carbonyl group or a sulfonyl group.

(84) The term alkynyl as used herein, represents monovalent straight or branched chain groups of from two to six carbon atoms comprising a carbon-carbon triple bond and is exemplified by ethynyl, 1-propynyl, and the like and may be optionally substituted with one, two, three or four substituents independently selected from the group consisting of: (1) alkoxy of one to six carbon atoms; (2) alkylsulfinyl of one to six carbon atoms; (3) alkylsulfonyl of one to six carbon atoms; (4) alkynyl of two to six carbon atoms; (5) amino; (6) aryl; (7) arylalkoxy, where the alkylene group comprises one to six carbon atoms; (8) azido; (9) cycloalkyl of three to eight carbon atoms; (10) halo; (11) heterocyclyl; (12) (heterocycle)oxy; (13) (heterocycle)oyl; (14) hydroxyl; (15) hydroxyalkyl of one to six carbon atoms; (16) N-protected amino; (17) nitro; (18) oxo or thiooxo; (19) perfluoroalkyl of 1 to 4 carbon atoms; (20) perfluoroalkoxyl of 1 to 4 carbon atoms; (21) spiroalkyl of three to eight carbon atoms; (22) thioalkoxy of one to six carbon atoms; (23) thiol; (24) OC(O)R.sup.A, where R.sup.A is selected from the group consisting of (a) substituted or unsubstituted C.sub.1-6 alkyl, (b) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (c) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (d) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (e) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (25) C(O)R.sup.B, where R.sup.B is selected from the group consisting of (a) hydrogen, (b) substituted or unsubstituted C.sub.1-6 alkyl, (c) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (d) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (e) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (f) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (26) CO.sub.2R.sup.B, where R.sup.B is selected from the group consisting of (a) hydrogen, (b) substituted or unsubstituted C.sub.1-6 alkyl, (c) substituted or unsubstituted C.sub.6 or C.sub.10 aryl, (d) substituted or unsubstituted C.sub.7-16 arylalkyl, where the alkylene group comprises one to six carbon atoms, (e) substituted or unsubstituted C.sub.1-9 heterocyclyl, and (f) substituted or unsubstituted C.sub.2-15 heterocyclylalkyl, where the alkylene group comprises one to six carbon atoms; (27) C(O)NR.sup.CR.sup.D, where each of R.sup.C and R.sup.D is independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; (28) S(O)R.sup.E, where R.sup.E is selected from the group consisting of (a) alkyl, (b) aryl, (c) arylalkyl, where the alkylene group comprises one to six carbon atoms, and (d) hydroxyl; (29) S(O).sub.2R.sup.E, where R.sup.E is selected from the group consisting of (a) alkyl, (b) aryl, (c) arylalkyl, where the alkylene group comprises one to six carbon atoms, and (d) hydroxyl; (30) S(O).sub.2NR.sup.FR.sup.G, where each of R.sup.F and R.sup.G is independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; and (31) NR.sup.HR.sup.I, where each of R.sup.H and R.sup.I is independently selected from the group consisting of (a) hydrogen; (b) an N-protecting group; (c) alkyl of one to six carbon atoms; (d) alkenyl of two to six carbon atoms; (e) alkynyl of two to six carbon atoms; (f) aryl; (g) arylalkyl, where the alkylene group comprises one to six carbon atoms; (h) cycloalkyl of three to eight carbon atoms, (i) alkcycloalkyl, where the cycloalkyl group comprises three to eight carbon atoms, and the alkylene group comprises one to ten carbon atoms, (j) alkanoyl of one to six carbon atoms, (k) aryloyl of 6 to 10 carbon atoms, (l) alkylsulfonyl of one to six carbon atoms, and (m) arylsulfonyl of 6 to 10 carbons atoms, with the proviso that no two groups are bound to the nitrogen atom through a carbonyl group or a sulfonyl group.

(85) The term aryl as used herein, represents mono- and/or bicyclic carbocyclic ring systems and/or multiple rings fused together and is exemplified by phenyl, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl, indenyl and the like and may be optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of: (1) alkanoyl of one to six carbon atoms; (2) alkyl of one to six carbon atoms; (3) alkoxy of one to six carbon atoms; (4) alkoxyalkyl, where the alkyl and alkylene groups independently comprise from one to six carbon atoms; (5) alkylsulfinyl of one to six carbon atoms; (6) alkylsulfinylalkyl, where the alkyl and alkylene groups independently comprise from one to six carbon atoms; (7) alkylsulfonyl of one to six carbon atoms; (8) alkylsulfonylalkyl, where the alkyl and alkylene groups are independently comprised of one to six carbon atoms; (9) aryl; (10) arylalkyl, where the alkyl group comprises one to six carbon atoms; (11) amino; (12) aminoalkyl of one to six carbon atoms; (13) aryl; (14) arylalkyl, where the alkylene group comprises one to six carbon atoms; (15) aryloyl; (16) azido; (17) azidoalkyl of one to six carbon atoms; (18) carboxaldehyde; (19) (carboxaldehyde)alkyl, where the alkylene group comprises one to six carbon atoms; (20) cycloalkyl of three to eight carbon atoms; (21) alkcycloalkyl, where the cycloalkyl group comprises three to eight carbon atoms and the alkylene group comprises one to ten carbon atoms; (22) halo; (23) haloalkyl of one to six carbon atoms; (24) heterocyclyl; (25) (heterocyclyl)oxy; (26) (heterocyclyl)oyl; (27) hydroxy; (28) hydroxyalkyl of one to six carbon atoms; (29) nitro; (30) nitroalkyl of one to six carbon atoms; (31) N-protected amino; (32) N-protected aminoalkyl, where the alkylene group comprises one to six carbon atoms; (33) oxo; (34) thioalkoxy of one to six carbon atoms; (35) thioalkoxyalkyl, where the alkyl and alkylene groups independently comprise from one to six carbon atoms; (36) (CH.sub.2).sub.qCO.sub.2R.sup.A, where q is an integer ranging from zero to four and R.sup.A is selected from the group consisting of (a) alkyl, (b) aryl, and (c) arylalkyl, where the alkylene group comprises one to six carbon atoms; (37) (CH.sub.2).sub.qC(O)NR.sup.BR.sup.C, where R.sup.B and R.sup.C are independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl, and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; (38) (CH.sub.2).sub.qS(O).sub.2R.sup.D, where R.sup.D is selected from the group consisting of (a) alkyl, (b) aryl, and (c) arylalkyl, where the alkylene group comprises one to six carbon atoms; (39) (CH.sub.2).sub.qS(O).sub.2NR.sup.ER.sup.F, where each of R.sup.E and R.sup.F is independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl, and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; (40) (CH.sub.2).sub.qNR.sup.GR.sup.H, where each of R.sup.G and R.sup.H is independently selected from the group consisting of (a) hydrogen; (b) an N-protecting group; (c) alkyl of one to six carbon atoms; (d) alkenyl of two to six carbon atoms; (e) alkynyl of two to six carbon atoms; (f) aryl; (g) arylalkyl, where the alkylene group comprises one to six carbon atoms; (h) cycloalkyl of three to eight carbon atoms, and (i) alkcycloalkyl, where the cycloalkyl group comprises three to eight carbon atoms, and the alkylene group comprises one to ten carbon atoms, with the proviso that no two groups are bound to the nitrogen atom through a carbonyl group or a sulfonyl group; (41) oxo; (42) thiol; (43) perfluoroalkyl; (44) perfluoroalkoxy; (45) aryloxy; (46) cycloalkoxy; (47) cycloalkylalkoxy; and (48) arylalkoxy.

(86) As used herein, the term alkylaryl represents an aryl group attached to the parent molecular group through an alkyl group.

(87) The term cycloalkyl as used herein, represents a monovalent saturated or unsaturated non-aromatic cyclic hydrocarbon group of three to eight carbon atoms, unless otherwise specified, and is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptyl and the like. The cycloalkyl groups of the present disclosure can be optionally substituted with: (1) alkanoyl of one to six carbon atoms; (2) alkyl of one to six carbon atoms; (3) alkoxy of one to six carbon atoms; (4) alkoxyalkyl, where the alkyl and alkylene groups independently comprise from one to six carbon atoms; (5) alkylsulfinyl of one to six carbon atoms; (6) alkylsulfinylalkyl, where the alkyl and alkylene groups independently comprise from one to six carbon atoms; (7) alkylsulfonyl of one to six carbon atoms; (8) alkylsulfonylalkyl, where the alkyl and alkylene groups independently comprise from one to six carbon atoms; (9) aryl; (10) arylalkyl, where the alkyl group comprises one to six carbon atoms; (11) amino; (12) aminoalkyl of one to six carbon atoms; (13) aryl; (14) arylalkyl, where the alkylene group comprises one to six carbon atoms; (15) aryloyl; (16) azido; (17) azidoalkyl of one to six carbon atoms; (18) carboxaldehyde; (19) (carboxaldehyde)alkyl, where the alkylene group comprises one to six carbon atoms; (20) cycloalkyl of three to eight carbon atoms; (21) alkcycloalkyl, where the cycloalkyl group comprises three to eight carbon atoms and the alkylene group comprises one to ten carbon atoms; (22) halo; (23) haloalkyl of one to six carbon atoms; (24) heterocyclyl; (25) (heterocyclyl)oxy; (26) (heterocyclyl)oyl; (27) hydroxy; (28) hydroxyalkyl of one to six carbon atoms; (29) nitro; (30) nitroalkyl of one to six carbon atoms; (31) N-protected amino; (32) N-protected aminoalkyl, where the alkylene group comprises one to six carbon atoms; (33) oxo; (34) thioalkoxy of one to six carbon atoms; (35) thioalkoxyalkyl, where the alkyl and alkylene groups independently comprise from one to six carbon atoms; (36) (CH.sub.2).sub.qCO.sub.2R.sup.A, where q is an integer ranging from zero to four and R.sup.A is selected from the group consisting of (a) alkyl, (b) aryl, and (c) arylalkyl, where the alkylene group comprises one to six carbon atoms; (37) (CH.sub.2).sub.qC(O)NR.sup.BR.sup.C, where each of R.sup.B and R.sup.C is independently selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl, and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; (38) (CH.sub.2).sub.qS(O).sub.2R.sup.D, where R.sup.D is selected from the group consisting of (a) alkyl, (b) aryl, and (c) arylalkyl, where the alkylene group comprises one to six carbon atoms; (39) (CH.sub.2).sub.qS(O).sub.2NR.sup.ER.sup.F, where each of R.sup.E and R.sup.F is independently, selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl, and (d) arylalkyl, where the alkylene group comprises one to six carbon atoms; (40) (CH.sub.2).sub.qNR.sup.GR.sup.H, where each of R.sup.G and R.sup.H is independently selected from the group consisting of (a) hydrogen; (b) an N-protecting group; (c) alkyl of one to six carbon atoms; (d) alkenyl of two to six carbon atoms; (e) alkynyl of two to six carbon atoms; (f) aryl; (g) arylalkyl, where the alkylene group comprises one to six carbon atoms; (h) cycloalkyl of three to eight carbon atoms and (i) alkcycloalkyl, where the cycloalkyl group comprises three to eight carbon atoms, and the alkylene group comprises one to ten carbon atoms, with the proviso that no two groups are bound to the nitrogen atom through a carbonyl group or a sulfonyl group; (41) oxo; (42) thiol; (43) perfluoroalkyl; (44) perfluoroalkoxy; (45) aryloxy; (46) cycloalkoxy; (47) cycloalkylalkoxy; and (48) arylalkoxy.

(88) The term halogen or halo as used interchangeably herein, represents F, Cl, Br and I.

(89) The term heteroatom as used herein, is understood as being oxygen, sulfur or nitrogen.

(90) The term carbonyl as used herein, represents a C(O) group, which can also be represented as CO.

(91) The terms acyl or alkanoyl as used interchangeably herein, represent an alkyl group, as defined herein, or hydrogen attached to the parent molecular group through a carbonyl group, as defined herein, and is exemplified by formyl, acetyl, propionyl, butanoyl and the like. Exemplary unsubstituted acyl groups comprise from 2 to 10 carbons.

(92) The term analogue as used herein, is understood as being a substance similar in structure to another compound but differing in some slight structural detail.

(93) The term salt(s) as used herein, is understood as being acidic and/or basic salts formed with inorganic and/or organic acids or bases. Zwitterions (internal or inner salts) are understood as being included within the term salt(s) as used herein, as are quaternary ammonium salts such as alkylammonium salts. Nontoxic, pharmaceutically acceptable salts are preferred, although other salts may be useful, as for example in isolation or purification steps. Examples of acid addition salts include but are not limited to acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, phosphoric, 2-hydroxyethanesulfonate, lactate, maleate, mandelate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Examples of base addition salts include but are not limited to alkali metal salts and alkaline earth metal salts. Non limiting examples of alkali metal salts include lithium, sodium and potassium salts. Non-limiting examples of alkaline earth metal salts include magnesium and calcium salts.

(94) The term immune disorder as used herein, is understood as a dysfunction of the immune system. The disorder may be characterized in several ways. For example by dysfunctional component(s) of the immune system, or by whether the immune system is overactive or underactive, or by whether the immune function is weakened or impaired or evaded, or by whether immune tolerance is dysfunctional, or by whether the condition is congenital or acquired.

(95) The term autoimmune disease as used herein, is understood as a disease which arises from abnormal immune response of the body against some of its own substances or tissues as though they were foreign substances or tissues.

(96) The inventors have designed and prepared novel chemical compounds. The compounds according to the invention may be used in the treatment of medical conditions involving GATA2; ERG, ETV1 or other immune disorders; STING and/or KRAS mutants. Such medical conditions may, for example, be various types of cancer or medical conditions with immune disorders.

(97) In an aspect, compounds according to the invention are GATA2 inhibitors. As such they may be used in the treatment of: KRAS mutant cancers, for example, KRAS mutant NSCLC and KRAS mutant colon cancer; prostate cancer, both AR positive prostate cancer and AR negative prostate cancer; leukemia; breast cancer including triple negative breast cancer and melanoma.

(98) In another aspect, compounds according to the invention are ERG inhibitors. As such, they may be used in the treatment of: prostate cancer including TMPRSS2-ERG positive prostate cancer; leukemia.

(99) In yet another aspect compounds according to the invention are ETV1 inhibitors. As such, they may be used in the treatment of: p53-negative or p-53 defective human cancers; prostate cancer including TMPRSS2-ETV1 positive cancer; gastrointestinal stromal tumors (GIST).

(100) In yet another aspect, compounds of the invention are STING agonists. As such, they may be used as immunotherapy for cancer patients or as stimulants in patients undergoing cancer treatment.

(101) In yet another aspect, compounds of the invention are direct inhibitors of various KRAS mutants including but not limited to G12D, G12C, G12V and G13D. As such, they may be used in the treatment of pancreatic cancer, lung cancer, colorectal cancer and other KRAS mutant-driven cancers.

(102) The present invention is illustrated in further details by the following non-limiting examples.

(103) Chemistry

(104) Compounds according to embodiments of the invention have a general formula I or formula I illustrated in FIG. 5.

Example 1Preparation of Certain Intermediate Compounds Used the Preparation of Compounds According to the Invention

(105) Scheme 1 below outlines the chemical synthesis of certain compounds that are intermediates in the various chemical syntheses of the compounds according to the invention. In particular, Scheme 1 outlines the chemical synthesis of Intermediates 4-25 shown in Table 1 below.

(106) ##STR00029##
Preparation of Intermediates 4-25.

(107) Preparation of the catalyst compound 3: It was prepared according to the literature procedures with modification..sup.60 A mixture of N-methylbenzimidazole (6.6 g, 50 mmol) and 1,12-dibromododecane (8.4 g, 25 mmol) in acetonitrile (100 mL) was refluxed for 24 hours. After cooling, the white precipitate 3 was collected by filtration, which was pure enough without further purification. Yield: 81.3%.

(108) General procedure for the preparation of Intermediates 4-25:

(109) Method (a): Intermediates 4-25 were synthesized according to the literature procedures with modifications as illustrated in Scheme 1..sup.60 Aryl aldehydes 1 (5 mmol) and 2 (5 mmol) was added to 10 mL water. Then catalyst 3 (10 mol %) and DBU (20 mol %) were added. The reaction mixture was stirred at room temperature vigorously for 3-6 hours. Dichloromethane was added. The combined organic phase was washed with brine, dried over Na.sub.2SO.sub.4 and concentrated under reduced pressure to give the crude residue, which was purified by column chromatography to give the desired Intermediates 4-11, 13-21 and 23-25.

(110) Method (b): A mixture of NaCN (490 mg, 10 mmol, 1 equiv) in water (2 mL) was added to aryl aldehyde 1 (1362 mg, 10 mmol, 1 equiv) in ethanol (10 mL) at room temperature. The reaction mixture was heated to reflux for 4 hours and then quenched with water (20 mL) at ambient temperature. The resulting mixture was extracted with CH.sub.2Cl.sub.2 (20 mL3). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography to give the desired Intermediates 12 and 22.

(111) TABLE-US-00001 TABLE 1 Structures of Intermediates 4-25. ID Structure 4 0 5 6 7 8 9 10 11 12 13 14 0 15 16 17 18 19 20 21 22 23 24 0 25
Characterization of Intermediates 6-25:

(112) 6: Colorless crystal. Yield: 68%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.50-7.44 (m, 2H), 7.29 (t, J=8.0 Hz, 1H), 7.24 (t, J=8.0 Hz, 1H), 7.08-7.05 (m, 1H), 6.97-6.90 (m, 1H), 6.86-6.84 (m, 1H), 6.83-6.79 (m, 1H), 5.89 (d, J=5.9 Hz, 1H), 4.51 (d, J=6.1 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H).

(113) 7: White solid. Yield: 71%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.95-7.86 (m, 2H), 7.26-7.24 (m, 2H), 6.92-6.80 (m, 4H), 5.85 (d, J=6.0 Hz, 1H), 4.57 (dd, J=6.0, 1.0 Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H).

(114) 8: White solid. Yield: 67%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.71-7.70 (m, 1H), 7.63-7.56 (m, 2H), 7.55-7.48 (m, 2H), 7.44 (t, J=7.7 Hz, 1H), 7.40-7.38 (m, 1H), 6.93 (d, J=7.8 Hz, 1H), 6.11 (d, J=5.0 Hz, 1H), 4.41 (d, J=5.0, 1H).

(115) 9: White solid. Yield: 65%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.39 (s, 1H), 8.30 (s, 2H), 8.19 (d, J=7.8 Hz, 2H), 7.97-7.93 (m, 2H), 7.90-7.88 (m, 1H), 7.70 (t, J=7.8 Hz, 2H), 7.65 (t, J=7.8 Hz, 1H).

(116) 10: White solid. Yield: 60%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.93 (ddd, J=8.2, 5.2, 2.5 Hz, 2H), 7.30 (ddd, J=8.2, 5.2, 2.5 Hz, 2H), 7.15-7.06 (m, 2H), 7.06-6.98 (m, 2H), 5.89 (d, J=5.8 Hz, 1H), 4.50 (d, J=5.8 Hz, 1H).

(117) 11: White solid. Yield: 72%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.89-7.81 (m, 1H), 7.49-7.43 (m, 1H), 7.22-7.11 (m, 3H), 7.08-6.91 (m, 3H), 6.06-6.04 (m, 1H), 4.47-4.40 (m, 1H)

(118) 12: White solid, yield: 68.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.70-7.60 (m, 1H), 7.58-7.55 (m, 1H), 7.37 (td, J=8.0, 5.5 Hz, 1H), 7.28 (td, J=8.0, 5.5 Hz, 1H), 7.25-7.16 (m, 1H), 7.09 (d, J=7.7 Hz, 1H), 7.04-6.91 (m, 2H), 5.87 (d, J=6.0 Hz, 1H), 4.43 (d, J=6.1 Hz, 1H).

(119) 13: White solid, yield: 77.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.16 (d, J=8.2 Hz, 1H), 7.97 (d, J=8.1 Hz, 2H), 7.70-7.66 (m, 2H), 7.58 (d, J=8.1 Hz, 2H), 7.43 (d, J=8.1 Hz, 2H), 5.99 (s, 1H).

(120) 19: White solid. Yield: 83%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.79 (d, J=8.3 Hz, 2H), 7.21-7.13 (m, 4H), 7.09 (d, J=7.9 Hz, 2H), 5.86 (d, J=6.0 Hz, 1H), 4.51 (d, J=6.0 Hz, 1H), 2.32 (s, 3H), 2.26 (s, 3H).

(121) 20: White solid. Yield: 42%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.95 (d, J=7.2 Hz, 2H), 7.53-7.50 (m, 1H), 7.39 (t, J=7.8 Hz, 2H), 7.33-7.25 (m, 1H), 7.20 (d, J=7.6 Hz, 1H), 6.94-6.89 (m, 2H), 6.28 (s, 1H), 3.88 (s, 3H).

(122) 21: White solid. Yield: 77%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.70-7.65 (m, 1H), 7.38-7.34 (m, 1H), 7.21-7.17 (m, 1H), 7.17-7.13 (m, 1H), 6.94-6.90 (m, 1H), 6.85-6.82 (m, 1H), 6.78-6.74 (m, 2H), 6.10 (d, J=5.7 Hz, 1H), 4.46 (d, J=5.7 Hz, 1H), 3.73 (s, 3H), 3.71 (s, 3H).

(123) 22: White solid, yield: 32%..sup.1H NMR (500 MHz, cdcl.sub.3) 7.61-7.59 (m, 1H), 7.34-7.29 (m, 1H), 7.27-7.23 (m, 2H), 7.21 (d, J=7.7 Hz, 1H), 7.15-7.10 (m, 1H), 7.03-6.95 (m, 1H), 6.56-6.51 (m, 1H), 5.76 (s, 1H).

(124) 23: White solid, yield: 77.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.39 (br, 1H), 7.23 (t, J=7.9 Hz, 1H), 7.02-6.99 (m, 1H), 6.96 (d, J=7.6 Hz, 1H), 6.90-6.88 (m, 1H), 6.82-6.78 (m, 2H), 6.20-6.18 (m, 1H), 5.60 (d, J=5.9 Hz, 1H), 4.41 (t, J=5.9 Hz, 1H), 3.75 (s, 3H).

(125) 24: White solid, yield: 54%..sup.1H NMR (500 MHz, CDCl.sub.3) 7.58-7.57 (m, 1H), 7.30-7.25 (m, 1H), 7.22-7.21 (m, 1H), 7.02-6.97 (m, 1H), 6.93-6.92 (m, 1H), 6.85-6.82 (m, 1H), 6.51-6.47 (m, 1H), 5.72 (s, 1H), 4.33 (br, 1H), 3.78 (s, 3H).

(126) 25: White solid, yield: 55%..sup.1H NMR (500 MHz, CDCl.sub.3) 7.59 (d, J=4.8 Hz, 1H), 7.40-7.30 (m, 1H), 7.24-7.21 (m, 2H), 6.51 (s, 1H), 6.43-6.36 (m, 1H), 6.33 (s, 1H), 5.77 (d, J=5.4 Hz, 1H).

Example 2Preparation of Compounds of Class Ia, Class Ib, Class Ic and Class Id

(127) Schemes 2-6 below outline the chemical synthesis of compounds identified as Class Ia. These compounds are shown in Table 2 below.

(128) ##STR00052##

(129) Compounds of Class Ia may be prepared by typical methods as illustrated in Scheme 2. The appropriate benzoin 4-19 is condensed with substituted indole acid 26, the intermediate ester 27 is obtained, which is then followed by the reaction with ammonium acetate in acetic acid under reflux for 2 hours to generate the desired products, compounds of Class Ia: 708, 630-632, 636-641, 649-663, 670-673, 677-679, 681, 696, 761, 762.

(130) ##STR00053##

(131) ##STR00054##

(132) Similarly, compounds of Class Ib and Ic may be prepared by the same method used for the preparation of the compounds of Class Ia as illustrated in Scheme 3 and Scheme 4. Compounds 700, 770, 866 and 857 were obtained.

(133) ##STR00055##

(134) ##STR00056##

(135) Several of the compounds of Class Ia prepared according to Scheme 2 were subject to additional transformations as indicated in Scheme 5 and Scheme 6. As illustrated in Scheme 5, by acylation of compounds of Class Ia, compounds of Class Id, for example compound 720, were obtained. Through demethylation of appropriate compounds of Class Ia with BBr.sub.3 as illustrated in Scheme 6, demethylated products, compounds of Class Ia: 648, 698, 675, 676, 697, 699, 718, 719, 891, 924, 925, 931, 936 were obtained.

(136) General Procedure for the Preparation of Intermediate Compound 27 as Illustrated in Scheme 2, Intermediate 28 as Illustrated in Scheme 3, and Intermediate 30 as Illustrated in Scheme 4.

(137) To a vacuum flame-dried flask was added 4-19 (1 mmol), acid 26 (or 29) (1.1 mmol), dicyclohexylcarbodiimide (0.206 g, 1 mmol), 4-dimethylaminopyridine (12.2 mg, 0.1 mmol), dichloromethane (10 mL) under nitrogen atmosphere. The reaction mixture was stirred for 2 hours at room temperature. Then ethyl acetate was added and the reaction mixture was filtered. The filtrate was then washed with 5% HCl, saturated NaHCO.sub.3, brine and dried with Na.sub.2SO.sub.4. After filtration, the solvent was concentrated in vacuum. This crude residue was then purified by flash chromatography to give Intermediate 27 (28 or 30).

(138) General Procedure for the Preparation of Compounds of Classes Ia-Ic as Illustrated in Schemes 2-4.

(139) A mixture of 27 (28 or 30) (0.5 mmol), ammonium acetate (2.5 mmol) in glacial acetic acid (5 mL) was refluxed for 2 hours. After cooling, water was added to the reaction mixture. After extracting with ethyl acetate, the combined organic phase was washed with saturated NaHCO.sub.3, brine, dried with Na.sub.2SO.sub.4, filtered, and concentrated in vacuum. The crude residue was then purified by flash chromatography to give the desired products, compounds of Classes Ia-Ic: 708, 630-632, 636-641, 649-663, 670-673, 677-679, 681, 696, 761, 762, 892, 916, 917, 932.

(140) General Procedure for the Preparation of Compounds of Class Id as Illustrated in Scheme 5.

(141) To a mixture of compounds of Class Ia (1 mmol), n-Bu.sub.4NHSO.sub.4 (7 g, 0.018 mmol) and powered NaOH (0.99 g, 25 mmol) in CH.sub.2Cl.sub.2 (10 mL), acetyl chloride (0.11 mL, 1.5 mmol) in CH.sub.2Cl.sub.2 (6 mL) was added dropwise to the vigorously stirring solution. After 2 hours at room temperature, TLC showed complete consumption of the 708. After removal of the solvent, the crude residue was purified by flash chromatography on silica gel to give compound 720 (0.332 g, 85%).

(142) General Procedure for the Preparation of Demethylated Compounds of Class Ia as Illustrated in Scheme 6.

(143) To a mixture of an appropriate compound of Class Ia (1 mmol) in dry dichloromethane (10 mL) at 0 C. under N.sub.2, BBr.sub.3 (1M in dichloromethane, 3.5 mL, 3.5 mmol) was added dropwise. The resulting mixture was allowed to warm to room temperature and stirred for 4 hours. Then ice water (50 mL) was added to quench the reaction and extracted with CH.sub.2Cl.sub.2 (315 mL). The combined organic phase was washed with water, brine and dried over magnesium sulfate. After removal of the solvent, the crude residue was purified by column chromatography to give the desired products, compounds of Class Ia: 648, 698, 675, 676, 697, 699, 718, 719, 891, 924, 925, 931, 936.

(144) TABLE-US-00002 TABLE 2 Structures of compounds of Classes Ia-Id. ID Structure 679 649 658 935 0 648 698 630 660 719 718 699 697 891 892 0 708 700 636 637 638 639 720 655 650 652 0 651 654 659 656 653 662 663 661 696 631 0 657 641 917 932 933 931 936 675 918 920 00 761 01 866 02 924 03 673 04 678 05 671 06 770 07 762 08 632 09 640 0 670 916 676 677 681 672 925 857

(145) Characterization of Compounds of Classes Ia-Id:

(146) 679: White solid, yield: 43.2%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 8.50 (s, 1H), 8.44-8.35 (m, 1H), 7.96 (d, J=2.8 Hz, 1H), 7.79-7.73 (m, 2H), 7.73-7.66 (m, 2H), 7.48-7.25 (m, 9H).

(147) 649: White solid, yield: 53.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.44-8.37 (m, 1H), 7.86 (s, 1H), 7.81-7.76 (m, 2H), 7.73-7.69 (m, 2H), 7.45-7.29 (m, 9H), 3.89 (s, 3H).

(148) 658: White solid, yield: 44.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.67 (d, J=2.2 Hz, 1H), 8.88 (d, J=1.9 Hz, 1H), 8.22-8.15 (m, 1H), 7.98-7.91 (m, 1H), 7.84-7.70 (m, 5H), 7.64-7.61 (m, 1H), 7.49-7.35 (m, 6H).

(149) 935: White solid, yield: 47.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.77 (br, 1H), 8.16-8.09 (m, 1H), 7.82 (s, 2H), 7.72 (d, J=2.7 Hz, 1H), 7.69 (d, J=7.5 Hz, 2H), 7.55 (d, J=7.8 Hz, 2H), 7.44 (t, J=7.8 Hz, 2H), 7.41-7.39 (m, 1H), 7.29-7.26 (m, 2H).

(150) 648: White solid, yield: 92.5%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 10.16 (br, 1H), 8.50 (s, 1H), 8.36 (s, 1H), 7.72 (d, J=7.8 Hz, 1H), 7.39 (d, J=7.8 Hz, 2H), 7.20 (dd, J=15.7, 7.8 Hz, 2H), 7.17-7.15 (m, 1H), 7.15-7.08 (m, 2H), 7.08-6.99 (m, 3H), 6.87-6.75 (m, 2H), 4.31 (s, 2H). MS (ESI) m/z Found: 383.1 [M+H].sup.+, Calcd: 383.4.

(151) 698: White solid, yield: 55%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 10.14 (br, 1H), 8.68 (s, 1H), 8.49 (s, 1H), 7.73 (d, J=7.9 Hz, 1H), 7.53-7.46 (m, 2H), 7.44-7.35 (m, 4H), 7.18-7.08 (m, 1H), 7.06-7.03 (m, 1H), 6.92-6.81 (m, 4H), 4.30 (s, 2H).

(152) 630: White solid, yield: 89.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.30 (br, 1H), 7.79 (d, J=7.7 Hz, 1H), 7.34 (d, J=8.0 Hz, 1H), 7.30-7.12 (m, 8H), 7.09 (s, 1H), 6.92-6.81 (m, 2H), 4.39 (s, 2H), 3.76 (s, 3H), 3.72 (s, 3H).

(153) 660: White solid, yield: 76%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.09 (br, 1H), 7.76 (d, J=7.8 Hz, 1H), 7.55-7.49 (m, 2H), 7.46-7.40 (m, 2H), 7.34 (d, J=7.2 Hz, 1H), 7.22-7.16 (m, 2H), 7.16-7.11 (m, 1H), 6.89-6.78 (m, 4H), 4.29 (s, 2H), 3.80 (s, 3H), 3.78 (s, 3H).

(154) 719: White solid, yield: 17%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 10.17 (s, 1H), 8.52 (s, 1H), 7.74-7.73 (m, 1H), 7.42-7.38 (m, 2H), 7.32-7.26 (m, 1H), 7.25-7.20 (m, 3H), 7.12-7.10 (m, 1H), 7.08-7.03 (m, 3H), 6.92-6.88 (m, 1H), 6.84-6.82 (m, 1H), 4.33 (s, 2H), 3.75 (s, 3H).

(155) 718: White solid, yield: 13%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 10.17 (s, 1H), 8.38 (s, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.41-7.40 (m, 2H), 7.30 (t, J=8.0 Hz, 1H), 7.21 (t, J=8.0 Hz, 1H), 7.19-7.17 (m, 1H), 7.16-7.10 (m, 4H), 7.07-7.04 (m, 1H), 6.92-6.90 (m, 1H), 6.84-6.80 (m, 1H), 4.33 (d, J=0.8 Hz, 2H), 3.73 (s, 3H).

(156) 699: Yellow syrup, yield: 17%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 10.14 (br, 1H), 7.72 (d, J=7.9 Hz, 1H), 7.58-7.52 (m, 2H), 7.42-7.32 (m, 4H), 7.11-7.08 (m, 1H), 7.06-6.99 (m, 1H), 6.97-6.89 (m, 2H), 6.89-6.80 (m, 2H), 4.29 (s, 2H), 3.81 (s, 3H).

(157) 697: White solid, yield: 14%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 10.14 (br, 1H), 8.52 (s, 1H), 7.73 (d, J=7.9 Hz, 1H), 7.50-7.43 (m, 4H), 7.39-7.36 (m, 2H), 7.13-7.08 (m, 1H), 7.06-7.02 (m, 1H), 6.96-6.90 (m, 2H), 6.88-6.81 (m, 2H), 4.29 (s, 2H), 3.80 (s, 3H).

(158) 891: Colorless crystal, yield: 57%..sup.1H NMR (500 MHz, acetone-d.sub.6) 11.15 (s, 1H), 10.20 (br, 1H), 8.69 (s, 1H), 7.76-7.65 (m, 1H), 7.42-7.40 (m, 2H), 7.39-7.36 (m, 2H), 7.16-7.07 (m, 3H), 7.07-7.02 (m, 2H), 7.02-6.96 (m, 1H), 6.86-6.81 (m, 1H), 6.61-6.58 (m, 1H), 4.43 (d, J=0.8 Hz, 2H).

(159) 892: White solid, yield: 69%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.12 (s, 1H), 7.81 (d, J=7.2 Hz, 1H), 7.56 (dd, J=7.6, 1.8 Hz, 1H), 7.37 (dd, J=7.6, 1.8 Hz, 1H), 7.36-7.33 (m, 1H), 7.29-7.24 (m, 2H), 7.24-7.21 (m, 1H), 7.17-7.12 (m, 1H), 6.97-6.94 (td, J=7.5, 1.0 Hz, 1H), 6.91 (td, J=7.5, 1.0 Hz, 1H), 6.82-6.79 (m, 2H), 4.35 (s, 2H), 3.37 (s, 6H).

(160) 708: White solid, yield: 87.6%. .sup.1H NMR (500 MHz, CDCl.sub.3), 8.32 (d, J=21.5 Hz, 1H), 7.77 (d, J=7.6 Hz, 1H), 7.66-7.60 (m, 2H), 7.53-7.50 (m, 2H), 7.39-7.25 (m, 7H), 7.22-7.09 (m, 3H), 4.43 (s, 1H), 4.39 (s, 1H). MS (ESI) m/z Found: 351.1 [M+H].sup.+, Calcd: 351.4.

(161) 700: White solid, yield: 65%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 9.51 (br, 1H), 7.66-7.59 (m, 2H), 7.56-7.53 (m, 2H), 7.45-7.31 (m, 5H), 7.24 (d, J=7.6 Hz, 1H), 7.19 (t, J=7.7 Hz, 1H), 6.95-6.91. (m, 2H), 4.01 (dd, J=8.2, 5.0 Hz, 1H), 3.61 (dd, J=16.0, 5.0 Hz, 1H), 3.29 (dd, J=16.0, 8.2 Hz, 1H), 2.80 (d, J=17.0 Hz, 3H). MS (ESI) m/z Found: 367.1 [M+H].sup.+, Calcd: 367.4.

(162) 636: White solid, yield 82.5%. C.sub.24H.sub.17FN.sub.2O, .sup.1H NMR (500 MHz, CDCl.sub.3) 8.15 (s, 1H), 7.68-7.62 (m, 2H), 7.60-7.52 (m, 2H), 7.44 (dd, J=9.6, 2.4 Hz, 1H), 7.40-7.27 (m, 8H), 6.96 (td, J=9.0, 2.5 Hz, 1H), 4.30 (s, 2H).

(163) 637: White solid, yield: 79.5%. C.sub.25H.sub.20N.sub.2O, .sup.1H NMR (500 MHz, CDCl.sub.3) 7.87 (br, 1H), 7.72-7.70 (m, 1H), 7.65-7.60 (m, 2H), 7.53-7.47 (m, 2H), 7.39-7.27 (m, 6H), 7.16-7.09 (m, 2H), 4.27 (s, 2H), 2.52 (s, 3H).

(164) 638: Colorless syrup, yield: 68.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.78 (d, J=7.9 Hz, 1H), 7.65-7.63 (m, 2H), 7.56-7.51 (m, 2H), 7.38-7.22 (m, 8H), 7.18-7.13 (m, 1H), 7.10 (s, 1H), 4.33 (s, 2H), 3.76 (s, 3H).

(165) 639: White solid, yield: 62.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.77 (s, 1H), 7.65-7.59 (m, 2H), 7.54-7.49 (m, 2H), 7.40-7.27 (m, 6H), 7.17 (t, J=5.7 Hz, 2H), 6.78 (dd, J=8.7, 2.5 Hz, 1H), 4.23 (s, 2H), 3.85 (s, 3H), 2.50 (s, 3H).

(166) 720: White solid, yield: 65%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.46 (d, J=7.6 Hz, 1H), 7.73-7.72 (m, 1H), 7.69-7.64 (m, 2H), 7.60-7.57 (m, 1H), 7.56-7.52 (m, 2H), 7.43-7.31 (m, 8H), 4.36 (s, 2H), 2.64 (s, 3H).

(167) 655: White solid, yield: 77.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.11 (br, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.67 (td, J=7.6, 1.8 Hz, 1H), 7.43 (td, J=7.6, 1.8 Hz, 1H), 7.36-7.33 (m, 1H), 7.31-7.26 (m, 2H), 7.23-7.14 (m, 4H), 7.13-7.09 (m, 1H), 7.05-6.98 (m, 2H), 4.36 (s, 2H).

(168) 650: White solid, yield: 76.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.08 (br, 1H), 7.78-7.72 (m, 1H), 7.40-7.25 (m, 5H), 7.23-7.19 (m, 2H), 7.17-7.14 (m, 1H), 7.04-6.94 (m, 2H), 4.32 (s, 2H).

(169) 652: White solid, yield: 83.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.08 (br, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.72 (d, J=8.0 Hz, 2H), 7.62-7.59 (m, 4H), 7.57 (d, J=8.6 Hz, 2H), 7.39-7.35 (m, 1H), 7.24 (d, J=2.3 Hz, 1H), 7.21-7.19 (m, 1H), 7.17-7.14 (m, 1H), 4.35 (s, 2H).

(170) 651: White solid, yield: 88.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.06 (br, 1H), 7.76 (d, J=7.6, 1H), 7.49 (s, 1H), 7.41-7.33 (m, 3H), 7.33-7.28 (m, 1H), 7.22-7.12 (m, 5H), 7.12-7.03 (m, 2H), 4.32 (s, 2H), 2.32 (s, 3H), 2.28 (s, 3H).

(171) 654: White solid, yield: 83.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.06 (br, 1H), 7.77-7.75 (m, 1H), 7.52-7.47 (m, 2H), 7.43-7.38 (m, 2H), 7.36-7.30 (m, 1H), 7.22-7.16 (m, 2H), 7.16-7.07 (m, 5H), 4.30 (s, 2H), 2.33 (s, 3H), 2.32 (s, 3H).

(172) 659: White solid, yield: 63%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.02 (br, 1H), 7.85-7.80 (m, 1H), 7.68 (d, J=7.9 Hz, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.60-7.57 (m, 1H), 7.55 (t, J=7.6 Hz, 1H), 7.50-7.42 (m, 4H), 7.31 (d, J=8.1 Hz, 1H), 7.18-7.15 (m, 1H), 7.1-7.12 (m, 2H), 7.09-7.15 (m, 1H), 3.95-3.79 (m, 2H).

(173) 656: Yellow syrup, yield: 66.9%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.10 (br, 1H), 7.90 (s, 1H), 7.77 (d, J=8.1 Hz, 3H), 7.64 (d, J=7.8 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.54 (d, J=7.8 Hz, 1H), 7.46 (t, J=7.8 Hz, 1H), 7.43 (t, J=7.8 Hz, 1H), 7.36 (d, J=8.1 Hz, 1H), 7.24 (d, J=2.3 Hz, 1H), 7.23-7.13 (m, 2H), 4.35 (s, 2H).

(174) 653: White solid, yield: 82.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.09 (br, 1H), 7.75 (d, J=8.2 Hz, 1H), 7.61-7.52 (m, 2H), 7.50-7.41 (m, 2H), 7.38-7.32 (m, 1H), 7.23-7.18 (m, 2H), 7.16-7.13 (m, 1H), 7.08-6.93 (m, 4H), 4.31 (s, 2H).

(175) 662: Yellow solid, yield: 79%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.08 (br, 1H), 7.77-7.72 (m, 1H), 7.64-7.63 (m, 1H), 7.52-7.50 (m, 1H), 7.46-7.42 (m, 1H), 7.39-7.32 (m, 2H), 7.31-7.23 (m, 4H), 7.23-7.18 (m, 2H), 7.17-7.14 (m, 1H), 4.32 (s, 2H).

(176) 663: White solid, yield: 82%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.08 (br, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.40-7.36 (m, 1H), 7.36-7.32 (m, 2H), 7.27-7.23 (m, 3H), 7.23-7.17 (m, 4H), 7.17-7.11 (m, 2H), 4.37 (s, 2H).

(177) 661: White solid, yield: 76%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.07 (br, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.54-7.49 (m, 2H), 7.44-7.38 (m, 2H), 7.35 (d, J=8.1 Hz, 1H), 7.33-7.25 (m, 4H), 7.22-7.18 (m, 2H), 7.14-7.12 (m, 1H), 4.31 (s, 2H).

(178) 696: White solid, yield: 65%. .sup.1H NMR (500 MHz, cdcl.sub.3) 8.31 (br, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.57-7.56 (m, 2H), 7.45-7.34 (m, 3H), 7.33-7.23 (m, 4H), 7.20 (t, J=7.5 Hz, 1H), 7.15 (t, J=7.5 Hz, 1H), 7.02-6.96 (m, 1H), 6.94 (d, J=8.3 Hz, 1H), 4.51-4.47 (m, 2H), 3.54 (s, 3H).

(179) 631: White solid, yield: 82.7%. .sup.1H NMR (500 MHz, CDCl.sub.3), 8.09 (br, 1H), 7.66-7.58 (m, 3H), 7.51-7.49 (m, 2H), 7.40-7.28 (m, 7H), 7.19-7.14 (m, 1H), 7.11-7.18 (m, 2H), 3.44-3.24 (m, 4H).

(180) 657: Yellow solid, yield: 55.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.44 (s, 1H), 8.05-8.00 (m, 1H), 7.83 (d, J=16.4 Hz, 1H), 7.75-7.65 (m, 4H), 7.52-7.26 (m, 10H), 7.05 (d, J=16.4 Hz, 1H).

(181) 641: White solid, yield: 86.3%..sup.1H NMR (500 MHz, CDCl.sub.3) 8.00 (br, 1H), 7.65-7.59 (m, 1H), 7.36-7.31 (m, 1H), 7.28-7.02 (m, 9H), 6.87-6.82 (m, 2H), 3.76 (s, 3H), 3.72 (s, 3H), 3.37-3.28 (m, 2H), 3.28-3.18 (m, 2H).

(182) 917: Colorless syrup, yield: 67%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.01 (br, 1H), 7.65 (d, J=6.8 Hz, 1H), 7.5-7.55 (m, 1H), 7.40-7.34 (m, 2H), 7.33-7.24 (m, 2H), 7.23-7.16 (m, 1H), 7.16-7.07 (m, 2H), 6.99-6.93 (m, 2H), 6.85-6.81 (m, 2H), 3.42 (s, 3H), 3.40 (s, 3H), 3.36-3.32 (m, 2H), 3.29-3.23 (m, 2H).

(183) 932: White solid, yield: 83.1%..sup.1H NMR (500 MHz, CDCl.sub.3) 8.04 (br, 1H), 7.64 (d, J=7.9 Hz, 1H), 7.59-7.53 (m, 2H), 7.48-7.44 (m, 2H), 7.35 (d, J=8.1 Hz, 1H), 7.22-7.16 (m, 1H), 7.15-7.09 (m, 1H), 7.05-7.04 (m, 1H), 6.92-6.85 (m, 4H), 3.83 (s, 3H), 3.82 (s, 3H), 3.34-3.31 (m, 2H), 3.25-3.19 (m, 2H).

(184) 933: White solid, yield: 77.6%..sup.1H NMR (500 MHz, CDCl.sub.3) 8.00 (br, 1H), 7.92 (s, 1H), 7.79 (d, J=7.7 Hz, 1H), 7.75 (s, 1H), 7.67-7.57 (m, 4H), 7.52-7.45 (m, 2H), 7.40-7.36 (m, 1H), 7.23-7.18 (m, 1H), 7.15-7.10 (m, 1H), 7.09-9.08 (m, 1H), 3.40-3.32 (m, 2H), 3.30-3.26 (m, 2H).

(185) 931: White solid, yield: 77.6%..sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.00 (s, 1H), 8.01 (br, 1H), 7.61-7.56 (m, 1H), 7.41-7.33 (m, 3H), 7.24-7.17 (m, 2H), 7.16-7.10 (m, 2H), 7.07 (d, J=2.4 Hz, 1H), 7.00 (dddd, J=6.2, 3.8, 3.0, 1.2 Hz, 3H), 6.72-6.99 (m, 1H), 3.38-3.32 (m, 2H), 3.31-3.26 (m, 2H).

(186) 936: White solid, yield: 83.6%..sup.1H NMR (500 MHz, Acetone-d.sub.6) 9.99 (br, 1H), 8.66 (br, 1H), 8.47 (br, 1H), 7.64-7.57 (m, 1H), 7.51-7.45 (m, 2H), 7.42-7.34 (m, 3H), 7.25-7.19 (m, 1H), 7.11-7.08 (m, 1H), 7.06-6.98 (m, 1H), 6.92-6.81 (m, 4H), 3.33-3.26 (m, 2H), 3.20-3.13 (m, 2H).

(187) 675: Yellow syrup, yield: 85%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 10.00 (br, 1H), 8.53 (s, 1H), 8.39 (s, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.26-7.17 (m, 4H), 7.16-6.99 (m, 5H), 6.86-6.81 (m, 2H), 3.33-3.30 (m, 2H), 3.23-3.20 (m, 2H).

(188) 918: White solid, yield: 73%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.00 (br, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.61-7.56 (m, 2H), 7.50-7.44 (m, 2H), 7.36 (d, J=8.1 Hz, 1H), 7.22-7.18 (m, 1H), 7.14-7.10 (m, 1H), 7.10-7.01 (m, 5H), 3.35-3.31 (m, 2H), 3.26-3.21 (m, 2H).

(189) 920: White solid, yield: 81%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.93 (br, 1H), 7.90 (d, J=7.6 Hz, 1H), 7.71 (d, J=7.9 Hz, 1H), 7.65 (t, J=8.7 Hz, 2H), 7.61-7.51 (m, 4H), 7.33 (d, J=8.1 Hz, 1H), 7.20-7.15 (m, 1H), 7.13 (s, 1H), 7.12-7.05 (m, 1H), 6.97 (d, J=2.3 Hz, 1H), 3.16-3.06 (m, 2H), 2.91-2.81 (m, 2H).

(190) 761: White solid, yield: 84.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.03 (br, 1H), 7.6-7.57 (m, 1H), 7.44-7.24 (m, 6H), 7.19-7.16 (m, 2H), 7.12-6.98 (m, 4H), 3.35-3.24 (m, 4H).

(191) 866: White solid. Yield: 74%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66 (s, 1H), 7.38-7.27 (m, 5H), 7.26-7.15 (m, 3H), 7.06-6.97 (m, 3H), 6.85 (d, J=7.8 Hz, 1H), 3.66 (t, J=6.1 Hz, 1H), 3.07-2.93 (m, 2H), 2.63-2.49 (m, 2H).

(192) 924: White solid, yield: 73%. .sup.1H NMR (500 MHz, CDCl.sub.3) 11.26 (s, 1H), 7.98 (br, 1H), 7.65-7.59 (m, 1H), 7.46-7.44 (m, 1H), 7.42-7.33 (m, 2H), 7.22-7.19 (m, 1H), 7.15-7.13 (m, 2H), 7.07-6.96 (m, 5H), 6.63-6.60 (m, 1H), 3.68 (s, 3H), 3.36-3.32 (m, 2H), 3.32-3.21 (m, 2H).

(193) 673: White solid, yield: 76%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.94 (br, 1H), 7.65-7.58 (m, 1H), 7.40-7.35 (m, 1H), 7.35-7.27 (m, 5H), 7.22-7.20 (m, 1H), 7.19-7.14 (m, 1H), 7.10-7.07 (m, 1H), 7.04-6.97 (m, 3H), 2.92-2.88 (m, 4H), 2.29-2.14 (m, 2H). MS (ESI) m/z Found: 415.2 [M+H].sup.+, Calcd: 414.5.

(194) 678: Yellow syrup, yield: 77%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.95 (br, 1H), 7.69-7.63 (m, 1H), 7.61 (d, J=7.9 Hz, 1H), 7.44-7.41 (m, 1H), 7.34-7.25 (m, 3H), 7.19-7.04 (m, 5H), 7.04-6.97 (m, 2H), 2.95-2.90 (m, 4H), 2.30-2.24 (m, 2H).

(195) 671: White solid, yield: 74%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.94 (br, 1H), 7.71 (d, J=8.1 Hz, 2H), 7.66-7.57 (m, 8H), 7.35-7.30 (m, 1H), 7.18-7.15 (m, 1H), 7.10-7.07 (m, 1H), 7.01 (d, J=2.2 Hz, 1H), 2.93-2.90 (m, 4H), 2.30-2.24 (m, 2H).

(196) 770: White solid, yield: 71%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66 (s, 1H), 7.44-7.38 (m, 1H), 7.38-7.28 (m, 4H), 7.25 (s, 1H), 7.22-7.16 (m, 2H), 7.05-7.00 (m, 3H), 6.84 (d, J=7.7 Hz, 1H), 3.52-3.50 (m, 1H), 2.99-2.89 (m, 2H), 2.13-2.08 (m, 2H), 2.02-1.82 (m, 2H).

(197) 762: Yellow syrup, yield: 81%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.92 (br, 1H), 7.59-7.50 (m, 2H), 7.43 (d, J=7.0 Hz, 1H), 7.35 (s, 1H), 7.31-7.16 (m, 7H), 7.08-7.00 (m, 2H), 2.95-2.85 (m, 2H), 2.34-2.24 (m, 2H).

(198) 632: White solid, yield: 83.2%..sup.1H NMR (500 MHz, CDCl.sub.3), 7.99 (br, 1H), 7.64-7.56 (m, 3H), 7.43-7.27 (m, 8H), 7.22 (s, 1H), 7.15-6.99 (m, 3H), 3.14 (d, J=6.7 Hz, 2H), 2.96 (t, J=6.9 Hz, 2H), 2.40-2.36 (m, 2H).

(199) 640: White solid, yield: 81.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.00 (s, 1H), 7.64 (d, J=8 Hz, 1H), 7.35 (d, J=8 Hz, 1H), 7.32-7.26 (m, 1H), 7.25-7.15 (m, 5H), 7.15-7.07 (m, 2H), 7.042-7.039 (m, 1H), 6.88-6.84 (m, 2H), 3.78 (s, 3H), 3.74 (s, 3H), 2.93 (t, J=7.3 Hz, 4H), 2.28 (p, J=7.5 Hz, 2H). MS (ESI) m/z Found: 439.2 [M+H].sup.+, Calcd: 439.5.

(200) 670: White solid, yield: 33%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.98 (br, 1H), 7.64-7.58 (m, 1H), 7.57-7.50 (m, 2H), 7.48-7.42 (m, 2H), 7.33-7.31 (m, 1H), 7.20-7.13 (m, 1H), 7.13-7.05 (m, 1H), 7.01-7.79 (m, 1H), 6.91-6.81 (m, 4H), 3.80 (s, 6H), 2.91-2.86 (m, 4H), 2.27-2.21 (m, 2H). MS (ESI) m/z Found: 439.2 [M+H].sup.+, Calcd: 439.5.

(201) 916: White solid, yield: 67%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.94 (br, 1H), 7.64 (d, J=7.9 Hz, 1H), 7.56 (dd, J=7.6, 1.8 Hz, 1H), 7.39 (dd, J=7.6, 1.8 Hz, 1H), 7.35 (d, J=8.1 Hz, 1H), 7.31-7.24 (m, 2H), 7.21-7.16 (m, 1H), 7.12-7.09 (m, 1H), 7.05 (d, J=2.2 Hz, 1H), 6.98-6.93 (m, 2H), 6.84 (d, J=8.4 Hz, 1H), 6.81 (d, J=8.4 Hz, 1H), 3.42 (s, 3H), 3.39 (s, 3H), 2.94 (t, J=7.6 Hz, 4H), 2.32-2.24 (m, 2H).

(202) 676: Yellow syrup, yield: 88%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 9.99 (br, 1H), 8.53 (s, 1H), 8.38 (s, 1H), 7.63 (d, J=7.9 Hz, 1H), 7.38 (d, J=8.1 Hz, 1H), 7.25-7.19 (m, 4H), 7.15 (d, J=7.7 Hz, 1H), 7.11-7.06 (m, 3H), 7.05-6.97 (m, 1H), 6.91-6.77 (m, 2H), 2.94 (t, J=7.5 Hz, 2H), 2.90 (t, J=7.5 Hz, 2H), 2.24 (p, J=7.5 Hz, 2H).

(203) 677: Yellow syrup, yield: 77%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.92-7.91 (m, 2H), 7.72 (d, J=7.9 Hz, 1H), 7.65-7.50 (m, 5H), 7.45 (t, J=7.6 Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.18-7.13 (m, 1H), 7.10 (s, 1H), 7.10-7.04 (m, 1H), 6.95 (d, J=2.2 Hz, 1H), 2.78 (t, J=7.3 Hz, 2H), 2.58-2.38 (m, 2H), 2.09-1.97 (m, 2H).

(204) 681: Colorless syrup, yield: 84%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.92 (br, 1H), 7.89 (s, 1H), 7.80-7.74 (m, 2H), 7.67-7.54 (m, 4H), 7.49-7.41 (m, 2H), 7.32 (d, J=8.1 Hz, 1H), 7.19-7.13 (m, 1H), 7.11-7.05 (m, 1H), 7.02 (d, J=2.2 Hz, 1H), 2.94-2.91 (m, 4H), 2.31-2.25 (p, J=7.4 Hz, 2H). HRMS (ESI) m/z Found: 515.15723 [M+H].sup.+, Calcd: 515.1526[M+M].sup.+.

(205) 672: Colorless crystal, yield: 86%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.95 (br, 1H), 7.60 (d, J=7.9 Hz, 1H), 7.58-7.52 (m, 2H), 7.50-7.42 (m, 2H), 7.33-7.32 (m, 1H), 7.19-7.14 (m, 1H), 7.13-7.06 (m, 1H), 7.06-6.98 (m, 5H), 2.92-2.87 (m, 4H), 2.28-2.22 (m, 2H).

(206) 925: White solid, yield: 73%. .sup.1H NMR (500 MHz, CDCl.sub.3) 11.05 (s, 2H), 7.97 (br 1H), 7.62-7.60 (m, 1H), 7.44-7.32 (m, 3H), 7.21-7.16 (m, 2H), 7.14-7.09 (m, 2H), 7.06-6.97 (m, 4H), 6.71-6.68 (m, 1H), 2.99-2.85 (m, 4H), 2.32-2.26 (m, 2H).

Example 3Preparation of Compounds of Class II

(207) Scheme 7 below outlines the chemical synthesis of compounds identified as compounds of Class II. These compounds are shown in Table 3 below.

(208) ##STR00119##

(209) Compounds of Class II may be prepared by typical methods as illustrated in Scheme 7. The appropriate benzoin 21-25 is condensed with substituted indole acid 26, the intermediate ester 31 is obtained, which is then followed by the reaction with ammonium acetate in acetic acid under reflux for 2 hours to generate the desired products, compounds of Class II: 817, 827, 831-834, 838-840, 842, 919, 927, 934.

(210) General Procedure for the Preparation of an Intermediate 31.

(211) To a vacuum flame-dried flask was added a compound 21-25 (1 mmol), acid 26 (1.1 mmol), dicyclohexylcarbodiimide (0.206 g, 1 mmol), 4-dimethylaminopyridine (12.2 mg, 0.1 mmol), dichloromethane (10 mL) under nitrogen atmosphere. The reaction mixture was stirred for 2 hours at room temperature. Then ethyl acetate was added and the reaction mixture was filtered. The filtrate was then washed with 5% HCl, saturated NaHCO.sub.3, brine and dried with Na.sub.2SO.sub.4. After filtration, the solvent was concentrated in vacuum. This crude residue was then purified by flash chromatography to give an intermediate 31.

(212) General Procedure for the Preparation of Compounds of Class II.

(213) A mixture of a compound 31 (0.5 mmol), ammonium acetate (2.5 mmol) in glacial acetic acid (5 mL) was refluxed for 2 hours. After cooling, water was added to the reaction mixture. After extracting with ethyl acetate, the combined organic phase was washed with saturated NaHCO.sub.3, brine, dried with Na.sub.2SO.sub.4, filtered, and concentrated in vacuum. The crude residue was then purified by flash chromatography to give the desired product.

(214) TABLE-US-00003 TABLE 3 Structures of compounds of Class II. ID Structure 827 0 832 919 934 831 817 838 839 834 842 840 0 833 830 927
Characterization of Compounds of Class II:

(215) 827: White solid. Yield: 36%. .sup.1H NMR (500 MHz, CDCl.sub.3) 10.19 (br, 1H), 7.70-7.67 (m, 2H), 7.41-7.39 (m, 2H), 7.13-7.10 (m, 1H), 7.04-7.02 (m, 2H), 6.90-6.89 (m, 1H), 6.62-6.58 (m, 2H), 4.33 (s, 2H).

(216) 832: White solid. Yield: 32%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.90 (br, 1H), 8.22 (br, 1H), 7.56 (d, J=8.0 Hz, 1H), 7.42 (d, J=8.2 Hz, 1H), 7.24 (d, J=8.0 Hz, 1H), 7.19 (s, 1H), 7.13 (t, J=7.5 Hz, 1H), 6.87 (br, 2H), 6.47 (br, 2H), 4.33 (s, 2H).

(217) 919: colorless syrup, yield: 47%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.02 (br, 1H), 7.65 (d, J=7.9 Hz, 1H), 7.55-7.53 (m, 2H), 7.38-7.30 (m, 1H), 7.19-7.17 (m, 1H), 7.14-7.12 (m, 1H), 7.03 (d, J=2.3 Hz, 1H), 6.98-6.89 (m, 2H), 6.54-6.50 (m, 2H), 3.36-3.30 (m, 2H), 3.28-3.20 (m, 2H).

(218) 934: Colorless syrup, yield: 23.4%..sup.1H NMR (500 MHz, CDCl.sub.3) 8.03 (br, 1H), 7.62 (t, J=8.3 Hz, 1H), 7.43-7.41 (m, 2H), 7.39-7.38 (m, 1H), 7.25-7.19 (m, 1H), 7.17-7.10 (m, 1H), 6.99-6.98 (m, 1H), 6.86-6.85 (m, 2H), 6.48-6.47 (m, 2H), 3.27-3.23 (m, 2H), 3.23-3.18 (m, 2H).

(219) 831: White solid. Yield: 55%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.94 (br, 1H), 7.62-7.58 (m, 1H), 7.52-7.50 (m, 2H), 7.33-7.31 (m, 1H), 7.18-7.13 (m, 1H), 7.10-7.07 (m, 1H), 7.01 (d, J=2.3 Hz, 1H), 6.92 (dd, J=3.4, 0.7 Hz, 1H), 6.90 (dd, J=3.4, 0.7 Hz, 1H), 6.51 (dd, J=3.4, 1.8 Hz, 1H), 6.49 (dd, J=3.4, 1.8 Hz, 1H), 2.90-2.84 (m, 4H), 2.28-2.19 (m, 2H). HRMS (ESI) m/z. Found: 359.1407 [M+H].sup.+, Calcd: 359.1390.

(220) 817: White solid. Yield: 10%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.05 (br, 1H), 7.99 (s, 1H), 7.57 (d, J=7.5 Hz, 1H), 7.41 (s, 2H), 7.32 (d, J=7.5 Hz, 1H), 7.16 (t, J=7.2 Hz, 1H), 7.08 (d, J=7.2 Hz, 1H), 6.97 (s, 1H), 6.90-6.70 (m, 2H), 6.46 (s, 2H), 2.86-2.78 (dt, J=26.2, 7.0 Hz, 4H), 2.23-2.09 (m, 2H). HRMS (ESI) m/z Found: 358.1555 [M+H].sup.+, Calcd: 358.1550.

(221) 838: White solid. Yield: 48%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.11 (s, 1H), 7.79-7.73 (m, 1H), 7.57 (ddd, J=7.8, 1.5, 1.0 Hz, 1H), 7.54-7.50 (m, 1H), 7.49 (dt, J=1.8, 1.1 Hz, 1H), 7.40-7.37 (m, 1H), 7.37-7.32 (m, 1H), 7.25-7.20 (m, 2H), 7.17 (ddd, J=8.0, 7.1, 1.1 Hz, 1H), 7.02 (tdd, J=8.4, 2.6, 0.9 Hz, 1H), 6.84-6.80 (m, 1H), 6.51 (td, J=3.5, 1.4 Hz, 1H), 4.34 (d, J=0.9 Hz, 2H).

(222) 839: Yellow syrup. Yield: 25%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.17 (s, 1H), 7.58 (d, J=7.9 Hz, 1H), 7.42 (d, J=8.2 Hz, 1H), 7.35 (br, 2H), 7.25-7.21 (m, 2H), 7.17-7.12 (m, 1H), 6.97 (s, 1H), 6.84 (d, J=7.5 Hz, 1H), 6.51 (s, 1H), 6.38 (s, 1H), 4.36 (d, J=0.7 Hz, 2H), 3.79 (s, 2H). MS (ESI) m/z Found: 358.14 [M+H].sup.+, Calcd: 358.40.

(223) 834: White solid. Yield: 45%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.95 (br, 1H), 7.65-7.61 (m, 1H), 7.59-7.57 (m, 1H), 7.57-7.51 (m, 1H), 7.51-7.48 (m, 1H), 7.41-7.33 (m, 2H), 7.21-7.17 (m, 1H), 7.13-7.10 (m, 1H), 7.07-7.01 (m, 2H), 6.82-6.79 (m, 1H), 6.52-6.51 (m, 1H), 2.94-2.90 (m, 4H), 2.32-2.23 (m, 2H). HRMS (ESI) m/z Found: 387.1520 [M+H].sup.+, Calcd: 387.1503.

(224) 842: White solid. Yield: 53%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.16 (s, 1H), 7.81-7.72 (m, 1H), 7.48-7.47 (m, 1H), 7.39-7.34 (m, 2H), 7.33-7.28 (m, 2H), 7.23-7.18 (m, 2H), 7.17-7.14 (m, 1H), 6.90-6.87 (m, 1H), 6.79-6.78 (m, 1H), 6.49-6.48 (m, 1H), 4.34 (d, J=0.7 Hz, 2H), 3.81 (s, 3H).

(225) 840: Yellow syrup. Yield: 48%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.98 (br, 1H), 7.63 (d, J=7.9 Hz, 1H), 7.48-7.47 (m, 1H), 7.39-7.30 (m, 4H), 7.21-7.16 (m, 1H), 7.12-7.09 (m, 1H), 7.04-7.03 (m, 1H), 6.91-6.89 (m, 1H), 6.78-6.77 (m, 1H), 6.50-6.49 (m, 1H), 3.83 (s, 3H), 2.93-2.90 (m, 4H), 2.32-2.22 (m, 2H).

(226) 833: White solid. Yield: 62%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.08 (br, 1H), 8.11 (br, 1H), 7.79-7.72 (m, 1H), 7.41-7.36 (m, 2H), 7.34 (t, J=7.9 Hz, 1H), 7.32-7.30 (m, 1H), 7.26-7.21 (m, 2H), 7.19-7.16 (m, 1H), 6.91-6.89 (m, 1H), 6.85-6.84 (m, 1H), 6.65-6.63 (m, 1H), 6.29-6.22 (m, 1H), 4.33 (d, J=0.8 Hz, 2H), 3.83 (s, 3H).

(227) 830: White solid. Yield: 44%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.96 (br, 1H), 7.95 (br, 1H), 7.70-7.61 (m, 1H), 7.38-7.29 (m, 4H), 7.20-7.18 (m, 1H), 7.14-7.09 (m, 1H), 7.03 (d, J=2.3 Hz, 1H), 6.90-6.87 (m, 1H), 6.84-6.83 (m, 1H), 6.62-6.61 (m, 1H), 6.29-6.20 (m, 1H), 3.83 (s, 3H), 2.96-2.83 (m, 4H), 2.29-2.23 (m, 2H).

(228) 927: White solid, yield: 73%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.98 (br, 1H), 7.65-7.64 (m, 1H), 7.58-7.54 (m, 1H), 7.53-7.47 (m, 2H), 7.38-7.36 m, 2H), 7.24-7.18 (m, 1H), 7.15-7.13 (m, 1H), 7.08-7.01 (m, 2H), 6.82-6.81 (m, 1H), 6.53-6.52 (m, 1H), 3.35-3.32 (m, 2H), 3.27-3.22 (m, 2H).

Example 4Preparation of Compounds of Class IIIa and Class IIIb

(229) Schemes 8-12 below outline the chemical synthesis of compounds identified as Class IIIa. These compounds are shown in Table 4 below.

(230) ##STR00134##

(231) Secondary amines of Class IIIa may be prepared according to the procedure described in Scheme 8. Bromides 32a and 32b were synthesized according to methods known in the art..sup.70,71 Secondary amines of Class IIIa were obtained by firstly protection of amine 33 with 2-nitrobenzenesulfonyl chloride to give 34, which then reacted with 32a (or 32b), intermediate compound 35 was obtained. Lastly, deprotection of 35 gave the desired secondary amines, compounds of Class IIIa: 795, 874, 1041, 1042, 1096, 1369.

(232) ##STR00135##

(233) Tertiary amines of Class IIIa were prepared by conventional methods as illustrated in Scheme 9. The Compounds of Class IIIa were reacted with bromide or acyl chloride in the presence of weak base such as K.sub.2CO.sub.3 or Et.sub.3N to generate the desired tertiary amines, compounds of Class IIIa: 1186-1188.

(234) ##STR00136##

(235) ##STR00137##

(236) ##STR00138##

(237) Intermediate compounds 36, 37 and 38 were synthesized according to methods known in the art..sup.70,71 By the condensation of 26 and 36 (Scheme 10), 33 and 37 (Scheme 11), 26 and 38 (Scheme 12), a series of amides, compounds of Class IIIa: 784, 853-856, 876, 1144, 1145 were obtained.

(238) Scheme 13 and Scheme 14 below outline the chemical synthesis of compounds identified as Class IIIb. These compounds are shown in Table 4 below.

(239) ##STR00139##

(240) ##STR00140##

(241) Alternatively, as illustrated in Scheme 13 and Scheme 14, by the reaction of 32 with substituted piperazines 39 or substituted piperidines 40 in the presence of K.sub.2CO.sub.3, a series of compounds of Class IIIb were obtained.

(242) General Procedure for the Preparation of Compound 34 (Scheme 8).

(243) To a mixture of 33 (2 mmol) and trimethylamine (0.278 mL, 49.6 mmol) in 10 mL of dichloromethane cooled in an ice-water bath, 0.44 g (2 mmol) of 2-nitrobenzenesulfonyl chloride was added portionwise over a period of 5 minutes under N.sub.2. Then the ice bath is removed and the reaction mixture is allowed to warm to room temperature and stirred for 30 minutes. Water was added to quench the reaction and extracted with CH.sub.2Cl.sub.2. The combined organic phase was washed with saturated NaHCO.sub.3 and dried with Na.sub.2SO.sub.4, filtered, concentrated in vacuum. The crude residue was subjected to chromatography on silica gel to give 34

(244) General Procedure for the Preparation of Compound 35 (Scheme 8).

(245) To a mixture of 35 (0.5 mmol), 0.21 g (1.5 mmol) of potassium carbonate, and 10 mL of anhydrous tetrahydrofuran, 32a (or 32b) (0.55 mmol) in 5 mL of anhydrous tetrahydrofuran was added dropwise under N.sub.2. The resulting mixture was heated at 60 C. for 2 hours. The reaction mixture is allowed to cool to room temperature, diluted with 250 mL of water, and extracted with dichloromethane (315 mL). The combined organic extracts were washed with brine (10 mL), dried over Na.sub.2SO.sub.4, filtered, and concentrated in vacuum. The crude residue is purified by column chromatography on silica gel to give 35.

(246) General Procedure for the Preparation of Compounds of Class IIIa as Illustrated in Scheme 8.

(247) To a solution of 0.11 mL (1 mmol) of thiophenol in 10 mL of acetonitrile, 0.1 mL 10.9 M aqueous potassium hydroxide solution (1 mmol) is added dropwise at 0 C. Then the reaction mixture is allowed to warm to room temperature and 0.24 g (0.42 mmol) of 35 in 5 mL of acetonitrile was added dropwise. The reaction mixture is heated in a 50 C. oil bath for 40 minutes. After cooling to room temperature, 10 mL water was added, and extracted with dichloromethane (315 mL). The combined organic extracts were washed with brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography to give the desired products, compounds of class IIIa as illustrated in Scheme 8: 795, 874, 1041, 1042, 1096.

(248) General Procedure for the Preparation of Compounds of Class IIIa as Illustrated in Scheme 9.

(249) Procedure (a): According to the same procedure outlined above for the preparation of 35. A series of compounds of class IIIa as illustrated in Scheme 9 were obtained: 1186-1188.

(250) Procedure (b): To a mixture of Compounds of Class IIIa (1 mmol) and NEt.sub.3 (0.83 mL, 6.0 mmol) in 10 mL of THF at 0 C. was added a solution of acyl chloride (1.1 mmol) in 4 mL of THF. The reaction mixture was heated under reflux for 2 hours. After cooling to room temperature, 10 mL water was added, and extracted with dichloromethane (315 mL). The combined organic extracts were washed with brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography to give the desired products, compounds of Class IIIa as illustrated in Scheme 9.

(251) General Procedure for the Preparation of Amides of Class IIIa as Illustrated in Scheme 10-12.

(252) To a suspension of acid 26 (or 37) (0.12 mmol) and 36 (or 33 or 38) (0.1 mmol) and Et.sub.3N (0.4 mmol) in DMSO (3 mL), HBTU (0.4 mmol) was added. The mixture was stirred at room temperature overnight. 10 mL water was added and extracted with dichloromethane (315 mL). The combined organic phases were washed with brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography to give products of Class IIIa: 784, 853-856, 876, 1144 and 1145.

(253) General Procedure for the Preparation of Compounds of Class IIIb as Illustrated in Scheme 13 and Scheme 14.

(254) A mixture of 32 (0.1 mmol), 39 or 40 (1 mmol) and 0.1 g (0.7 mmol) of potassium carbonate in 10 mL of anhydrous tetrahydrofuran was heated at 60 C. for 2 hours. The reaction mixture is allowed to cool to room temperature, diluted with 250 mL of water, and extracted with dichloromethane (315 mL). The combined organic extracts were washed with brine (10 mL), dried over Na.sub.2SO.sub.4, filtered, and concentrated in vacuum. The crude residue was purified by column chromatography on silica gel to give the desired products, compounds of Class IIIb.

(255) TABLE-US-00004 TABLE 4 Structures of compounds of Class IIIa and Class IIIb. ID Structure 795 874 1041 1042 1096 1369 1186 1187 1188 784 0 876 853 854 855 856 1144 1145 1076 1077 1078 0 1079 1080 1089 1090 1091 1092 1093 1094 1097 1098 0 1099 1100 1101 1102 1103 1104 1120 1121 1122 1123 0 1124 1125 1126 1127 1129 1137 1139 1140 1141 1142 0 1143 1173 1174 1175 1176 1177 1178 1179 1180 1181 00 1182 01 1183 02 1184 03 1209 04 1210 05 1211 06 1212 07 1213 08 1214 09 1227 0 1229 1284 1285 1286 1287 1288 1289 1290 1291 1312 0 1313 1314 1315 1357 1358 1359 1360 1361 1362 1363 0 1364 1366 1367 1368 1369 1370 1371 1372 1394 1395 0 1396 1397 1400 1401 1402 1403 1404 1405 1039 1040 0 1373
Characterization of Intermediate:

(256) 35a: White solid. Yield: 82%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.04-7.94 (m, 2H), 7.59-7.52 (m, 3H), 7.51-7.49 (m, 2H), 7.47-7.41 (m, 3H), 7.40-7.31 (m, 6H), 7.28 (d, J=8.1 Hz, 1H), 7.16-7.11 (m, 1H), 7.07 (s, 1H), 7.03-6.99 (m, 1H), 4.89 (s, 2H), 3.80-3.77 (m, 2H), 3.18-3.10 (m, 2H).

(257) Characterization of Compounds of Class IIIa and Class IIIb:

(258) 784: White solid. Yield: 58%. .sup.1H NMR (500 MHz, acetone-d.sub.6) 10.15 (br, 1H), 7.65 (d, J=8.0 Hz, 1H), 7.61-7.57 (m, 3H), 7.51 (d, J=7.5 Hz, 2H), 7.45-7.32 (m, 7H), 7.11 (t, J=7.6 Hz, 1H), 6.99 (t, J=7.5 Hz, 1H), 4.58 (d, J=5.7 Hz, 2H), 3.75 (s, 2H). HRMS (ESI) m/z Found: 408.17033 [M+H].sup.+, Calcd: 408.17065 [M+H].sup.+.

(259) 795: Colorless syrup. Yield: 65%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.30 (s, 1H), 7.67-7.51 (m, 5H), 7.40-7.28 (m, 8H), 7.18-7.13 (m, 2H), 7.05-7.01 (m, 1H), 4.72 (d, J=17.4 Hz, 1H), 4.19 (s, 2H), 3.38-3.22 (m, 4H).

(260) 874: White solid. Yield: 49%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.00 (br, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.34 (d, J=8.1 Hz, 1H), 7.29-7.22 (m, 3H), 7.20-7.08 (m, 5H), 7.03 (d, J=2.1 Hz, 1H), 6.98-6.94 (m, 2H), 3.97 (s, 2H), 3.03-3.06 (m, 2H), 3.02-2.99 (m, 2H). HRMS (ESI) m/z. Found: 429.18897 [M+H].sup.+, Calcd: 429.18886 [M+H].sup.+.

(261) 876: White solid. Yield: 64%. .sup.1H NMR (500 MHz, CDCl.sub.3) 11.35 (br, 1H), 8.12 (br, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.37 (d, J=8.1 Hz, 1H), 7.33-7.24 (m, 4H), 7.24-7.17 (m, 3H), 7.15-7.08 (m, 2H), 7.02-6.98 (m, 1H), 6.97-6.91 (m, 1H), 4.61-4.42 (m, 4H).

(262) 1096: White solid. Yield: 86.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.61 (d, J=7.9 Hz, 1H), 7.29-7.20 (m, 5H), 7.19-7.08 (m, 6H), 7.03-6.92 (m, 2H), 4.06 (s, 2H), 4.01 (s, 2H) 3.70 (s, 3H).

(263) 1144: white solid. Yield: 83.2%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.26 (br, 1H), 10.14 (br, J=5.0 Hz, 1H), 7.65-7.59 (m, 1H), 7.56 (br, 1H), 7.45-7.17 (m, 8H), 7.11-6.98 (m, 4H), 4.48-4.39 (m, 2H), 3.72 (s, 2H). HRMS (ESI) m/z Found: 443.16855 [M+H].sup.+, Calcd: 443.16779 [M+H].sup.+.

(264) 1145: white solid. Yield: 77.3%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 10.14 (br, 1H), 7.63-7.62 (m, 1H), 7.56 (br, 1H), 7.46-7.45 (m, 4H), 7.40-7.38 (m, 1H), 7.32-7.29 (m, 5H), 7.26-7.23 (m, 2H), 7.12-7.09 (m, 1H), 7.01-6.98 (m, 1H), 4.44 (d, J=5.5 Hz, 2H), 3.72 (s, 2H).

(265) 1369: White solid. Yield: 80.1%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 7.60 (d, J=7.8 Hz, 1H), 7.51 (d, J=7.5 Hz, 5H), 7.36 (d, J=8.2 Hz, 1H), 7.31 (t, J=7.5 Hz, 4H), 7.24 (t, J=7.3 Hz, 2H), 7.18 (s, 1H), 7.09-7.06 (m, 1H), 6.98 (t, J=7.5 Hz, 1H), 4.00 (s, 2H), 3.10-3.04 (m, 2H), 3.03-2.98 (m, 2H).

(266) 1186: White solid. Yield: 89.5%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.48 (br, 1H), 9.99 (br, 1H), 7.57-7.55 (m, 1H), 7.48-7.43 (m, 1H), 7.41-7.27 (m, 5H), 7.23-7.18 (m, 2H), 7.15-7.12 (m, 1H), 7.08-7.04 (m, 1H), 7.01-6.92 (m, 2H), 3.99 (s, 2H), 3.96 (s, 2H), 3.07-2.99 (m, 4H). HRMS (ESI) m/z Found: 468.20018 [M+H].sup.+, Calcd: 468.19943 [M+H].sup.+.

(267) 1187: White solid. Yield: 92.1%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.32 (br, 1H), 9.98 (br, 1H), 7.69-7.14 (m, 13H), 7.10-7.03 (m, 1H), 6.96-6.93 (m, 1H), 3.99 (s, 2H), 3.94 (s, 2H), 3.06-2.99 (m, 4H). HRMS (ESI) m/z Found: 432.21891 [M+H].sup.+, Calcd: 432.21827 [M+H].sup.+.

(268) 1188: colorless syrup. Yield: 88.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.96 (br, 1H), 7.67-7.64 (m, 2H), 7.64-7.56 (m, 3H), 7.41-7.31 (m, 7H), 7.22-7.14 (m, 1H), 7.12-7.03 (m, 2H), 4.03 (s, 2H), 3.86 (s, 2H), 3.15-3.09 (m, 2H), 3.08-3.04 (m, 2H).

(269) 1076: White solid. Yield: 88.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.68-7.63 (m, 2H), 7.63-7.58 (m, 2H), 7.41-7.31 (m, 6H), 7.26 (d, J=9.0 Hz, 1H), 6.95 (d, J=2.9 Hz, 1H), 6.74 (dd, J=9.0, 2.9 Hz, 1H), 3.87 (s, 2H), 3.28-3.18 (m, 4H), 2.87-2.80 (m, 4H).

(270) 1077: White solid. Yield: 92.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.73-7.64 (m, 4H), 7.64-7.59 (m, 2H), 7.41-7.30 (m, 6H), 7.30-7.25 (m, 2H), 6.14 (br, 1H), 3.85 (s, 2H), 3.20-3.18 (m, 2H), 3.00 (d, J=4.9 Hz, 3H), 2.60-2.53 (m, 1H), 2.45-2.30 (m, 2H), 1.89-1.85 (m, 4H).

(271) 1078: White solid. Yield: 89.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66-7.61 (m, 2H), 7.60-7.55 (m, 4H), 7.44 (d, J=8.0 Hz, 2H), 7.40-7.30 (m, 6H), 3.84 (s, 2H), 3.61 (s, 2H), 2.75 (br, 4H), 2.59 (br, 4H).

(272) 1079: White solid. Yield: 92.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.68-7.64 (m, 2H), 7.63-7.59 (m, 2H), 7.40-7.31 (m, 6H), 7.29-7.23 (m, 2H), 6.94-6.92 (m, 2H), 6.88-6.84 (m, 1H), 3.88 (s, 2H), 3.31-3.23 (m, 4H), 2.89-2.82 (m, 4H).

(273) 1080: White solid. Yield: 92.6%..sup.1H NMR (500 MHz, CDCl.sub.3) 7.69-7.65 (m, 2H), 7.64-7.60 (m, 2H), 7.50-7.31 (m, 10H), 3.86 (s, 2H), 3.21-3.19 (m, 2H), 2.62-2.56 (m, 1H), 2.42-2.35 (m, 2H), 1.91-1.87 (m, 4H).

(274) 1089: White solid. Yield: 83.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.14-8.10 (m, 2H), 7.67-7.63 (m, 2H), 7.63-7.58 (m, 2H), 7.42-7.31 (m, 6H), 6.85-6.79 (m, 2H), 3.88 (s, 2H), 3.52-3.46 (m, 4H), 2.86-2.81 (m, 4H).

(275) 1090: White solid. Yield: 87.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.68-7.63 (m, 2H), 7.63-7.58 (m, 2H), 7.52-7.47 (m, 2H), 7.40-7.33 (m, 6H), 6.89-6.83 (m, 2H), 3.87 (s, 2H), 3.44-3.34 (m, 4H), 2.84-2.79 (m, 4H).

(276) 1091: White solid. Yield: 85.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.47 (br, 1H), 7.41-7.17 (m, 7H), 7.13-7.11 (m, 1H), 7.07-7.00 (m, 1H), 6.97-6.91 (m, 3H), 6.90-6.85 (m, 1H), 3.78 (s, 2H), 3.36-3.17 (m, 4H), 2.89-2.70 (m, 4H).

(277) 1092: White solid. Yield: 88.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.38 (br, 1H), 7.43-7.16 (m, 6H), 7.13-7.10 (m, 1H), 7.06-7.03 (m, 1H), 6.96-6.93 (m, 2H), 6.76-6.74 (m, 1H), 3.78 (s, 2H), 3.33-3.13 (m, 4H), 2.83-2.66 (m, 4H).

(278) 1093: White solid. Yield: 92.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.53 (br, 1H), 7.57 (d, J=8.0 Hz, 2H), 7.44 (d, J=8.0 Hz, 2H), 7.36-7.29 (m, 3H), 7.25-7.20 (m, 1H), 7.19-7.17 (m, 1H), 7.11-7.09 (m, 1H), 7.05-7.01 (m, 1H), 6.94-6.91 (m, 1H), 3.72 (s, 2H), 3.57 (s, 2H), 2.62 (br, 4H), 2.51 (br, 4H).

(279) 1094: White solid. Yield: 91.7%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67-7.63 (m, 2H), 7.63-7.58 (m, 2H), 7.40-7.30 (m, 6H), 6.86-6.84 (m, 2H), 6.79-6.72 (m, 2H), 4.59 (br, 1H), 3.88 (s, 2H), 3.18-3.09 (m, 4H), 2.89-2.80 (m, 4H).

(280) 1097: White solid. Yield: 90.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.69-7.64 (m, 2H), 7.64-7.58 (m, 2H), 7.42-7.30 (m, 8H), 6.84-6.74 (m, 2H), 3.87 (s, 2H), 3.25-3.17 (m, 4H), 2.89-2.78 (m, 4H).

(281) 1098: White solid. Yield: 93.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.42 (br, 1H), 7.71-7.21 (m, 11H), 6.97-6.96 (m, 1H), 6.75-6.73 (m, 1H), 3.78 (s, 2H), 3.26-3.15 (m, 4H), 2.80-2.65 (m, 4H).

(282) 1099: White solid. Yield: 92.8%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.47 (br, 1H), 7.70-7.16 (m, 12H), 6.94-6.92 (m, 2H), 6.88-6.85 (m, 1H), 3.79 (s, 2H), 3.31-3.15 (m, 4H), 2.85-2.66 (m, 4H).

(283) 1100: White solid. Yield: 91.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.57 (br, 1H), 7.69-7.66 (m, 1H), 7.35-7.31 (m, 3H), 7.28-7.18 (m, 4H), 7.15-7.00 (m, 2H), 6.94 (s, 1H), 3.78 (s, 2H), 3.13-3.11 (m, 3H), 2.42-2.38 (m, 2H), 2.19-2.07 (m, 4H).

(284) 1101: White solid. Yield: 83.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.50 (br, 1H), 7.59-7.56 (m, 4H), 7.47-7.27 (m, 9H), 7.23-7.20 (m, 1H), 3.73 (s, 2H), 3.56 (s, 2H), 2.62 (s, 4H), 2.49 (s, 4H).

(285) 1102: White solid. Yield: 87.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.51-7.49 (m, 2H), 7.41-7.35 (m, 2H), 7.33-7.23 (m, 6H), 7.23-7.17 (m, 2H), 6.98-6.94 (m, 2H), 4.16 (s, 2H), 3.23-3.09 (m, 4H), 2.47-2.40 (m, 2H), 2.13 (s, 1H), 1.91-1.88 (m, 2H).

(286) 1103: White solid. Yield: 89.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.69-7.65 (m, 2H), 7.63-7.60 (m, 2H), 7.53-7.50 (m, 2H), 7.40-7.30 (m, 8H), 7.29-7.24 (m, 1H), 3.90 (s, 2H), 3.01-2.99 (m, 2H), 2.82-2.77 (m, 2H), 2.31-2.25 (m, 2H), 1.82-1.78 (m, 2H).

(287) 1104: White solid. Yield: 80.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.40 (br, 1H), 7.52-7.49 (m, 2H), 7.40-7.18 (m, 5H), 7.13-7.11 (m, 1H), 7.08-7.03 (m, 1H), 6.96-6.93 (m, 1H), 6.90-6.85 (m, 2H), 3.78 (s, 2H), 3.41-3.33 (m, 4H), 2.78-2.70 (m, 4H).

(288) 1120: White solid. Yield: 81.7%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.91 (br, 1H), 7.17-7.10 (m, 2H), 7.10-6.69 (m, 10H), 6.60-6.53 (m, 2H), 3.17 (s, 2H), 2.94-2.89 (m, 4H), 2.23-2.12 (m, 4H).

(289) 1121: White solid. Yield: 82.9%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.37 (br, 1H), 7.48-7.38 (m, 5H), 7.38-7.27 (m, 3H), 7.26-6.94 (m, 5H), 3.84 (br, 2H), 3.75 (s, 2H), 3.49 (br, 2H), 2.66-2.56 (m, 4H).

(290) 1122: White solid. Yield: 88.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.51-7.48 (m, 4H), 7.43-7.38 (m, 5H), 7.34-7.31 (m, 4H), 7.29-7.27 (m, 2H), 3.86 (br, 2H), 3.78 (s, 2H), 3.49 (br, 2H), 2.70-2.55 (m, 4H).

(291) 1123: Colorless syrup. Yield: 90.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66-7.62 (m, 2H), 7.62-7.57 (m, 2H), 7.44-7.31 (m, 11H), 3.90-3.87 (m, 4H), 3.53 (br, 2H), 2.81 (br, 2H), 2.67 (br, 2H), 2.50 (br, 1H).

(292) 1124: Colorless syrup. Yield: 91.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.70-7.66 (m, 2H), 7.66-7.62 (m, 2H), 7.42-7.32 (m, 7H), 7.18-7.15 (m, 1H), 7.09-7.06 (m, 1H), 6.98-6.96 (m, 1H), 4.01 (br, 2H), 3.26 (br, 2H), 2.88-2.82 (m, 1H), 2.55 (br, 2H), 2.05 (s, 2H), 1.99 (br, 2H).

(293) 1125: White solid. Yield: 81.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.43 (br, 1H), 7.59-7.27 (m, 11H), 7.01-7.00 (m, 1H), 6.48-6.47 (m, 1H), 3.84 (br, 4H), 3.76 (s, 2H), 2.68-2.62 (m, 4H).

(294) 1126: Colorless syrup. Yield: 87.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67-7.63 (m, 2H), 7.63-7.57 (m, 2H), 7.47-7.46 (m, 1H), 7.41-7.29 (m, 6H), 7.00-6.99 (m, 1H), 6.47-6.46 (m, 1H), 3.88 (br, 4H), 3.85 (s, 2H), 2.78-2.71 (m, 4H).

(295) 1127: Colorless syrup. Yield: 91.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.78 (s, 1H), 7.71-7.70 (m, 1H), 7.62-7.51 (m, 4H), 7.51-7.43 (m, 2H), 7.40-7.35 (m, 2H), 7.33-7.31 (m, 2H), 7.22-7.06 (m, 2H), 3.91 (s, 1H), 3.82 (s, 2H), 2.94-2.83 (m, 4H), 2.74-2.70 (m, 2H), 2.20-2.16 (m, 2H).

(296) 1128: White solid. Yield: 85.9%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.24-8.09 (m, 2H), 7.81-7.63 (m, 3H), 7.34-7.20 (m, 1H), 7.15-6.98 (m, 1H), 3.89 (s, 2H), 3.18-3.09 (m, 3H), 2.47-2.42 (m, 2H), 2.23-2.02 (m, 5H).

(297) 1129: White solid. Yield: 83.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.81 (s, 1H), 7.72-7.65 (m, 3H), 7.64-7.60 (m, 2H), 7.53-7.52 (m, 1H), 7.49-7.45 (m, 1H), 7.40-7.31 (m, 6H), 3.88 (s, 2H), 3.02-3.0 (m, 2H), 2.77-2.73 (m, 2H), 2.29-2.23 (m, 2H), 2.17 (s, 1H), 1.83-1.73 (m, 2H).

(298) 1137: White solid. Yield: 83.8%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 10.11 (br, 1H), 7.75-7.73 (m, 1H), 7.43-7.34 (m, 10H), 7.10-7.07 (m, 3H), 7.02-6.98 (m, 1H), 4.62 (s, 2H), 3.75-3.63 (m, 2H), 3.45-3.40 (m, 2H), 2.48-2.29 (m, 5H).

(299) 1139: White solid. Yield: 88.1%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.52 (br, 1H), 7.78 (br, 1H), 7.49-7.21 (m, 5H), 7.14-7.11 (m, 1H), 6.99-6.96 (m, 1H), 6.89-6.79 (m, 2H), 6.79-6.66 (m, 2H), 3.70 (s, 2H), 3.10-2.98 (m, 4H), 2.84 (br, 1H), 2.73-2.63 (m, 4H).

(300) 1140: White solid. Yield: 86.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 12.99 (s, 1H), 7.63 (d, J=8.3 Hz, 2H), 7.47-7.44 (m, 1H), 7.24-7.19 (m, 3H), 7.17-7.09 (m, 5H), 6.85 (s, 2H), 3.88 (s, 2H), 3.35-3.33 (m, 2H), 3.04 (d, J=4.9 Hz, 3H), 2.55-2.51 (m, 1H), 2.45-2.40 (m, 2H), 1.84-1.81 (m, 2H), 1.35-1.21 (m, 2H).

(301) 1141: White solid. Yield: 87.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.51 (br, 1H), 7.37-7.30 (m, 3H), 7.28-7.22 (m, 1H), 7.22-7.14 (m, 2H), 7.12-7.10 (m, 1H), 7.06-7.02 (m, 1H), 6.95-6.92 (m, 1H), 6.55-6.53 (m, 1H), 6.48-6.40 (m, 2H), 3.79 (s, 3H), 3.77 (s, 2H), 3.29-3.19 (m, 4H), 2.79-2.69 (m, 4H).

(302) 1142: White solid. Yield: 91.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.69-7.63 (m, 2H), 7.63-7.58 (m, 2H), 7.40-7.30 (m, 6H), 7.20-7.14 (m, 1H), 6.56-6.52 (m, 1H), 6.47-6.46 (m, 1H), 6.44-6.39 (m, 1H), 3.87 (s, 2H), 3.78 (s, 3H), 3.29-3.21 (m, 4H), 2.87-2.79 (m, 4H).

(303) 1143: White solid. Yield: 82.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.48 (br, 1H), 7.51 (br, 4H), 7.39-7.23 (m, 6H), 7.19-7.16 (m, 1H), 6.55-6.53 (m, 1H), 6.52-6.40 (m, 2H), 3.79 (s, 2H), 3.79 (s, 3H), 3.32-3.18 (m, 4H), 2.81-2.71 (m, 4H).

(304) 1173: White solid. Yield: 77.4%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.51 (br, 1H), 7.47-7.43 (m, 1H), 7.41-7.28 (m, 6H), 7.26-7.23 (m, 1H), 7.15-7.11 (m, 1H), 7.00-6.96 (m, 1H), 6.92-6.88 (m, 2H), 3.71 (s, 2H), 3.22-3.16 (m, 4H), 2.82 (br, 1H), 2.73-2.67 (m, 4H).

(305) 1174: White solid. Yield: 88.2%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.57 (br, 1H), 7.69-7.21 (m, 8H), 7.17-6.75 (m, 4H), 3.73 (s, 2H), 3.29-3.14 (m, 4H), 2.77-2.66 (m, 4H).

(306) 1175: White solid. Yield: 80.5%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.46 (br, 1H), 7.46-7.42 (m, 1H), 7.40-7.27 (m, 8H), 7.26-7.20 (m, 2H), 7.14-7.10 (m, 1H), 6.98-6.95 (m, 1H), 3.64 (s, 2H), 3.48 (s, 2H), 2.56 (br, 4H), 2.44 (br, 4H).

(307) 1176: Colorless syrup. Yield: 92.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66-7.61 (m, 2H), 7.61-7.57 (m, 2H), 7.40-7.29 (m, 10H), 7.25-7.22 (m, 1H), 3.82 (s, 2H), 3.52 (s, 2H), 2.71 (br, 4H), 2.54 (br, 4H). HRMS (ESI) m/z Found: 410.22416 [M+H].sup.+, Calcd: 410.22269 [M+H].sup.+.

(308) 1177: White solid. Yield: 79.3%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.47 (br, 1H), 7.57-7.19 (m, 10H), 7.12 (br, 1H), 6.96 (br, 1H), 3.64 (s, 2H), 3.48 (s, 2H), 2.56 (br, 4H), 2.44 (br, 4H).

(309) 1178: White solid. Yield: 82.4%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.55 (br, 1H), 7.57-6.96 (m, 12H), 3.76 (br, 2H), 3.73 (s, 2H), 3.36-3.34 (m, 2H), 2.67-2.65 (m, 2H), 2.57 (br, 2H).

(310) 1179: White solid. Yield: 86.9%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.52 (br, 1H), 7.56-6.92 (m, 12H), 3.71-3.62 (m, 4H), 3.45 (br, 2H), 2.60 (br, 4H).

(311) 1180: Colorless syrup. Yield: 91.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67-7.63 (m, 2H), 7.61-7.59 (m, 2H), 7.47-7.30 (m, 8H), 7.11-7.05 (m, 2H), 3.86-3.75 (m, 4H), 3.51 (br, 2H), 2.75-2.65 (m, 4H).

(312) 1181: White solid. Yield: 86.2%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.51 (br, 1H), 8.04 (br, 1H), 7.51-7.21 (m, 6H), 7.18-7.10 (m, 1H), 7.06-6.94 (m, 2H), 6.46-6.38 (m, 2H), 6.29-6.27 (m, 1H), 3.70 (s, 2H), 3.17-3.12 (m, 4H), 2.71-2.65 (m, 4H).

(313) 1182: White solid. Yield: 88.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.69-7.62 (m, 2H), 7.60-7.58 (m, 2H), 7.39-7.28 (m, 6H), 7.10-7.06 (m, 1H), 6.50-6.48 (m, 1H), 6.38 (s, 1H), 6.31-6.29 (m, 1H), 5.55 (br, 1H), 3.86 (s, 2H), 3.25-3.18 (m, 4H), 2.85-2.78 (m, 4H).

(314) 1183: White solid. Yield: 85.4%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.51 (br, 1H), 7.53-7.22 (m, 7H), 7.18-7.09 (m, 2H), 6.99-6.95 (m, 2H), 6.87-6.75 (m, 2H), 3.73 (s, 2H), 2.94-2.93 (m, 4H), 2.76 (br, 4H).

(315) 1184: White solid. Yield: 87.9%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.69-7.60 (m, 4H), 7.42-7.31 (m, 7H), 7.19-7.17 (m, 1H), 7.08-7.06 (m, 1H), 6.95-6.93 (m, 1H), 6.88-6.85 (m, 1H), 3.90 (s, 2H), 2.98-2.97 (m, 4H), 2.87 (Br, 4H).

(316) 1209: White solid. Yield: 85.4. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.48 (br, 1H), 7.88 (s, 1H), 7.81-7.79 (m, 1H), 7.57-7.56 (m, 2H), 7.44-6.97 (m, 8H), 4.19 (s, 1H), 3.74 (s, 2H), 2.87-2.85 (m, 2H), 2.75-2.70 (m, 2H), 2.17-2.11 (m, 2H), 1.75-1.72 (m, 2H).

(317) 1210: White solid. Yield: 87.9%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.34 (br, 1H), 7.65-7.44 (m, 6H), 7.42-7.11 (m, 8H), 3.99 (br, 1H), 3.70 (s, 2H), 2.85-2.81 (m, 4H), 2.71-2.66 (m, 2H), 1.70-1.68 (m, 2H).

(318) 1211: White solid. Yield: 91.8%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 12.16 (br, 1H), 7.52-7.47 (m, 8H), 7.45-7.44 (m, 3H), 7.18-7.15 (m, 2H), 7.11-7.08 (m, 1H), 3.93 (s, 2H), 3.01 (d, J=11.1 Hz, 2H), 2.74-2.69 (m, 2H), 1.84-1.78 (m, 2H), 1.71-1.60 (m, 2H).

(319) 1212: White solid. Yield: 88.7%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 7.45-7.29 (m, 6H), 7.08-7.01 (m, 2H), 6.87-6.82 (m, 2H), 6.79-6.72 (m, 2H), 4.65 (s, 1H), 3.87 (s, 2H), 3.17-3.10 (m, 4H), 2.85-2.81 (m, 4H).

(320) 1213: White solid. Yield: 91.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.45-7.22 (m, 8H), 7.10-7.01 (m, 2H), 6.94-6.93 (m, 2H), 6.88-6.85 (m, 1H), 3.87 (s, 2H), 3.32-3.21 (m, 4H), 2.91-2.80 (m, 4H).

(321) 1214 Colorless syrup. Yield: 77.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) .sup.1H NMR (500 MHz, CDCl.sub.3) 7.98 (br, 1H), 7.67-7.65 (m, 1H), 7.47-7.33 (m, 7H), 7.21-7.18 (m, 1H), 7.13-7.04 (m, 3H), 7.00-6.98 (m, 1H), 3.89 (s, 2H), 3.21-3.18 (m, 2H), 2.91-2.82 (m, 1H), 2.48-2.44 (m, 2H), 2.12-2.10 (m, 2H), 1.97-1.92 (m, 2H).

(322) 1227: White solid. Yield: 86.4%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.20-8.18 (m, 1H), 7.70-7.58 (m, 4H), 7.50-7.44 (m, 1H), 7.42-7.29 (m, 6H), 6.69-6.58 (m, 2H), 3.87 (s, 2H), 3.66-3.55 (m, 4H), 2.81-2.78 (m, 4H).

(323) 1228: Colorless syrup. Yield: 89.7%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.00 (br, 1H), 7.68-7.64 (m, 1H), 7.62-7.59 (m, 2H), 7.45-7.39 (m, 1H), 7.38-7.33 (m, 1H), 7.31-7.28 (m, 1H), 7.24-7.17 (m, 1H), 7.15-7.10 (m, 2H), 4.08 (s, 2H), 3.88 (s, 2H), 3.20-2.94 (m, 4H).

(324) 1229: White solid. Yield: 89.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.20 (d, J=5.2 Hz, 1H), 7.69-7.58 (m, 4H), 7.44-7.30 (m, 6H), 6.52 (d, J=5.2 Hz, 1H), 3.84 (s, 2H), 3.19-3.16 (m, 2H), 2.53-2.42 (m, 1H), 2.38-2.32 (m, 2H), 1.94-1.81 (m, 4H), 1.65 (br, 2H).

(325) 1284: White solid. Yield: 81.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.70 (br, 1H), 8.56-8.55 (m, 1H), 7.67-7.63 (m, 1H), 7.58-7.42 (br, 3H), 7.40 (d, J=7.8 Hz, 1H), 7.39-7.20 (m, 6H), 7.18-7.15 (m, 1H), 3.73 (s, 2H), 3.67 (s, 2H), 2.65 (s, 4H), 2.56 (s, 4H).

(326) 1285: Colorless syrup. Yield: 82.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.56 (d, J=4.2 Hz, 1H), 7.68-7.56 (m, 5H), 7.42-7.30 (m, 7H), 7.17-7.14 (m, 1H), 3.83 (s, 2H), 3.69 (s, 2H), 2.75 (br, 4H), 2.62 (br, 4H).

(327) 1286: Colorless syrup. Yield: 87.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.71-7.62 (m, 2H), 7.62-7.56 (m, 2H), 7.41-7.29 (m, 6H), 7.29-7.20 (m, 1H), 7.13-7.04 (m, 2H), 6.95-6.91 (m, 1H), 3.82 (s, 2H), 3.51 (s, 2H), 2.72 (br, 4H), 2.54 (br, 4H).

(328) 1287: Colorless syrup. Yield: 84.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66-7.62 (m, 2H), 7.62-7.57 (m, 2H), 7.41-7.30 (m, 6H), 7.24-7.18 (m, 2H), 6.87-6.82 (m, 2H), 3.81 (s, 2H), 3.79 (s, 3H), 3.46 (s, 2H), 2.70 (br, 4H), 2.52 (br, 4H).

(329) 1288: Colorless syrup. Yield: 91.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.65-7.63 (m, 2H), 7.62-7.57 (m, 2H), 7.42-7.29 (m, 6H), 7.29-7.22 (m, 1H), 7.08-7.05 (m, 2H), 6.98-6.89 (m, 1H), 3.82 (s, 2H), 3.52 (s, 2H), 2.72 (br, 4H), 2.54 (br, 4H).

(330) 1289: White solid. Yield: 88.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67-7.62 (m, 2H), 7.62-7.57 (m, 2H), 7.41-7.30 (m, 6H), 7.21 (t, J=7.9 Hz, 1H), 6.90-6.89 (m, 2H), 6.81-6.76 (m, 1H), 3.81 (s, 2H), 3.80 (s, 3H), 3.50 (s, 2H), 2.71 (br, 4H), 2.54 (br, 4H).

(331) 1290: White solid. Yield: 91.0%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.58 (br, 1H), 7.39-7.22 (m, 5H), 7.16 (d, J=7.6 Hz, 1H), 7.11-6.99 (m, 4H), 6.96-6.92 (m, 2H), 3.71 (s, 2H), 3.51 (s, 2H), 2.62 (br, 4H), 2.49 (br, 4H).

(332) 1291: White solid. Yield: 88.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.61 (br, 1H), 7.32 (br, 3H), 7.24-6.90 (m, 7H), 6.89-6.82 (m, 2H), 3.80 (s, 3H), 3.70 (s, 2H), 3.46 (s, 2H), 2.60 (br, 4H), 2.47 (br, 4H).

(333) 1312: White solid. Yield: 91.5%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.56 (br, 1H), 7.52-6.92 (m, 9H), 6.76-6.74 (m, 1H), 6.68-6.64 (m, 1H), 6.55-6.46 (m, 1H), 3.72 (s, 2H), 3.27-3.20 (m, 4H), 2.77-2.65 (m, 4H).

(334) 1313: Colorless syrup. Yield: 87.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.70-7.57 (m, 4H), 7.47-7.31 (m, 6H), 7.22-7.15 (m, 1H), 6.68-6.66 (m, 1H), 6.64-6.47 (m, 2H), 3.87 (s, 2H), 3.31-3.20 (m, 4H), 2.87-2.78 (m, 4H).

(335) 1314: White solid. Yield: 89.3%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.36 (br, 1H), 7.69-7.12 (m, 11H), 6.76-6.74 (m, 1H), 6.68-6.65 (m, 1H), 6.51-6.47 (m, 1H), 3.70 (s, 2H), 3.29-3.21 (m, 4H), 2.75-2.67 (m, 4H).

(336) 1315: White solid. Yield: 87.6%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.30 (br, 1H), 7.82-7.09 (m, 15H), 3.63 (s, 2H), 3.48 (s, 2H), 2.56 (br, 4H), 2.44 (br, 4H).

(337) 1357: White solid. Yield: 92.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.65-7.61 (m, 2H), 7.61-7.56 (m, 2H), 7.39-7.30 (m, 7H), 7.25-7.20 (m, 1H), 7.11-7.07 (m, 1H), 7.05-6.99 (m, 1H), 3.81 (s, 2H), 3.62 (s, 2H), 2.72 (br, 4H), 2.59 (br, 4H).

(338) 1358: White solid. Yield: 88.5%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 11.28 (br, 1H), 7.60-7.58 (m, 2H), 7.48-7.41 (m, 3H), 7.39-7.21 (m, 6H), 7.20-7.14 (m, 2H), 7.10-7.05 (m, 1H), 3.62 (s, 2H), 3.55 (s, 2H), 2.56 (br, 4H), 2.48 (br, 4H).

(339) 1359: Colorless syrup. Yield: 77.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.63 (s, 1H), 7.57-7.55 (m, 2H), 7.51-7.47 (m, 4H), 7.45-7.42 (m, 1H), 7.35-7.29 (m, 4H), 7.29-7.24 (m, 3H), 3.97 (s, 2H), 3.57 (s, 2H), 2.82 (br, J=4.9 Hz, 4H), 2.59 (br, 4H).

(340) 1360: Colorless syrup. Yield: 91.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67-7.63 (m, 3H), 7.62-7.58 (m, 2H), 7.58-7.52 (m, 2H), 7.43-7.30 (m, 7H), 3.82 (s, 2H), 3.54 (s, 2H), 2.71 (br, 4H), 2.53 (br, 4H).

(341) 1361: Colorless syrup. Yield: 82.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66-7.62 (m, 2H), 7.62-7.58 (m, 4H), 7.45-7.44 (m, 2H), 7.39-7.31 (m, 6H), 3.82 (s, 2H), 3.56 (s, 2H), 2.71 (br, 4H), 2.53 (br, 4H).

(342) 1362: Colorless syrup. Yield: 85.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.64-7.60 (m, 2H), 7.51-7.42 (m, 6H), 7.35-7.29 (m, 4H), 7.29-7.24 (m, 3H), 3.97 (s, 2H), 3.60 (s, 2H), 2.81 (br, 4H), 2.59 (br, 4H).

(343) 1363: Colorless syrup. Yield: 89.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.49 (br, 1H), 7.65-7.63 (m, 1H), 7.56-7.55 (m, 3H), 7.51-7.27 (m, 8H), 3.71 (s, 4H), 2.63 (br, 4H), 2.57 (br, 4H).

(344) 1364: Colorless syrup. Yield: 77.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67-7.62 (m, 3H), 7.62-7.58 (m, 2H), 7.54-7.53 (m, 2H), 7.39-7.30 (m, 7H), 3.81 (s, 2H), 3.73 (s, 2H), 2.71 (s, 4H), 2.61 (s, 4H).

(345) 1366: Colorless syrup. Yield: 82.8%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.39-8.38 (m, 1H), 7.66-7.62 (m, 2H), 7.61-7.57 (m, 2H), 7.43-7.42 (m, 1H), 7.40-7.29 (m, 6H), 7.10-7.07 (m, 1H), 3.80 (s, 2H), 3.66 (s, 2H), 2.69 (br, 4H), 2.60 (br, 4H).

(346) 1367: White solid. Yield: 73.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.68 (br, 1H), 8.39-8.38 (m, 1H), 7.62-7.40 (m, 5H), 7.39-7.22 (m, 6H), 7.10 (dd, J=7.6, 4.8 Hz, 1H), 3.73 (s, 2H), 3.66 (s, 2H), 2.61 (br, 4H), 2.56 (br, 4H).

(347) 1368: Colorless syrup. Yield: 81.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.01-7.99 (m, 2H), 7.60-7.54 (m, 4H), 7.50-7.43 (m, 3H), 7.40-7.29 (m, 6H) 3.86 (s, 2H), 3.81 (s, 2H), 2.73 (br, 4H), 2.64 (br, 4H).

(348) 1369: White solid. Yield: 80.1%. .sup.1H NMR (500 MHz, Acetone-d.sub.6) 7.60 (d, J=7.8 Hz, 1H), 7.51 (d, J=7.5 Hz, 5H), 7.36 (d, J=8.2 Hz, 1H), 7.31 (t, J=7.5 Hz, 4H), 7.24 (t, J=7.3 Hz, 2H), 7.18 (s, 1H), 7.09-7.06 (m, 1H), 6.98 (t, J=7.5 Hz, 1H), 4.00 (s, 2H), 3.10-3.04 (m, 2H), 3.03-2.98 (m, 2H).

(349) 1370: Colorless syrup. Yield: 86.0%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66-7.62 (m, 2H), 7.61-7.57 (m, 2H), 7.39-7.29 (m, 6H), 3.82 (s, 2H), 3.50 (t, J=5.6 Hz, 2H), 3.33 (s, 3H), 2.74 (s, 4H), 2.65-2.55 (m, 6H).

(350) 1371: Colorless syrup. Yield: 89.3%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.66 (br, 1H), 7.66-7.19 (m, 10H), 3.73 (s, 2H), 3.54-3.46 (m, 2H), 3.35 (t, J=3.3 Hz, 3H), 2.66 (s, 4H), 2.60-2.50 (m, 6H).

(351) 1372: White solid. Yield: 83.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.93 (br, 1H), 7.69-7.65 (m, 2H), 7.64-7.57 (m, 3H), 7.40-7.30 (m, 7H), 7.16-7.13 (m, 1H), 7.05-7.03 (m, 1H), 7.02-6.98 (m, 1H), 6.01-5.93 (m, 1H), 5.36-5.17 (m, 2H), 4.04 (s, 2H), 3.41 (d, J=6.5 Hz, 2H), 3.11-2.92 (m, 4H).

(352) 1394: White solid. Yield: 81.0%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.67-7.61 (m, 2H), 7.60-7.58 (m, 2H), 7.39-7.27 (m, 8H), 7.12 (t, J=8.0 Hz, 1H), 3.79 (s, 2H), 3.78 (s, 2H), 2.68 (br, 8H).

(353) 1395: White solid. Yield: 83.7%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66-7.61 (m, 2H), 7.60-7.58 (m, 2H), 7.41-7.29 (m, 6H), 7.19 (d, J=7.9 Hz, 2H), 7.11 (d, J=7.9 Hz, 2H), 3.81 (s, 2H), 3.50 (s, 2H), 2.71 (br, 4H), 2.54 (br, 4H), 2.32 (s, 3H).

(354) 1396: Colorless syrup. Yield: 82.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.72 (br, 1H), 7.85 (br, 1H), 7.51-7.48 (m, 1H), 7.35-7.16 (m, 11H), 7.16-7.09 (m, 1H), 7.02-6.99 (m, 2H), 6.92-6.66 (m, 3H), 3.83 (s, 2H), 3.82 (s, 2H), 3.04-3.02 (m, 2H), 2.99-2.96 (m, 2H).

(355) 1397: Colorless syrup. Yield: 77.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 13.32 (br, 1H), 7.52-7.43 (m, 9H), 7.37-7.28 (m, 5H), 7.21-7.03 (m, 3H), 5.81-5.73 (m, 1H), 5.34-5.17 (m, 2H), 4.06 (s, 2H), 3.47 (d, J=7.0 Hz, 2H), 3.09-3.06 (m, 2H), 2.92-2.89 (m, 2H).

(356) 1039: Yellow syrup. Yield: 91.5%..sup.1H NMR (500 MHz, CDCl.sub.3) 9.71 (br, 1H), 7.89-7.84 (m, 2H), 7.70-7.61 (m, 2H), 7.61-7.50 (m, 1H), 7.37-7.24 (m, 4H), 7.17 (d, J=8.8 Hz, 1H), 7.13-6.93 (m, 5H), 6.81 (dd, J=8.8, 2.4 Hz, 1H), 4.69 (s, 2H), 3.81-3.77 (m, 2H), 3.77 (s, 3H), 3.09-3.02 (m, 2H).

(357) 1040: Yellow syrup. Yield: 93.1%..sup.1H NMR (500 MHz, CDCl.sub.3) 8.14 (s, 1H), 8.00 (d, J=7.7 Hz, 1H), 7.77-7.61 (m, 3H), 7.57 (s, 1H), 7.25-7.10 (m, 6H), 7.03-6.90 (m, 6H), 6.46 (s, 1H), 4.76 (s, 2H), 4.60 (s, 2H).

Example 5Preparation of Compounds of Class IV

(358) Scheme 15 outlines the chemical synthesis of compounds identified as Class IV. These compounds are shown in Table 5 below.

(359) ##STR00252##
General Procedure for the Preparation of Intermediate Compound 42..sup.56

(360) To a vacuum flame-dried flask was added a benzoin 4 or its other derivatives (0.212 g, 1 mmol), acid 41 (1.1 mmol), dicyclohexylcarbodiimide (0.206 g, 1 mmol), 4-dimethylaminopyridine (12.2 mg, 0.1 mmol), dichloromethane (10 mL) under nitrogen atmosphere. The reaction mixture was stirred for 2 hours at room temperature. Then ethyl acetate was added and the reaction mixture was filtered. The filtrate was then washed with 5% HCl, saturated NaHCO.sub.3, brine and dried with Na.sub.2SO.sub.4. After filtration, the solvent was concentrated in vacuum. This crude residue was then purified by flash chromatography to give Intermediates 42.

(361) General Procedure for the Preparation of Compounds of Class IV

(362) A mixture of 42 (0.5 mmol), ammonium acetate (2.5 mmol) in glacial acetic acid (5 mL) was refluxed for 2 hours. After cooling, water was added to the reaction mixture. After extracting with ethyl acetate, the combined organic phase was washed with saturated NaHCO.sub.3, brine, dried with Na.sub.2SO.sub.4, filtered, and concentrated in vacuum. The crude residue was then purified by flash chromatography to give the desired product, compounds of Class IV: 684-689, 692, 693, 926, 1011-1033, 1033-1037.

(363) TABLE-US-00005 TABLE 5 Structures of compounds of Class IV. ID Structure 684 685 686 687 688 689 692 693 0 926 1011 1012 1013 1033 1034 1035 1036 1037
Characterization of Compounds of Class IV:

(364) 684: White solid, yield: 86%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.71-7.62 (m, 4H), 7.55 (d, J=16.3 Hz, 1H), 7.40-7.30 (m, 6H), 7.28 (d, J=8.0 Hz, 1H), 7.14 (d, J=7.7 Hz, 1H), 7.08-7.06 (m, 1H), 6.99 (d, J=16.3 Hz, 1H), 6.88 (dd, J=8.2, 2.4 Hz, 1H), 3.83 (s, 3H).

(365) 685: Yellow solid, yield: 83%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.72-7.60 (m, 5H), 7.38-7.28 (m, 7H), 7.19 (d, J=3.5 Hz, 1H), 7.04-7.01 (m, 1H), 6.81 (d, J=16.1 Hz, 1H).

(366) 686: Yellow solid, yield: 85%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.69-7.58 (m, 5H), 7.45 (d, J=16.2 Hz, 1H), 7.43-7.41 (m, 1H), 7.40-7.27 (m, 6H), 6.70 (d, J=16.1 Hz, 1H), 6.65-6.64 (m, 1H).

(367) 687: Yellow syrup, yield: 92%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66 (s, 1H), 7.63-7.60 (m, 2H), 7.58 (d, J=7.6 Hz, 1H), 7.54-7.50 (m, 3H), 7.46-7.40 (m, 1H), 7.37-7.28 (m, 6H), 4.23 (s, 2H).

(368) 688: White solid, yield: 69%. .sup.1H NMR (500 MHz, CDCl.sub.3) 8.39 (s, 1H), 8.31 (d, J=7.9 Hz, 1H), 7.72-7.64 (m, 6H), 7.40-7.34 (m, 6H).

(369) 689: White solid, yield: 88%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.73-7.71 (m, 3H), 7.61-7.56 (m, 2H), 7.53-7.48 (m, 2H), 7.37-7.27 (m, 6H), 3.30 (t, J=7.6 Hz, 2H), 3.19 (t, J=7.5 Hz, 2H).

(370) 692: Yellow solid, yield: 89%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66-7.61 (m, 4H), 7.45 (s, 1H), 7.40-7.27 (m, 7H), 6.87 (d, J=16.1 Hz, 1H), 6.55-6.42 (m, 2H).

(371) 693: White solid, yield: 91%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.77 (s, 1H), 7.71 (d, J=7.7 Hz, 1H), 7.67-7.63 (m, 4H), 7.59 (d, J=16.5 Hz, 1H), 7.56 (s, 1H), 7.50 (t, J=7.7 Hz, 1H), 7.41-7.30 (m, 6H), 7.06 (d, J=16.4 Hz, 1H).

(372) 926: White solid, yield: 73.0%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.46 (br, 1H), 7.59 (s, 1H), 7.54-7.48 (m, 2H), 7.45-7.41 (m, 1H), 7.08-7.04 (m, 1H), 7.02-6.99 (m, 1H), 6.99-6.95 (m, 1H), 6.93-6.91 (m, 1H), 6.88-6.86 (m, 1H), 6.56 (s, 1H), 6.22-6.20 (m, 1H), 3.90-3.81 (m, 2H), 3.77 (s, 3H).

(373) 1011: White solid, yield: 82.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.53-7.38 (m, 6H), 7.34-7.24 (m, 8H), 3.19 (t, J=7.6 Hz, 2H), 3.10-3.06 (m, 2H).

(374) 1012: White solid, yield: 85.7%. .sup.1H NMR (500 MHz, CDCl.sub.3) 57.76 (s, 1H), 7.74 (s, 2H), 7.40-7.28 (m, 5H), 7.24-7.22 (m, 1H), 7.09-7.02 (m, 2H), 3.33 (t, J=7.6 Hz, 2H), 3.24-3.19 (m, 2H).

(375) 1013: Yellow solid, yield: 81.6%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.97 (s, 2H), 7.83 (s, 1H), 7.71-7.61 (m, 4H), 7.43-7.34 (m, 5H), 7.16 (d, J=16.4 Hz, 1H).

(376) 1033: White solid, yield: 89.5%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.75-7.74 (m, 3H), 7.31-7.24 (m, 3H), 7.23-7.16 (m, 2H), 7.15-7.11 (m, 1H), 7.11-7.07 (m, 1H), 6.91-6.85 (m, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 3.33 (t, J=7.6 Hz, 2H), 3.21 (t, J=7.6 Hz, 2H).

(377) 1034: White solid, yield: 84.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.42-7.41 (m, 1H), 7.34-7.26 (m, 4H), 7.24-7.19 (m, 3H), 7.00-6.97 (m, 2H), 6.82 (d, J=16.1 Hz, 1H), 6.46-6.38 (m, 2H).

(378) 1035: White solid, yield: 81.7%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.66 (s, 1H), 7.51 (d, J=16.2 Hz, 1H), 7.48-7.32 (m, 7H), 7.10-7.02 (m, 2H), 6.71 (d, J=16.2 Hz, 1H), 6.67-6.66 (m, 1H).

(379) 1036: White solid, yield: 43.2%. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.68 (d, J=15.9 Hz, 1H), 7.62 (d, J=16.3 Hz, 1H), 7.50-7.49 (m, 1H), 7.47-7.28 (m, 7H), 7.11-7.03 (m, 1H), 6.83 (d, J=16.3 Hz, 1H), 6.27 (d, J=15.9 Hz, 1H).

(380) 1037: White solid, yield: 23.1%. .sup.1H NMR (500 MHz, CDCl.sub.3) 9.50 (br, 1H), 7.37 (d, J=16.4 Hz, 1H), 7.34-7.15 (m, 9H), 7.01-6.98 (t, J=7.4 Hz, 2H), 6.82 (d, J=16.4 Hz, 1H).

Example 6Preparation of Compounds V-131 Analogues and V-154 Analogues

(381) Scheme 16 below outlines the chemical synthesis of compounds identified as V131 Analogues; and Scheme 17 below outlines the chemical synthesis of compounds identified as V154 Analogues. These compounds are shown in Table 6 below.

(382) ##STR00270##

(383) ##STR00271##
General Procedure for the Preparation of Intermediates 45

(384) A mixture of 6-mercaptopurine 43 (10 mmol) and K.sub.2CO.sub.3 (10 mmol) in 25 mL of DMF was stirred for 5 minutes at room temperature. Then bromide 44 (10 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 4 hours and 200 mL H.sub.2O was added. The precipitate was collected by filtration, the solid was washed with EtOAc and CH.sub.2Cl.sub.2 and dried. Yielded 45 as white powder: 91%.

(385) General Procedure for the Preparation of V131 Analogues.

(386) To a solution of 45 (1.0 equiv) in 60 mL of anhydrous ethyl acetate at 50 C. was added and p-toluene-sulfonic acid (0.1 equiv). The mixture was vigorously stirred and 46 (3 equiv) was added dropwise. The reaction mixture was stirred for 1 hour and cooled to rt. Then concentrated aqueous ammonia was added and stirred for 5 minutes. The ethyl acetate phase was separated and washed twice with water. The ethyl acetate layer was dried with Na.sub.2SO.sub.4 and concentrated under reduced pressure. Recrystallization from petroleum ether to afford V131 Analogues.

(387) General Procedure for the Preparation of V151 and V154 Analogues.

(388) Preparation of V151: A mixture of 47 (2 mmol) and aldehyde 48 (5 mmol) was heated at 100 C. for 1.5 hour. Then 50 ml of anhydrous EtOH was added to the reaction mixture. On cooling, yellowish orange crystal was formed and collected by filtration, which was recrystallized from EtOH, V151 analogues were obtained.

(389) Preparation of V154 Analogues: To V151 analogues (1 mmol) in 15 mL acetone, 10 mL 5% HCl was added, the mixture was stirred for 5 minutes at rt. Then Na.sub.2CO.sub.3 was added to adjust pH7. The mixture was extracted with dichloromethane (315 mL). The combined organic extracts were washed with brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure. The residue is purified by column chromatography to give the desired products, compounds V154 Analogues as illustrated in Scheme 17.

(390) TABLE-US-00006 TABLE 6 Structures of compounds V131 and V154 and analogues. ID Structure V131 (known in the art) V154 (known in the art) V151 (known in the art)
Characterization of Compounds V131, V154, 151:

(391) V131: White solid. .sup.1H NMR (500 MHz, acetone-d.sub.6) 8.76-8.70 (m, 1H), 8.35 (s, 1H), 7.66-7.59 (m, 1H), 7.38-7.28 (m, 1H), 7.17-7.10 (m, 2H), 6.40-6.38 (m, 1H), 4.73 (s, 2H), 4.31-4.26 (m, 1H), 4.07-3.97 (m, 1H), 2.64-2.62 (m, 1H), 2.58-2.48 (m, 1H), 2.35-2.25 (m, 1H), 2.20-2.09 (m, 1H).

(392) V154: White solid. .sup.1H NMR (500 MHz, acetone-d.sub.6) 7.92-7.89 (m, 2H), 7.62-7.59 (m, 1H), 7.53-7.48 (m, 2H), 7.46-7.41 (m, 2H), 7.37-7.32 (m, 2H), 7.31-7.25 (m, 1H), 6.26-6.21 (m, 1H), 4.18 (dd, J=31.7, 13.0 Hz, 2H).

Example 7Preparation of Compounds V-248 Analogues

(393) Scheme 18, Scheme 19 and Scheme 20 below outlines the chemical synthesis of compounds identified as V248 Analogues. These compounds are shown in Table 7 below.

(394) ##STR00275##

(395) ##STR00276##

(396) ##STR00277##

(397) General Procedure for the Preparation of Intermediates.

(398) Preparation of intermediates 51: Aldehyde 49 (1.0 equiv) was added to a solution of ketone 50 (1.0 equiv, 0.5 M in EtOH). Then a 10% aqueous solution of NaOH (0.5 equiv) was added dropwise at 0 C. The reaction was stirred at 0 C. for 4 hours. The mixture was diluted with water and extracted 3 times with CH.sub.2Cl.sub.2. The mixture was diluted with water (10 mL for each mmol of starting ketone 50) and extracted 3 times with CH.sub.2Cl.sub.2 (10 mL for each mmol of starting ketone 6). The organic layers were combined and dried over Na.sub.2SO.sub.4. Solvents were removed under reduced pressure to afford the crude products, which were purified through flash chromatography on silica gel (Hexane/EtOAc 50:1 to 20:1 as the eluent). The obtained product (1.0 equiv) was then dissolved in MeOH. 10% Pd/C was added and the flask was aerated with H.sub.2. After stirring for 2 hours at room temperature, the mixture was filtered. Solvents were removed under reduced pressure to afford the crude product, which were purified through flash chromatography on silica gel (Hexane/EtOAc 50:1 to 15:1 as the eluent) to give 51.

(399) Preparation of intermediates 52 and 57: Freshly activated zinc (2.5 equiv) in powder was kept in a flame-dried flask under N.sub.2 atmosphere. Traces of iodine and 4 mL of dry THF were added. Then, ethyl bromoacetate (2.0 equiv) was added and the mixture was heated to make sure the reaction was initiated. A solution of compound 51 (1.0 equiv) in THF was added dropwise at room temperature. The reaction was stirred overnight at room temperature (when needed, warming up the reaction to 50 C. Monitored by TLC.) The reaction mixture was filtered through celite, diluted with EtOAc and washed with 0.5 M HCl aqueous. The organic layer was dried over Na.sub.2SO.sub.4. Solvents were removed under reduced pressure, the crude residue was then purified through flash chromatography on silica gel (Hexane/EtOAc 50:1 to 15:1 as the eluent) to give the ester, which (1.0 equiv) was dissolved in MeOH. KOH (2.0 equiv) was added to the solution. The mixture was stirred at 50 C. for 4 hours until full conversion of compound 9. Then the mixture was diluted with CH.sub.2Cl.sub.2 and extracted with water. The pH of aqueous phase was then adjusted to 2 by slowly adding a 1 M HCl solution. The aqueous phase was extracted with CH.sub.2Cl.sub.2 for 5 times. The organic layers were combined and dried over Na.sub.2SO.sub.4. Solvents were removed under reduced pressure, the crude products was purified through recrystallization (solvents: Hexane/DCM=1:1) to give 52.

(400) Intermediates 57 were obtained according to the same procedure for the preparation of intermediates 52 as described above.

(401) General Procedure for the Preparation of V248 Analogues.

(402) Procedure A: To a mixture of acid 52 (0.12 mmol), 53 (0.1 mmol) and Et.sub.3N (0.4 mmol) in DMSO (3 mL), HBTU (0.4 mmol) was added. The mixture was stirred at room temperature overnight. 10 mL water was added and extracted with dichloromethane (315 mL). The combined organic phases were washed with brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography to give the desired products, compounds V248 analogues (Scheme 18).

(403) Procedure B: To a solution of compound 52 (or 57) (1.0 equiv) in dry CH.sub.2Cl.sub.2, oxalyl (1.2 equiv) and catalytic amount of DMF were added in turn. The mixture was refluxed for 30 minutes and the solvent was removed through distillation to give a mixture of 54 and 55 (or 58 and 59), which was then dissolved in dry THF and used without further purification. To a solution of compound 53 (1.2 equiv) and Et.sub.3N (1.5 equiv). The above solution was added dropwise at 0 C. The mixture was stirred at 0 C. for 30 minutes. Then the reaction was quenched with water and extracted with EtOAc. The organic layer was dried over Na.sub.2SO.sub.4. Solvents were removed under reduced pressure, the crude residue was then purified through flash chromatography on silica gel (Hexane/EtOAc 5:1 to 2:1 as the eluent) to give compounds V248 analogues (Schemes 19 and 20).

(404) TABLE-US-00007 TABLE 7 Structure of compound V248 and its analogues. ID Structure V248 859 858 0 860 868 869 870 871 872 880 881 882 883 0 889 895 1200 1201 1225 1235 1236 1237 1238 1239 00 1240 01 1241 02 1244 03 1245 04 1246 05 1247 06 1248 07 1249 08 1250 09 1257 0 1258 1259 1260 1261 1262 1273 1274 1275 1276 1298 0 1299 1300 1301 1302 1303 1306 1307 1308 1309 1310 0 1303 1306 1307 1308 1309 1310 1311 1320 1321 1322 0 1323 1345 1348 1406 1407
Characterization of Compound V248 and its Analogues

(405) V248: Light yellow solid. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.54-7.45 (m, 2H), 7.44-7.33 (m, 5H), 7.31-7.20 (m, 5H), 7.13 (q, J=7.4 Hz, 3H), 6.44 (s, 1H), 6.14 (s, 1H), 4.47 (t, J=14.5 Hz, 1H), 3.68 (dd, J=29.3, 13.6 Hz, 1H), 3.56-3.31 (m, 1H), 3.06 (t, J=15.3 Hz, 1H), 3.01-2.91 (m, 1H), 2.86-2.76 (m, 1H), 2.70-2.67 (m, 1H), 2.41-2.04 (m, 3H), 2.03-1.86 (m, 1H), 1.83-1.69 (m, 1H), 1.62-1.58 (m, 1H), 1.30-1.21 (m, 1H).

(406) 858: Light yellow solid, 71.2% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.47-7.42 (m, 4H), 7.41-7.32 (m, 5H), 7.29 (dt, J=3.9, 1.6 Hz, 1H), 7.08 (d, J=8.6 Hz, 2H), 6.79 (d, J=8.6 Hz, 2H), 6.22 (s, 1H), 5.30 (s, 1H), 4.62 (d, J=13.1 Hz, 1H), 3.83-3.75 (m, 1H), 3.75 (s, 3H), 3.46 (td, J=12.9, 2.7 Hz, 1H), 3.18 (td, J=12.7, 2.7 Hz, 1H), 3.13-3.01 (m, 2H), 2.66 (t, J=8.1 Hz, 2H), 2.04 (s, 1H), 1.93-1.80 (m, 2H), 1.78-1.72 (m, 2H). TOF MS (ESI), m/z: 442.24 [M+H].sup.+.

(407) 859: light yellow solid, 57.5% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.47-7.42 (m, 4H), 7.42-7.33 (m, 5H), 7.31-7.21 (m, 3H), 7.19-7.12 (m, 3H), 6.22 (s, 1H), 4.60 (ddd, J=29.7, 16.0, 13.7 Hz, 1H), 3.75 (ddd, J=31.7, 17.0, 6.7 Hz, 1H), 3.56-3.37 (m, 1H), 3.17 (td, J=13.0, 3.0 Hz, 1H), 3.10 (q, J=7.9 Hz, 2H), 2.72 (t, J=8.0 Hz, 2H), 2.10-2.00 (m, 1H), 1.93-1.71 (m, 3H), 1.67 (s, 1H). TOF MS (ESI), m/z: 412.23 [M+H].sup.+.

(408) 860: Light yellow syrup, 50.0% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.49-7.33 (m, 9H), 7.32-7.27 (m, 1H), 7.19 (td, J=7.9, 6.1 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 6.89-6.81 (m, 2H), 6.23 (s, 1H), 4.72-4.56 (m, 1H), 3.82-3.73 (m, 1H), 3.48 (td, J=13.1, 2.9 Hz, 1H), 3.18 (td, J=12.9, 3.0 Hz, 1H), 3.14-3.03 (m, 2H), 2.72 (t, J=8.0 Hz, 2H), 2.06 (td, J=13.3, 4.8 Hz, 1H), 1.93-1.72 (m, 3H), 1.64 (s, 1H). TOF MS (ESI), m/z: 430.22 [M+H].sup.+.

(409) 868: Colorless syrup, 67.5% in yield..sup.1H NMR (500 MHz, CDCl.sub.3) 7.47-7.31 (m, 13H), 7.31-7.26 (m, 1H), 6.23 (s, 1H), 4.60 (d, J=11.0 Hz, 1H), 3.74 (d, J=13.4 Hz, 1H), 3.45 (t, J=11.4 Hz, 1H), 3.23-3.04 (m, 3H), 2.79 (t, J=7.5 Hz, 2H), 2.04 (td, J=13.3, 4.8 Hz, 1H), 1.91-1.79 (m, 2H), 1.79-1.71 (m, 2H).

(410) 869: Light yellow syrup, 52.3% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.64 (s, 1H), 7.60 (d, J=8.0 Hz, 2H), 7.51 (t, J=7.8 Hz, 1H), 7.47-7.42 (m, 2H), 7.37 (t, J=7.6 Hz, 2H), 7.29 (t, J=7.3 Hz, 1H), 7.24 (t, J=7.4 Hz, 2H), 7.18-7.10 (m, 3H), 6.24 (s, 1H), 4.62 (d, J=13.2 Hz, 1H), 3.74 (d, J=15.5 Hz, 1H), 3.48 (td, J=13.0, 2.9 Hz, 1H), 3.19 (td, J=12.9, 3.0 Hz, 1H), 3.16-3.03 (m, 2H), 2.71 (t, J=8.0 Hz, 2H), 2.11-2.00 (m, 1H), 1.94-1.73 (m, 3H), 1.62 (s, 1H).

(411) 870: Light yellow syrup, 49.1% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.47-7.42 (m, 2H), 7.39-7.33 (m, 4H), 7.29 (t, J=7.3 Hz, 1H), 7.24 (d, J=7.4 Hz, 2H), 7.20 (d, J=7.9 Hz, 2H), 7.19-7.12 (m, 3H), 6.20 (s, 1H), 4.61 (d, J=15.2 Hz, 1H), 3.77 (d, J=13.3 Hz, 1H), 3.44 (td, J=13.0, 2.8 Hz, 1H), 3.16 (td, J=12.8, 2.7 Hz, 1H), 3.12-3.02 (m, 2H), 2.72 (t, J=8.1 Hz, 2H), 2.39 (s, 3H), 2.12-1.99 (m, 1H), 1.94-1.70 (m, 3H), 1.58 (s, 1H).

(412) 871: White solid, 64.5% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.44 (d, J=7.2 Hz, 2H), 7.42-7.34 (m, 4H), 7.31-7.26 (m, 1H), 7.24 (d, J=7.4 Hz, 2H), 7.19-7.13 (m, 3H), 6.93 (d, J=8.8 Hz, 2H), 6.18 (s, 1H), 4.61 (d, J=13.2 Hz, 1H), 3.84 (s, 3H), 3.78 (d, J=13.3 Hz, 1H), 3.45 (td, J=13.0, 2.3 Hz, 1H), 3.16 (td, J=12.9, 2.7 Hz, 1H), 3.11-3.04 (m, 2H), 2.72 (t, J=8.0 Hz, 2H), 2.09-2.01 (m, 1H), 1.93-1.69 (m, 3H), 1.63 (s, 1H).

(413) 872: Light yellow solid, 59.0% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.84 (d, J=16.2 Hz, 1H), 7.66 (d, J=7.8 Hz, 1H), 7.59 (s, 1H), 7.50 (d, J=7.8 Hz, 1H), 7.46-7.37 (m, 8H), 7.34 (t, J=7.5 Hz, 2H), 7.30-7.26 (m, 1H), 6.55 (d, J=16.3 Hz, 1H), 6.16 (s, 1H), 4.71 (d, J=13.2 Hz, 1H), 3.95 (d, J=13.5 Hz, 1H), 3.65 (td, J=13.1, 2.7 Hz, 1H), 3.27 (td, J=12.9, 2.9 Hz, 1H), 2.12 (td, J=13.3, 4.8 Hz, 1H), 1.99 (td, J=13.2, 4.7 Hz, 1H), 1.88 (dd, J=14.0, 2.5 Hz, 1H), 1.82 (dd, J=13.7, 2.4 Hz, 1H), 1.64 (s, 1H).

(414) 880: Colorless syrup, 30.0% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.54 (dt, J=8.3, 1.8 Hz, 2H), 7.42-7.34 (m, 10H), 7.33-7.27 (m, 3H), 6.99 (s, 1H), 4.51 (d, J=13.2 Hz, 1H), 3.78 (q, J=16.0 Hz, 2H), 3.65 (d, J=13.5 Hz, 1H), 3.46 (td, J=13.2, 2.8 Hz, 1H), 3.04 (td, J=13.0, 2.7 Hz, 1H), 1.93-1.82 (m, 1H), 1.78 (td, J=13.1, 4.6 Hz, 1H), 1.73-1.66 (m, 2H), 1.52 (s, 1H).

(415) 881: Colorless syrup, 33.7% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.46-7.38 (m, 7H), 7.36-7.29 (m, 3H), 7.27-7.19 (m, 4H), 7.13 (t, J=7.2 Hz, 1H), 6.47 (s, 1H), 4.70-4.61 (m, 1H), 4.23 (d, J=15.0 Hz, 1H), 4.13 (d, J=15.0 Hz, 1H), 3.98-3.87 (m, 1H), 3.58 (td, J=12.9, 3.3 Hz, 1H), 3.25-3.13 (m, 2H), 2.03 (td, J=13.3, 4.9 Hz, 1H), 1.88-1.74 (m, 3H), 1.62 (s, 1H).

(416) 882: Colorless syrup, 57.8% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.48-7.42 (m, 2H), 7.40-7.26 (m, 5H), 7.23-7.16 (m, 3H), 6.94 (d, J=7.7 Hz, 1H), 6.89-6.78 (m, 2H), 6.21 (s, 1H), 4.61 (d, J=13.1 Hz, 1H), 3.77 (d, J=11.3 Hz, 1H), 3.47 (td, J=13.0, 2.8 Hz, 1H), 3.17 (td, J=13.0, 2.9 Hz, 1H), 3.12-3.02 (m, 2H), 2.72 (t, J=8.0 Hz, 2H), 2.38 (s, 3H), 2.05 (td, J=13.3, 4.8 Hz, 1H), 1.92-1.71 (m, 3H), 1.66 (s, 1H).

(417) 883: Light yellow syrup, 57.5% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.47-7.42 (m, 2H), 7.36 (t, J=7.7 Hz, 2H), 7.31-7.22 (m, 3H), 7.19-7.11 (m, 3H), 7.02 (dd, J=8.3, 2.1 Hz, 1H), 6.94 (d, J=2.1 Hz, 1H), 6.88 (d, J=8.4 Hz, 1H), 6.18 (s, 1H), 4.62 (d, J=13.0 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.83-3.76 (m, 1H), 3.54-3.42 (m, 1H), 3.18 (td, J=12.9, 2.7 Hz, 1H), 3.10-2.98 (m, 2H), 2.74 (t, J=8.1 Hz, 2H), 2.06 (td, J=13.5, 4.6 Hz, 1H), 1.90-1.68 (m, 3H), 1.63 (s, 1H).

(418) 884: Light yellow syrup, 60.0% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.51-7.44 (m, 2H), 7.43-7.35 (m, 3H), 7.34-7.29 (m, 1H), 7.26-7.21 (m, 1H), 7.19-7.12 (m, 1H), 7.12-7.04 (m, 3H), 6.85-6.79 (m, 2H), 6.24 (s, 1H), 4.63 (d, J=12.3 Hz, 1H), 3.82-3.71 (m, 4H), 3.48 (t, J=12.0 Hz, 1H), 3.20 (td, J=12.7, 0.9 Hz, 1H), 3.13-2.99 (m, 2H), 2.68 (t, J=7.6 Hz, 2H), 2.07 (td, J=12.9, 4.3 Hz, 1H), 1.96-1.75 (m, 3H), 1.71 (s, 1H).

(419) 888: Colorless syrup, 63.2% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.43-7.37 (m, 2H), 7.31 (t, J=7.9 Hz, 1H), 7.10-6.99 (m, 5H), 6.97-6.94 (m, 1H), 6.89 (dd, J=7.9, 2.2 Hz, 1H), 6.83-6.75 (m, 2H), 6.20 (s, 1H), 4.60 (d, J=13.5 Hz, 1H), 3.84 (s, 3H), 3.79-3.76 (m, 1H), 3.75 (s, 3H), 3.42 (td, J=13.2, 2.8 Hz, 1H), 3.14 (td, J=12.9, 2.8 Hz, 1H), 3.09-2.97 (m, 2H), 2.66 (t, J=8.0 Hz, 2H), 2.00 (td, J=13.4, 4.9 Hz, 1H), 1.89-1.76 (m, 2H), 1.76-1.68 (m, 1H), 1.66 (s, 1H).

(420) 889: Light yellow solid, 68.9% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.43-7.36 (m, 4H), 7.09-7.01 (m, 4H), 6.94-6.89 (m, 2H), 6.81-6.77 (m, 2H), 6.15 (s, 1H), 4.60 (d, J=13.4 Hz, 1H), 3.84 (s, 3H), 3.79-3.77 (m, 1H), 3.75 (s, 3H), 3.42 (td, J=13.1, 2.6 Hz, 1H), 3.14 (td, J=12.7, 2.4 Hz, 1H), 3.09-3.00 (m, 2H), 2.66 (t, J=8.0 Hz, 2H), 2.00 (td, J=13.3, 4.7 Hz, 1H), 1.89-1.76 (m, 2H), 1.76-1.66 (m, 2H).

(421) 895: Light yellow syrup, 39.5% in yield. .sup.1H NMR (500 MHz, CDCl.sub.3) 7.49-7.32 (m, 6H), 7.31-7.26 (m, 1H), 7.12-6.99 (m, 2H), 6.95-6.87 (m, 2H), 6.82-6.75 (m, 2H), 6.17 (s, 1H), 4.61 (d, J=13.5 Hz, 1H), 3.84 (s, 3H), 3.78 (d, J=4.3 Hz, 1H), 3.49-3.42 (m, 1H), 3.16 (td, J=13.2, 2.8 Hz, 1H), 3.09-2.99 (m, 2H), 2.67 (t, J=6.5 Hz, 2H), 2.05 (td, J=13.1, 3.8 Hz, 1H), 1.91-1.72 (m, 3H), 1.60 (s, 1H). HRMS-ESI (m/z): [M+H].sup.+ calcd for C29H31FNO3, 460.2283; found 460.2296.

(422) 1200: Colorless syrup, 80.0% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.77 (s, 1H), 7.63 (d, J=7.9 Hz, 1H), 7.57 (d, J=7.8 Hz, 1H), 7.50 (t, J=7.8 Hz, 1H), 7.45-7.33 (m, 5H), 6.90 (d, J=12.6 Hz, 1H), 6.87-6.80 (m, 2H), 6.23 (s, 1H), 4.68 (d, J=13.4 Hz, 1H), 3.86-3.78 (m, 4H), 3.48 (t, J=12.2 Hz, 1H), 3.22-3.02 (m, 3H), 2.67 (td, J=7.9, 2.4 Hz, 2H), 2.08 (dt, J=13.3, 5.1 Hz, 1H), 1.95-1.80 (m, 2H), 1.77 (d, J=13.6 Hz, 1H), 1.72 (s, 1H).

(423) 1201: Colorless syrup, 78.6% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.64 (d, J=8.4 Hz, 2H), 7.59 (d, J=8.4 Hz, 2H), 7.47-7.34 (m, 5H), 6.91 (d, J=12.7 Hz, 1H), 6.88-6.81 (m, 2H), 6.23 (s, 1H), 4.67 (d, J=13.4 Hz, 1H), 3.94-3.74 (m, 4H), 3.47 (t, J=12.6 Hz, 1H), 3.26-3.00 (m, 3H), 2.67 (t, J=7.9 Hz, 2H), 2.07 (td, J=13.2, 5.9 Hz, 1H), 1.93-1.78 (m, 2H), 1.75 (d, J=13.1 Hz, 1H), 1.66 (s, 1H).

(424) 1225: Colorless syrup, 27.5% in yield. .sup.1H NMR (400 MHz, cdcl.sub.3) 7.35-7.13 (m, 9H), 6.92-6.84 (m, 3H), 6.81 (dd, J=8.7, 1.0 Hz, 2H), 5.82 (s, 1H), 3.77 (s, 3H), 3.68-3.59 (m, 2H), 3.20-3.09 (m, 2H), 3.03-2.93 (m, 2H), 2.86-2.68 (m, 4H), 2.63-2.51 (m, 2H).

(425) 1235: Colorless syrup, 29.0% in yield. .sup.1H NMR (400 MHz, cdcl.sub.3) 7.36-7.10 (m, 8H), 6.92-6.81 (m, 2H), 6.49-6.39 (m, 2H), 6.34 (t, J=2.3 Hz, 1H), 5.82 (s, 1H), 3.78 (s, 3H), 3.77 (s, 3H), 3.67-3.57 (m, 2H), 3.18-3.09 (m, 2H), 3.02-2.92 (m, 2H), 2.83-2.75 (m, 2H), 2.75-2.68 (m, 2H), 2.61-2.52 (m, 2H).

(426) 1236: Colorless syrup, 52.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.49-7.35 (m, 5H), 7.20 (t, J=8.4 Hz, 1H), 6.93-6.75 (m, 3H), 6.60-6.50 (m, 1H), 6.50-6.41 (m, 2H), 6.22 (s, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.64-3.52 (m, 2H), 3.25-3.14 (m, 2H), 3.14-3.05 (m, 4H), 2.72-2.59 (m, 2H).

(427) 1237: Colorless syrup, 23.7% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.39-7.28 (m, 5H), 7.15 (t, J=8.2 Hz, 1H), 6.94-6.80 (m, 3H), 6.47-6.38 (m, 2H), 6.33 (t, J=2.3 Hz, 1H), 5.90 (s, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 3.65-3.58 (m, 2H), 3.24-3.16 (m, 2H), 2.99-2.91 (m, 2H), 2.83-2.76 (m, 2H), 2.71-2.64 (m, 2H), 2.55-2.46 (m, 2H).

(428) 1238: Colorless syrup, 55.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.47-7.35 (m, 5H), 7.33-7.28 (m, 2H), 6.98-6.78 (m, 6H), 6.22 (s, 1H), 3.88-3.83 (m, 2H), 3.81 (s, 3H), 3.64-3.56 (m, 2H), 3.23-3.16 (m, 2H), 3.13-3.06 (m, 4H), 2.70-2.62 (m, 2H).

(429) 1239: Colorless syrup, 21.0% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.41-7.21 (m, 7H), 6.96-6.76 (m, 6H), 5.90 (s, 1H), 3.88 (s, 3H), 3.67-3.58 (m, 2H), 3.26-3.17 (m, 2H), 2.99-2.91 (m, 2H), 2.85-2.75 (m, 2H), 2.72-2.64 (m, 2H), 2.57-2.47 (m, 2H).

(430) 1240: Colorless syrup, 50.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.49-7.31 (m, 9H), 6.99-6.76 (m, 3H), 6.22 (s, 1H), 4.63 (s, 1H), 3.84 (s, 3H), 3.79 (s, 1H), 3.45 (s, 1H), 3.08 (d, J=6.7 Hz, 2H), 2.66 (t, J=7.9 Hz, 2H), 2.01 (s, 1H), 1.78 (s, 3H), 1.63 (s, 2H). HRMS-ESI (m/z): [M+H].sup.+ calcd for C.sub.29H.sub.30ClFNO.sub.3, 494.1893; found 494.1909.

(431) 1241: Colorless syrup, 22.1% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.40-7.32 (m, 5H), 7.31-7.27 (m, 2H), 7.16-7.12 (m, 2H), 6.95-6.78 (m, 3H), 5.92 (s, 1H), 4.54-4.45 (m, 1H), 3.86 (s, 3H), 3.63-3.54 (m, 1H), 3.10 (td, J=13.0, 2.8 Hz, 1H), 2.97-2.86 (m, 1H), 2.86-2.71 (m, 2H), 2.71-2.63 (m, 2H), 1.67-1.52 (m, 3H), 1.48 (s, 1H), 1.27 (s, 1H). HRMS-ESI (m/z): [M+H].sup.+ calcd for C.sub.29H.sub.30ClFNO.sub.3, 494.1893; found 494.1965.

(432) 1244: Colorless syrup, 48.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.49-7.31 (m, 7H), 7.10-7.01 (m, 2H), 6.95-6.79 (m, 3H), 6.22 (s, 1H), 4.63 (d, J=10.6 Hz, 1H), 3.83 (s, 3H), 3.78 (t, J=11.7 Hz, 1H), 3.45 (dd, J=25.9, 12.3 Hz, 1H), 3.25-2.99 (m, 3H), 2.66 (t, J=8.0 Hz, 2H), 1.92-1.72 (m, 3H), 1.63 (s, 2H).

(433) 1245: Colorless syrup, 21.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.42-7.30 (m, 5H), 7.22-7.15 (m, 2H), 7.00 (t, J=8.7 Hz, 2H), 6.92-6.81 (m, 3H), 5.92 (s, 1H), 4.55-4.45 (m, 1H), 3.86 (s, 3H), 3.64-3.54 (m, 1H), 3.10 (td, J=13.0, 2.8 Hz, 1H), 2.98-2.87 (m, 1H), 2.85-2.72 (m, 2H), 2.68 (d, J=8.1 Hz, 2H), 1.67-1.59 (m, 2H), 1.40 (s, 1H), 1.33-1.25 (m, 3H).

(434) 1246: Colorless syrup, 55.8% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.52 (s, 1H), 7.46-7.38 (m, 5H), 7.07 (dd, J=3.5, 0.8 Hz, 1H), 6.93-6.79 (m, 3H), 6.52 (dd, J=3.5, 1.8 Hz, 1H), 6.19 (s, 1H), 3.87-3.82 (m, 5H), 3.81-3.68 (m, 4H), 3.60-3.46 (m, 2H), 3.19-3.06 (m, 2H), 2.72-2.58 (m, 2H).

(435) 1247: Colorless syrup, 50.6% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.44-7.37 (m, 5H), 7.14 (t, J=8.1 Hz, 1H), 6.92-6.79 (m, 3H), 6.51 (dd, J=8.3, 1.7 Hz, 1H), 6.44-6.36 (m, 2H), 6.21 (s, 1H), 3.82 (s, 5H), 3.58 (s, 2H), 3.23-3.14 (m, 2H), 3.14-3.03 (m, 4H), 2.71-2.61 (m, 2H).

(436) 1248: Colorless oil, 25.0% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.39-7.28 (m, 5H), 7.10 (t, J=8.1 Hz, 1H), 6.93-6.79 (m, 3H), 6.39 (s, 2H), 5.90 (s, 1H), 3.88 (s, 4H), 3.64 (s, 2H), 3.23 (s, 2H), 2.95 (s, 2H), 2.86-2.74 (m, 2H), 2.71-2.61 (m, 3H), 2.57-2.43 (m, 2H).

(437) 1249: Colorless syrup, 45.8% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.49-7.44 (m, 2H), 7.42-7.33 (m, 4H), 7.30 (d, J=7.3 Hz, 1H), 6.96-6.80 (m, 5H), 6.19 (s, 1H), 4.63 (d, J=13.2 Hz, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.80-3.77 (m, 1H), 3.56-3.43 (m, 1H), 3.24-3.13 (m, 1H), 3.13-2.99 (m, 2H), 2.72-2.61 (m, 2H), 2.12-2.06 (m, 1H), 1.94-1.72 (m, 3H), 1.64 (s, 1H).

(438) 1250: Colorless syrup, 18.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.37-7.27 (m, 5H), 7.23-7.19 (m, 2H), 6.94-6.82 (m, 5H), 5.87 (s, 1H), 4.59-4.48 (m, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.64-3.57 (m, 1H), 3.15 (td, J=13.0, 2.8 Hz, 1H), 2.96 (td, J=12.8, 3.3 Hz, 1H), 2.83-2.64 (m, 4H), 1.73-1.54 (m, 4H), 1.46 (s, 1H).

(439) 1257: Colorless syrup, 47.0% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.42-7.32 (m, 6H), 6.96-6.81 (m, 5H), 6.18 (s, 1H), 4.63 (d, J=12.9 Hz, 1H), 3.85 (d, J=2.0 Hz, 3H), 3.84 (s, 3H), 3.82-3.76 (m, 1H), 3.50-3.40 (m, 1H), 3.19-3.11 (m, 1H), 3.11-3.00 (m, 2H), 2.67 (t, J=8.0 Hz, 2H), 2.04-1.97 (m, 1H), 1.88-1.70 (m, 3H), 1.27 (t, J=7.2 Hz, 1H).

(440) 1258: Colorless syrup, 16.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.35-7.27 (m, 4H), 7.18-7.09 (m, 2H), 6.95-6.78 (m, 5H), 5.86 (s, 1H), 4.60-4.48 (m, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.65-3.56 (m, 1H), 3.13 (td, J=13.0, 2.7 Hz, 1H), 2.93 (td, J=12.6, 3.7 Hz, 1H), 2.84-2.62 (m, 4H), 1.30-1.23 (m, 3H), 0.90-0.80 (m, 1H), 0.72 (td, J=13.2, 4.8 Hz, 1H).

(441) 1259: Colorless syrup, 49.6% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.46-7.30 (m, 7H), 7.25-7.18 (m, 3H), 6.96-6.78 (m, 3H), 6.23 (s, 1H), 4.84 (d, J=13.2 Hz, 1H), 4.00 (t, J=10.2 Hz, 1H), 3.84 (s, 3H), 3.15-2.99 (m, 3H), 2.81-2.62 (m, 4H), 1.95 (d, J=13.2 Hz, 1H), 1.86 (d, J=12.9 Hz, 1H), 1.73-1.62 (m, 1H), 1.58-1.51 (m, 1H).

(442) 1260: Colorless syrup, 18.9% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.42-7.34 (m, 5H), 7.30-7.24 (m, 2H), 7.20 (t, J=7.3 Hz, 1H), 6.99 (d, J=7.2 Hz, 2H), 6.93-6.80 (m, 3H), 5.93 (s, 1H), 4.69 (d, J=11.3 Hz, 1H), 3.86 (s, 3H), 3.78 (dd, J=11.3, 2.0 Hz, 1H), 2.85-2.72 (m, 2H), 2.72-2.61 (m, 2H), 2.55-2.41 (m, 2H), 1.73 (d, J=13.3 Hz, 1H), 1.46 (d, J=13.0 Hz, 1H), 1.36-1.24 (m, 2H), 0.62 (qd, J=12.8, 4.3 Hz, 1H).

(443) 1261: Colorless syrup, 51.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.45-7.35 (m, 5H), 7.08-7.02 (m, 1H), 6.97-6.81 (m, 6H), 6.23 (s, 1H), 3.89 (s, 3H), 3.89-3.85 (m, 2H), 3.83 (s, 3H), 3.66 (dd, J=9.9, 5.0 Hz, 2H), 3.12-3.04 (m, 4H), 3.01-2.95 (m, 2H), 2.67 (dd, J=9.1, 6.8 Hz, 2H).

(444) 1262: Colorless syrup, 22.3% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.39-7.29 (m, 5H), 7.06-6.97 (m, 1H), 6.92-6.83 (m, 5H), 6.71 (dd, J=7.8, 1.4 Hz, 1H), 5.91 (s, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.70-3.62 (m, 2H), 3.31-3.23 (m, 2H), 2.84-2.74 (m, 4H), 2.72-2.64 (m, 2H), 2.45-2.35 (m, 2H).

(445) 1273: Colorless syrup, 50.8% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.49-7.43 (m, 2H), 7.43-7.35 (m, 4H), 7.33-7.28 (m, 1H), 7.15-7.05 (m, 2H), 6.93-6.78 (m, 3H), 6.19 (s, 1H), 3.85 (d, J=18.8 Hz, 3H), 3.35 (s, 1H), 3.09-3.00 (m, 2H), 2.70-2.59 (m, 2H), 2.18 (s, 1H), 1.98 (s, 2H), 1.82 (d, J=13.1 Hz, 2H), 1.68 (s, 2H), 1.33-1.24 (m, 1H).

(446) 1274: Colorless syrup, 19.6% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.39-7.31 (m, 4H), 7.30-7.23 (m, 4H), 7.13-7.03 (m, 2H), 6.93-6.77 (m, 3H), 5.94 (s, 1H), 4.56-4.44 (m, 1H), 3.86 (s, 3H), 3.61-3.52 (m, 1H), 3.15 (td, J=13.0, 2.9 Hz, 1H), 3.01-2.92 (m, 1H), 2.80-2.73 (m, 2H), 2.70-2.64 (m, 2H), 1.76-1.67 (m, 1H), 1.67-1.63 (m, 1H), 1.46 (s, 1H), 1.41 (dd, J=13.8, 2.4 Hz, 1H), 1.02 (td, J=13.2, 4.8 Hz, 1H).

(447) 1275: Colorless syrup, 49.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.45-7.36 (m, 2H), 7.37-7.29 (m, 2H), 7.26-7.15 (m, 3H), 7.13-7.03 (m, 2H), 6.94-6.79 (m, 3H), 6.19 (s, 1H), 4.84 (d, J=13.3 Hz, 1H), 4.03-3.93 (m, 1H), 3.84 (s, 3H), 3.16-2.97 (m, 3H), 2.82-2.59 (m, 5H), 1.95 (d, J=13.4 Hz, 1H), 1.87 (d, J=12.7 Hz, 1H), 1.73-1.61 (m, 1H), 1.58-1.49 (m, 1H).

(448) 1276: Colorless syrup, 18.9% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.36-7.28 (m, 4H), 7.23-7.18 (m, 1H), 7.15-7.05 (m, 2H), 7.04-6.98 (m, 2H), 6.94-6.76 (m, 3H), 5.93 (s, 1H), 4.78-4.62 (m, 1H), 3.86 (s, 3H), 3.81-3.71 (m, 1H), 2.85-2.72 (m, 2H), 2.70-2.64 (m, 3H), 2.58-2.43 (m, 2H), 1.76 (d, J=13.3 Hz, 1H), 1.52 (d, J=13.2 Hz, 1H), 1.41-1.29 (m, 1H), 0.74 (qd, J=12.7, 4.3 Hz, 1H).

(449) 1298: Colorless syrup, 53.0% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.45-7.35 (m, 2H), 7.34-7.27 (m, 2H), 7.14-7.05 (m, 2H), 6.97-6.78 (m, 6H), 6.18 (s, 1H), 3.88-3.82 (m, 2H), 3.81 (s, 3H), 3.63-3.56 (m, 2H), 3.23-3.16 (m, 2H), 3.13-3.04 (m, 4H), 2.65 (dd, J=8.8, 6.9 Hz, 2H).

(450) 1299: Colorless syrup, 17.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.32-7.21 (m, 4H), 7.10-7.00 (m, 2H), 6.96-6.76 (m, 6H), 5.90 (s, 1H), 3.88 (s, 3H), 3.68-3.57 (m, 2H), 3.26-3.17 (m, 2H), 3.03-2.95 (m, 2H), 2.84-2.73 (m, 2H), 2.72-2.63 (m, 4H).

(451) 1300: Colorless syrup, 55.1% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.59 (d, J=8.0 Hz, 2H), 7.46 (d, J=8.0 Hz, 2H), 7.42-7.34 (m, 5H), 6.92-6.86 (m, 1H), 6.86-6.81 (m, 2H), 6.16 (s, 1H), 3.86 (s, 3H), 3.75-3.66 (m, 2H), 3.57 (s, 2H), 3.49-3.41 (m, 2H), 3.06 (dd, J=9.0, 6.9 Hz, 2H), 2.64 (dd, J=8.9, 6.9 Hz, 2H), 2.51-2.43 (m, 2H), 2.39-2.31 (m, 2H).

(452) 1301: Colorless syrup, 22.4% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.56 (d, J=8.1 Hz, 2H), 7.40-7.31 (m, 4H), 7.30-7.25 (m, 3H), 6.93-6.78 (m, 3H), 5.85 (s, 1H), 3.83 (s, 3H), 3.54-3.45 (m, 2H), 3.38 (s, 2H), 3.10-3.03 (m, 2H), 2.79-2.72 (m, 2H), 2.65 (dd, J=9.3, 6.2 Hz, 2H), 2.21 (t, J=5.0 Hz, 2H), 1.84-1.76 (m, 2H).

(453) 1302: Colorless syrup, 48.9% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.47-7.34 (m, 5H), 6.95-6.80 (m, 7H), 6.22 (s, 1H), 3.87-3.83 (m, 2H), 3.82 (s, 3H), 3.79 (s, 3H), 3.64-3.57 (m, 2H), 3.13-3.03 (m, 4H), 3.01-2.94 (m, 2H), 2.70-2.62 (m, 2H).

(454) 1303: Colorless syrup, 18.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.39-7.28 (m, 5H), 6.92-6.74 (m, 7H), 5.90 (s, 1H), 3.87 (s, 3H), 3.77 (s, 3H), 3.67-3.58 (m, 2H), 3.25-3.18 (m, 2H), 2.86-2.76 (m, 4H), 2.68 (dd, J=9.3, 6.3 Hz, 2H), 2.43-2.35 (m, 2H).

(455) 1306: Colorless syrup, 44.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.48-7.43 (m, 2H), 7.42-7.33 (m, 7H), 6.91-6.81 (m, 3H), 6.21 (s, 1H), 4.62 (dd, J=10.9, 2.3 Hz, 1H), 3.83 (s, 3H), 3.75 (d, J=13.2 Hz, 1H), 3.53-3.44 (m, 1H), 3.20 (td, J=12.9, 2.9 Hz, 1H), 3.12-2.97 (m, 2H), 2.68-2.61 (m, 2H), 2.11-2.02 (m, 1H), 1.94-1.76 (m, 4H).

(456) 1307: Colorless syrup, 16.8% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.40-7.35 (m, 4H), 7.33-7.29 (m, 2H), 7.25-7.21 (m, 2H), 6.95-6.77 (m, 3H), 5.95 (s, 1H), 4.59-4.42 (m, 1H), 3.86 (s, 3H), 3.64-3.50 (m, 1H), 3.19 (td, J=13.0, 2.8 Hz, 1H), 2.97 (td, J=12.7, 3.4 Hz, 1H), 2.82-2.70 (m, 2H), 2.70-2.62 (m, 2H), 1.73-1.62 (m, 4H), 1.38 (dd, J=13.8, 2.4 Hz, 1H), 1.27 (s, 1H).

(457) 1308: Colorless syrup, 48.5% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.42-7.27 (m, 6H), 6.98-6.78 (m, 6H), 6.20 (s, 1H), 3.86-3.82 (m, 2H), 3.81 (s, 3H), 3.65-3.53 (m, 2H), 3.24-3.14 (m, 2H), 3.13-3.00 (m, 4H), 2.72-2.56 (m, 2H).

(458) 1309: Colorless syrup, 20.7% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.39 (s, 2H), 7.34 (d, J=8.4 Hz, 2H), 7.23 (d, J=8.4 Hz, 2H), 6.99-6.79 (m, 6H), 5.92 (s, 1H), 3.88 (s, 3H), 3.67-3.61 (m, 2H), 3.25-3.19 (m, 2H), 3.03-2.97 (m, 2H), 2.77 (t, J=7.6 Hz, 2H), 2.72-2.63 (m, 4H).

(459) 1310: Colorless syrup, 45.0% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.51-7.44 (m, 4H), 7.42-7.31 (m, 6H), 6.87-6.79 (m, 2H), 6.70 (dd, J=8.7, 4.5 Hz, 1H), 6.25 (s, 1H), 4.56 (s, 1H), 3.77 (s, 3H), 3.34-3.16 (m, 1H), 3.12-2.96 (m, 2H), 2.75-2.67 (m, 2H), 2.14-1.86 (m, 3H), 1.88-1.77 (m, 3H), 1.38-1.18 (m, 1H).

(460) 1311: Colorless syrup, 15.6% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.44-7.29 (m, 7H), 7.29-7.25 (m, 1H), 7.24-7.20 (m, 2H), 6.90-6.70 (m, 3H), 5.94 (s, 1H), 4.62-4.44 (m, 1H), 3.79 (s, 3H), 3.66-3.55 (m, 1H), 3.12 (td, J=13.0, 2.9 Hz, 1H), 3.02-2.90 (m, 1H), 2.84-2.68 (m, 4H), 1.75-1.59 (m, 3H), 1.33 (ddd, J=13.7, 4.8, 2.4 Hz, 1H), 0.90 (td, J=13.2, 4.8 Hz, 1H).

(461) 1320: Colorless syrup, 47.7% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.51-7.28 (m, 7H), 6.98-6.73 (m, 6H), 6.24 (s, 1H), 3.87-3.82 (m, 2H), 3.75 (s, 3H), 3.66-3.60 (m, 2H), 3.23-3.18 (m, 2H), 3.15-3.10 (m, 2H), 3.09-3.03 (m, 2H), 2.74-2.69 (m, 2H).

(462) 1321: Colorless syrup, 23.0% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.36-7.32 (m, 4H), 7.31-7.28 (m, 1H), 7.27-7.23 (m, 2H), 6.93-6.83 (m, 2H), 6.83-6.73 (m, 4H), 5.91 (s, 1H), 3.80 (s, 3H), 3.64 (dd, J=10.1, 4.9 Hz, 2H), 3.25-3.18 (m, 2H), 2.99-2.91 (m, 2H), 2.83-2.70 (m, 4H), 2.55-2.48 (m, 2H).

(463) 1322: Colorless syrup, 46.9% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.69-7.32 (m, 9H), 6.98-6.73 (m, 3H), 6.29 (s, 1H), 4.59 (d, J=13.7 Hz, 1H), 3.95 (d, J=12.9 Hz, 1H), 3.86 (s, 3H), 3.75 (d, J=12.7 Hz, 1H), 3.24-2.94 (m, 4H), 2.80-2.62 (m, 2H), 1.99 (s, 3H), 1.27 (s, 1H).

(464) 1323: Colorless syrup, 15.6% in yield. .sup.1H NMR (500 MHz, cdcl.sub.3) 7.52-7.28 (m, 9H), 6.97-6.80 (m, 3H), 5.93 (s, 1H), 4.40 (d, J=13.6 Hz, 1H), 3.88 (s, 3H), 3.63 (dd, J=22.9, 13.1 Hz, 1H), 2.89-2.75 (m, 2H), 2.75-2.59 (m, 4H), 1.90-1.75 (m, 3H), 1.44-1.32 (m, 2H).

(465) Biological Results According to Aspects of the Invention

(466) Embodiments of the invention relate to compounds 648, V131 and a series of other novel compounds as potent inhibitor of ERG (FIG. 1.1-1.1d). According to embodiments of the invention, the compounds also inhibit other member of ETS family, including ETV1 (FIG. 1.4a-1.4d) and ESE-1 and ETS-2 (FIG. 1.2a and FIG. 1.3a). Direct binding of 648 with ERG was confirmed by SPR analysis (FIG. 1.5a and FIG. 1.5b). Compound 648 potently inhibits invasion of VCaP and C4-2B cells, but not the DU145 cells (FIG. 1.7). VCaP and C4-2B cells endogenously express ERG and ETV-1, respectively. In contract, DU145 is ERG-negative and ETV1-negative. In embodiments of the invention, compounds 827 and 832 are cytotoxic in the ETV1-postive LNCaP cells (FIG. 1.8a).

(467) In embodiments of the invention, the androgen-bound AR is regressing GATA2 expression and inhibition of AR via castration or use of antiandrogen releases such expression. This suggest a feedback loop between AR and GATA2, in which inhibition of AR rapidly leads to elevated expression of GATA2, which subsequently results in resistance to castration and antiandrogen by activating the AR. Our findings are consistent with the recent work done by He et al. which found that activated AR binds with promoter region of GATA2 and regulates GATA2 expression..sup.61 Embodiments of the inventions relate to a series of novel compounds that potently inhibit GATA2-dependent reporter assay in IHH cells (FIG. 2.1a, FIG. 2.1b and FIG. 2.2a-2.2g). Further embodiments of the invention demonstrate that 673 and its analogues selectively inhibit GATA2 among GATA family members (FIG. 2.3a-2.3c and FIG. 2.4). Direct binding of 670, 673, 817 and V248 with GATA2 was confirmed by SPR analysis, using recombinant protein of human GATA2 (FIG. 2.5a and FIG. 2.5b). Other embodiments showed that 673 potently inhibits the AR signaling in C4-2B CRPC prostate cancer cells (FIG. 2.6) and are cytotoxic to A549 and H23 KRAS mutant NSCLC cells (FIG. 2.7). Overexpression of GATA2 confers resistance to antiandrogen bicalutamide (Bic) (FIG. 2.9). Compound 673 is effective against the LNCaP stably transfected with GATA2-expressing plasmid (referred to as LNCaP-GATA2 cells) (FIG. 2.8). By breaking AR-GATA2 feedback loop, 673 suppresses the AR signalling in CRPC cells (FIG. 11). Further, we demonstrated the synergistic effect of 673 with bicalutamide (Bic) in PSA-luc reporter assay and BrdU cell proliferation assay in LNCaP-GATA2 cells (FIG. 12). The embodiment in FIG. 10 indicated that 673 is targeting the N-terminal domain of GATA2.

(468) Further embodiments of the invention relate to a series of novel compounds that activate human Sting (hSting) and/or mouse Sting (mSting)-dependent reporter assay (FIG. 3.1a-3.1e, FIG. 3.2, and FIG. 3.4a-3.4j). Direct binding of 817 with hSting was confirmed by SPR analysis (FIG. 3.3). Embodiments of the invention demonstrated that 834, 874, 761, 840 and 1176 activate interferon signaling pathway in THP-1 cells, which endogenously express hSting (FIG. 3.5).

(469) Direct binding of compounds 784 and 895 with KRAS G12D mutant was confirmed by Surface Plasmon Resonance (SPR) analysis, using recombinant human KRAS 12D mutant protein (TP700052, ORIGENE) (FIG. 4.1). The SPR analysis revealed that 895 is a tighter binder of the G12D mutant than 784 (Kd of 784 and 895 are 190 and 45 M, respectively). Since activation of KRAS leads to activation of NF-kB,.sup.69 we performed in vitro screening of our compounds by KRAS mutant-dependent NF-kB-luc reporter assay in HEK293 cells. We demonstrated that 784, 895 and a series of other compounds potently inhibited KRAS G12D, G12V and G12C mutants (FIGS. 4.2a)-4.2c)). Next, we demonstrated that our compounds are active in PANC 10.05 pancreatic cancer cells, which endogenously express KRAS G12D mutant. Specifically, compounds of the invention inhibit NF-kB-luc reporter activity in PANC 10.05 cells (FIGS. 4.3a)-4.3i)). Compounds of the invention inhibit ERK phosphorylation in Panc 10.05 and HCT-116 cells, which express endogenous KRAS G12D and G13D mutants, respectively (FIGS. 4.4a)-4.4c)). Also, compounds of the invention are cytotoxic to PANC 10.05 pancreatic cancer cells, H23 NSCLC cells and HCT-116 colorectal cancer cells (FIG. 4.5).

(470) Although the present invention has been described hereinabove by way of specific embodiments thereof, it may be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims.

(471) The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.

REFERENCES

(472) 1. Riely, G. J.; Marks, J.; Pao, W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 2009, 6, 201-205. 2. Whyte, D. B.; Kirschmeier, P.; Hockenberry, T. N.; Nunez-Oliva, I.; James, L.; Catino, J. J.; Bishop, W. R.; Pai, J. K. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 1997, 272, 14459-14464. 3. Gysin, S.; Salt, M.; Young, A.; McCormick, F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2, 359-372. 4. Mallucci, L.; Wells, V. The end of KRAS, and other, cancers? A new way forward. Drug Discov. Today 2014, 19, 383-387. 5. Scholl, C.; Frohling, S.; Dunn, I. F.; Schinzel, A. C.; Barbie, D. A.; Kim, S. Y.; Silver, S. J.; Tamayo, P.; Wadlow, R. C.; Ramaswamy, S.; Dohner, K.; Bullinger, L.; Sandy, P.; Boehm, J. S.; Root, D. E.; Jacks, T.; Hahn, W. C.; Gilliland, D. G. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells. Cell 2009, 137, 821-834. 6. Singh, A.; Greninger, P.; Rhodes, D.; Koopman, L.; Violette, S.; Bardeesy, N.; Settleman, J. A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival. Cancer Cell 2009, 15, 489-500. 7. Kumar, M. S.; Hancock, D. C.; Molina-Arcas, M.; Steckel, M.; East, P.; Diefenbacher, M.; Armenteros-Monterroso, E.; Lassailly, F.; Matthews, N.; Nye, E.; Stamp, G.; Behrens, A.; Downward, J. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012, 149, 642-655. 8. Steckel, M.; Molina-Arcas, M.; Weigelt, B.; Marani, M.; Warne, P. H.; Kuznetsov, H.; Kelly, G.; Saunders, B.; Howell, M.; Downward, J.; Hancock, D. C. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 2012, 22, 1227-1245. 9. Shen, S.; Mao, C. Q.; Yang, X. Z.; Du, X. J.; Liu, Y.; Zhu, Y. H.; Wang, J. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma. Mol. Pharm. 2014, 11, 2612-2622. 10. Katsumura, K. R.; Yang, C. X.; Boyer, M. E.; Li, L. J.; Bresnick, E. H. Molecular basis of crosstalk between oncogenic Ras and the master regulator of hematopoiesis GATA-2. EMBO Rep. 2014, 15, 938-947. 11. Munugalavadla, V.; Dore, L. C.; Tan, B. L.; Hong, L.; Vishnu, M.; Weiss, M. J.; Kapur, R. Repression of c-kit and its downstream substrates by GATA-1 inhibits cell proliferation during erythroid maturation. Mol. Cell Biol. 2005, 25, 6747-6759. 12. Rylski, M.; Welch, J. J.; Chen, Y. Y.; Letting, D. L.; Diehl, J. A.; Chodosh, L. A.; Blobel, G. A.; Weiss, M. J. GATA-1-mediated proliferation arrest during erythroid maturation. Mol. Cell Biol. 2003, 23, 5031-5042. 13. Zheng, R.; Blobel, G. A. GATA Transcription Factors and Cancer. Genes Cancer 2010, 1, 1178-1188. 14. Bresnick, E. H.; Katsumura, K. R.; Lee, H. Y.; Johnson, K. D.; Perkins, A. S. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. Nucleic Acids Res. 2012, 40, 5819-5831. 15. Masuda, A.; Hashimoto, K.; Yokoi, T.; Doi, T.; Kodama, T.; Kume, H.; Ohno, K.; Matsuguchi, T. Essential role of GATA transcriptional factors in the activation of mast cells. J. Immunol. 2007, 178, 360-368. 16. Culig Z., Klocker H., Bartsch G., Hobisch A. Androgen receptors in prostate cancer. Endocr. Relat Cancer 2002, 9(3), 155-170. 17. Balk S. P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002, 60(3A), 132-138. 18. Taplin M. E., Ho S. M. The endocrinology of prostate cancer. J. Clin. Endocrinol. Metab. 2001, 86(8), 3467-3477. 19. Tannock I. F., de Wit R., Berry W. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351(15), 1502-1512. 20. Petrylak D. P., Tangen C. M., Hussain M. H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351(15), 1513-1520. 21. Ang J. E., Olmos D., de Bono J. S. CYP17 blockade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br. J. Cancer 2009, 100(5), 671-675. 22. Scher H. I., Beer T. M., Higano C S et al. Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC). J. Clin. Oncol. (Meeting Abstracts) 2008, 26(15_suppl), 5006. 23. Tran C., Ouk S., Clegg N. J. et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science 2009, 324(5928), 787-790. 24. Scher H. I., Beer T. M., Higano C. S. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375(9724), 1437-1446. 25 Attard G., Cooper C. S., de Bono J. S. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009, 16(6), 458-462. 26. Attard G., Reid A. H. M., Olmos D., de Bono J. S. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 2009, 69(12), 4937-4940. 27. Shen H. C., Balk S. P. Development of Androgen Receptor Antagonists with Promising Activity in Castration-Resistant Prostate Cancer. Cancer Cell 2009, 15(6), 461-463. 28. Tomlins S. A., Rhodes D. R., Perner S. et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science 2005, 310(5748), 644-648. 29. Tomlins S. A., Bjartell A., Chinnaiyan A. M. et al. ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice. Eur. Urol. 2009, 56(2), 275-286. 30. Mehra R., Tomlins S. A., Yu J. J. et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008, 68(10), 3584-3590. 31. Oikawa T. ETS transcription factors: possible targets for cancer therapy. Cancer Sci. 2004, 95(8), 626-633. 32. Tomlins S. A., Laxman B., Varambally S. et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10(2), 177-188. 33. St. John J., Powell K., Katie Conley-LaComb M., Chinni S. R. TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. Journal of Cancer Science and Therapy 2012, 4(4), 94-101. 34. Demichelis F., Fall K., Perner S. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 26(31), 4596-4599. 35. Attard G., Clark J., Ambroisine L. et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27(3), 253-263. 36. FitzGerald L. M., Agalliu I., Johnson K. et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008, 8, 230. 37. Mehra R., Tomlins S. A., Shen R. et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 2007, 20(5), 538-544. 38. Perner S., Svensson M. A., Hossain R. R. et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2010, 75(4), 762-767. 39. Furusato B., Tan S. H., Young D. et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010, 13(3), 228-237. 40. Gao X., Li L. Y., Zhou F. J. et al. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis. Clin. Cancer Res. 2012, 18(15), 4163-4172. 41. Wang J., Cai Y., Yu W., Ren C., Spencer D. M., Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res. 2008, 68(20), 8516-8524. 42. Sun C., Dobi A., Mohamed A. et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008, 27(40), 5348-5353. 43. Rosen P., Sesterhenn I. A., Brassell S. A., McLeod D. G., Srivastava S., Dobi A. Clinical potential of the ERG oncoprotein in prostate cancer. Nature Reviews Urology 2012, 9(3), 131-137. 44. Braun M., Goltz D., Shaikhibrahim Z. et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancerA comparative study of two monoclonal antibodies. Prostate Cancer and Prostatic Diseases 2012, 15(2), 165-169. 45. Rubin M. A., Maher C. A., Chinnaiyan A. M. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 2011, 29(27), 3659-3668. 46. Sreenath T. L., Dobi A., Petrovics G., Srivastava S. Oncogenic activation of ERG: A predominant mechanism in prostate cancer. J. Carcinog. 2011, 10, 37. 47. Leshem O., Madar S., Kogan-Sakin I. et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS ONE 2011, 6(7). 48. Yu J., Yu J., Mani R. S. et al. An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell 2010, 17(5), 443-454. 49. Flajollet S., Tian T. V., Flourens A. et al. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin. Molecular Cancer Research 2011, 9(7), 914-924. 50. Kunderfranco P., Mello-Grand M., Cangemi R. et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS ONE 2010, 5(5). 51. Mohamed A. A., Tan S. H., Sun C. et al. ERG oncogene modulates prostaglandin signaling in prostate cancer cells. Cancer Biology & Therapy 2011, 11(4), 410-417. 52. Wang J., Cai Y., Shao L. J. et al. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res. 2011, 71(4), 1325-1333. 53. Nelson W. G., De Marzo A. M., Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinol. 2009, 150(9), 3991-4002. 54. Sebastian de Bono J., Sandhu S., Attard G. Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. Cancer Cell 2011, 19(5), 573-574. 55. Rahim S., Beauchamp E. M., Kong Y., Brown M. L., Toretsky J. A., oeren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PLoS ONE 2011, 6(4). 56. Baena E., Shao Z., Linn D. E. et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 2013, 27(6), 683-698. 57. Ran L., Sirota I., Cao Z. et al. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov. 2015, 5(3), 304-315. 58. Xie L., Gazin C., Park S. M. et al. A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells. PLoS Genet. 2012, 8(12), e1003151. 59. Woo S. R., Fuertes M. B., Corrales L. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41(5), 830-842. 60. Iwamoto, K.-I., Kimura, H., Oike, M., Sato. M. Org. Biomol. Chem. 2008, 6, 912-915. 61. He B., Lanz R. B., Fiskus W. et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc. Natl. Acad. Sci. USA 2014, 111(51), 18261-18266. 62. Ryan D P, Hong T S, Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014, 371(22), 2140-2141. 63. Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat. Rev. Clin. Oncol. 2015, 12(6), 319-334. 64. Collins M A, Bednar F, Zhang Y et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 2012, 122(2), 639-653. 65. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11(11), 761-774. 66. Ostrem J M, Peters U, Sos M L, Wells J A, Shokat K M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503(7477), 548-551. 67. Lito P, Solomon M, Li L S, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 2016, 351(6273), 604-608. 68. Lim S M, Westover K D, Ficarro S B et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem. Int. Ed. Engl. 2014, 53(1), 199-204. 69. Mizumoto Y, Kyo S, Kiyono T et al. Activation of NF-kappaB is a novel target of KRAS-induced endometrial carcinogenesis. Clin. Cancer Res. 2011, 17(6), 1341-1350. 70. Meanwell, N. A. et al. J. Med. Chem. 1993, 36, 3884-3903. 71. Meanwell, N. A.; Rosenfeld, M. J.; Trehan, A. K. Wright, J. J. K.; Brassard, C. L.; Buchanan, J.; Federici, M. E.; Fleming, J. S.; Gamberdella, M.; Zavoico, G. B.; Seiler, S. M. J. Med. Chem. 1992, 35, 3483-3497.